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Abstract 
 
Ribosome production is an energetically expensive and, therefore, highly regulated 
process. Defects in ribosome biogenesis lead to genetic diseases called 
Ribosomopathies, such as Dyskeratosis Congenita (DC), and mutations in ribosomal 
proteins and ribosome biogenesis factors are linked to multiple types of cancer. During 
ribosome biogenesis, the ribosomal RNAs (rRNAs) are processed and modified, and 
defects in ribosome biogenesis lead to the activation of p53. This project aimed to 
investigate the functions of Dyskerin, mutated in X-linked DC, in human ribosome 
biogenesis and p53 regulation, and to explore the link between ribosome production 
and p53 homeostasis. 
 
Dyskerin is an rRNA pseudouridine synthase and required for telomere maintenance. 
There is some debate as to whether DC is the result of telomere maintenance or 
ribosome biogenesis defects. It is shown here that human Dyskerin is required for the 
production of both LSU and SSU, and knockdown of Dyskerin leads to p53 activation 
via inhibition of MDM2 via the 5S RNP, an LSU assembly intermediate which 
accumulates after ribosome biogenesis defects. My data indicate that p53 activation, 
due to defects in ribosome biogenesis, may contribute to the clinical symptoms seen 
in patients suffering with DC. 
 
In addition, it is shown that defects in early or late stages of SSU or LSU biogenesis, 
result in activation of p53 via the 5S RNP-MDM2 pathway, and that p53 is induced in 
less than 12 hours after ribosome biogenesis defects. SSU defects do not cause any 
obvious defects in LSU production, but they result in inhibition of export of the pre-LSU 
in the cytoplasm, suggesting that p53 activation after SSU defects is probably due to 
defects in pre-LSU export. Finally, there are evidence that RPS27a or RPL40, two 
ribosomal proteins produced as ubiquitin-fusion precursors in the cell, might be novel 
regulators of the 5S RNP-MDM2 pathway. 
 
In conclusion, this work shows the importance of ribosome biogenesis in the regulation 
of p53 for the development of Ribosomopathies and cancer. 
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1. Chapter One. Introduction 
 
1.1. The eukaryotic ribosome 
 
Ribosomes are ribonucleoproteins complexes consisting of protein and RNA 
components, essential for protein synthesis. Eukaryotic ribosomes consist of two 
subunits: the large (LSU or 60S) and the small (SSU or 40S) ribosomal subunit. The 
LSU contains the peptidyl-transferase centre where the catalysis of the peptide bond 
formation occurs for the synthesis of the nascent polypeptide chain. The SSU has a 
decoding function, where the complementarity of the tRNA with the mRNA is inspected 
(Gamalinda and Woolford, 2015). Ribosomes are structurally well-conserved across 
all organisms, even though the prokaryotic ribosomes (70S) are smaller than the 
eukaryotic ones (80S) (Moore and Steitz, 2002). 
 
In eukaryotes, the LSU (60S) consists of the 28S (25S in yeast), 5.8S and 5S ribosomal 
(r)RNAs, as defined by their sedimentation co-efficient, and 46 ribosomal proteins. In 
contrast, the SSU (40S) contains the 18S rRNA and approximately 33 ribosomal 
proteins (Gamalinda and Woolford, 2015). The 28S, 18S and 5.8S rRNAs are 
transcribed in the nucleolus by RNA polymerase (pol) I as a single 47S transcript, 
which is subsequently processed and modified for the production of the mature rRNAs. 
The 5S rRNA is transcribed in the nucleoplasm by RNA polymerase III (Granneman 
and Baserga, 2004, Orsolic et al., 2015). 
 
1.2. Ribosome Biogenesis 
 
In mammals, there are approximately 10 million ribosomes in each cell (Kenmochi et 
al., 1998) and ribosome production is a major energy-consuming process, and, 
therefore, very tightly regulated. In yeast, approximately 60% of the cellular energy is 
predicted to be consumed by ribosome biogenesis (Warner, 1999). More than 200 
proteins were shown to be involved in rRNA processing and maturation, which takes 
place in different compartments in the cell (Henras et al., 2008), including the 
nucleolus, nucleus and cytoplasm (Kressler et al., 2010). Ribosome production was 
found to be up-regulated during cell growth (Sulic et al., 2005), and down-regulated 
during cell proliferation and differentiation (Warner, 1999). Not surprisingly, ribosome 
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biogenesis was found to play a key role in cancer, since it is up-regulated during 
tumourigenesis (Ruggero and Pandolfi, 2003). 
 
1.2.1. The nucleolus 
 
The first steps of ribosome biogenesis take place in a distinct nuclear compartment, 
called the nucleolus (Boisvert et al., 2007). The 28S, 18S and 5.8S rRNAs are 
transcribed from ribosomal DNA (rDNA) repeats in a telomere-to-centromere fashion 
(Worton et al., 1988, McStay and Grummt, 2008), which cluster in the nuclear organizer 
regions (NORs) within the nucleolus (Henderson et al., 1972). These genes are found 
on the short arms of the acrocentric chromosomes 13, 14, 15, 21 and 22 in humans 
(Kenmochi et al., 1998), so that they are separated from genes transcribed by RNA 
polymerases II and III (Henderson et al., 1972). The NORs are highly conserved, since 
the 5’-end of the rDNA clusters as well as the non-rDNA repeats around it are 
conserved in all 5 pairs of chromosomes. 
 
The nucleolus is formed around rRNA-transcribing genes and it is organized in three 
distinct compartments, as identified by Electon-Microscopy (EM): the fibrillarin centre 
(FC), the dense fibrillarin component (DFC) and the granular component (GC) (Figure 
1.1) (Haaf et al., 1991, Haaf and Schmid, 1991, Smirnov et al., 2016). It was shown 
that the pre-rRNAs grow on the rDNA as small fibrils, which create a structure of 
approximately 4.5-6µm in length (Cheutin et al., 2002). Transcription of the 47S 
precursor rRNA by RNA polymerase I takes place at the border between the FC and 
DFC, whereas processing of the pre-rRNAs takes place in DFC (Cheutin et al., 2002). 
Indeed, RNA polymerase I is found in high levels in the FC region in the nucleolus 
(Boisvert et al., 2007). The first cleavage steps of the 47S rRNA are believed to take 
place in the DFC compartment (Derenzini et al., 1990), whereas later steps of the rRNA 
precursor processing take place in the GC compartment (Gerbi and Borovjagin, 1997), 
where most ribosomal proteins are found (Boisvert et al., 2007). 
 
The nucleolus has been linked to cancer for the past few years. Silver-staining of NORs 
(Ag-NOR staining) has shown that the nucleolar structure changes in tumour cells, 
since it is usually increased in size and numbers, leading to an up-regulation of 
ribosome biogenesis (Orsolic et al., 2015). 
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Figure 1.1. Structure of the nucleolus revealed by electron microscopy. (A) The 
nucleoli shown in the nucleus of a HeLa cell, as indicated by the arrows, by differential 
interfering contrast (DIC). (B) Nitrogen-enriched image showing the fibrillarin centre 
(FC), dense fibrillarin component (DFC) and granular component (GC). (From: 
(Boisvert et al., 2007)). 
 
1.2.2. rRNA transcription 
 
The 28S (25S in yeast), 18S and 5.8S rRNAs are transcribed as a single transcript 
(47S, 35S in yeast) by RNA polymerase I in the nucleolus (Woolford and Baserga, 
2013). In yeast, there is a promoter region upstream of the rDNA gene and a terminator 
sequence downstream of the gene. In humans, the upstream region of the rRNA gene 
contains a promoter and an upstream control element, whereas several termination 
sequences are found at the 3’ end of the rDNA genes (Russell and Zomerdijk, 2005). 
The upstream control element in humans is bound by the upstream binding factor 
(UBF), which then recruits the human selectivity factor (SL1 complex) to the promoter 
region (Russell and Zomerdijk, 2005). The SL1 complex consists of the TATA-box-
binding protein (TBP) and three TBP-associated factors (Grummt, 1999). Binding of 
the SL1 recruits the RNA polymerase I to the promoter region, forming the pre-initiation 
complex, consisting of UBF, SL1 and RNA polymerase I, which leads to promoter 
opening (Russell and Zomerdijk, 2005). The RNA polymerase I is then able to move 
across the gene so that transcription is initiated, but the UBF and SL1 complex remain 
bound to the promoter region so that multiple RNA polymerase I units can be recruited 
to the promoter for a number of transcription rounds (Panov et al., 2001). The 
clearance of the promoter region by RNA polymerase I shift appears to be the rate-
limiting step for the transcription of the rRNAs (Panov et al., 2001). Finally, RNA 
polymerase I halts when it reaches the TTF-1 factor, which is bound at the termination 
sequences, and it gets released by the PTRF factor, which is associated with TTF-1 at 
3 
 
the termination sequence (Jansa and Grummt, 1999). The 47S rRNA precursor 
produced is processed co-transcriptionally for the formation of the mature 28S, 5.8S 
and 18S rRNAs (Russell and Zomerdijk, 2005). 
 
The 5S rRNA is transcribed in the nucleoplasm by RNA polymerase III (Paule and 
White, 2000), which is found at multiple sites in the nucleus (Pombo et al., 1999). The 
5S rDNA gene clusters, found on human chromosome 1, contain a 5’ flanking region, 
which is necessary for its transcription by RNA polymerase III (Sorensen and 
Frederiksen, 1991). In lower eukaryotes, this region contains internal elements, 
including the A-box at the 5’, the intermediate element (IE) and the C-box at the 3’ 
(Cloix et al., 2003). This class of promoter regions was found in X. leavis (Pieler et al., 
1987), D. melanogaster (Sharp and Garcia, 1988) and S. cerevisiae (Lee et al., 1995), 
which are bound by the RNA polymerase III and three transcription factors: TFIIIA, 
which is specific to 5S rRNA (Pelham and Brown, 1980), TFIIIB, TFIIIC (Cloix et al., 
2003). In humans and other higher eukaryotes, such as mice, an additional element, 
called the D-box is found upstream of the 5S rDNA gene, which is required for the 
efficient transcription of the 5S rRNA (Hallenberg and Frederiksen, 2001). TFIIIA binds 
the C-box at the 5’ region of the 5S rDNA, which then recruits TFIIIC. TFIIIA and TFIIIC 
binding position TFIIIB at the promoter region, so that RNA polymerase III is assembled 
at the promoter (Ishiguro et al., 2002). Once transcription is initiated, TFIIIC is released 
but TFIIIB remains bound on the promoter region for multiple rounds of initiation 
(Kassavetis et al., 1998, Kumar et al., 1998). 
 
1.2.3. rRNA processing 
 
Most of our knowledge on the rRNA processing pathway and the factors involved are 
known from yeast, where the primary 35S rRNA transcript is processed both co-
transcriptionally and post-transcriptionally. Removal of 5’ ETS occurs by the co-
transcriptional cleavage at sites A0, A1 and A2, which occurs simultaneously (Figure 
1.2). The mechanisms and enzymes responsible for cleavage at sites A0 and A1 are 
yet to be determined, but there is evidence for the requirement of the SSU processome 
complex (Phipps et al., 2011, Osheim et al., 2004), U3 (Dragon et al., 2002), U14 
(Henras et al., 2015) and snR30/U17 snoRNAs (Fayet-Lebaron et al., 2009, Tollervey, 
1987), and a number of ribosomal proteins (O'Donohue et al., 2010) (Figure 1.2). It 
was originally thought that the endonuclease Rcl1p is involved in cleavage at site A2 
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(Horn et al., 2011), whereas recent evidence suggest that this is not the case and the 
endonuclease Utp24 was shown to be essential for this (Figure 1.2) (Wells et al., 2016). 
Separation of the LSU and SSU precursors occurs after cleavage at A2 site of the ITS1 
(internal transcribed spacer 1) (Kressler et al., 1999), resulting in the formation of the 
20S SSU and the 27S LSU rRNA precursors (Figure 1.2) (Henras et al., 2015). 
Cleavage at site A3 involved the MRP RNase (Lygerou et al., 1996), and the RNA-
binding protein Rrp5p (Venema and Tollervey, 1996) and Nop4p protein (Berges et al., 
1994, Sun and Woolford, 1994) were shown to be important (Figure 1.2). 
 
The 20S SSU rRNA precursor is exported to the cytoplasm, where it is further cleaved 
at site D for the production of the mature 18S rRNA (Figure 1.2). This cleavage step is 
dependent upon the action of Nob1p endonuclease (Pertschy et al., 2009) and Dim1 
dimethylase (Kressler et al., 1999). The 27S LSU rRNA precursor is processed for the 
production of the mature 5.8S and 25S rRNAs (Figure 1.2). The 5’ end of the 5.8S 
rRNA is processed by the exonuclease Rat1p (Kressler et al., 1999) and the rRNA 
processing protein Rrp17p (Petfalski et al., 1998, Oeffinger et al., 2009). Separation of 
the 5.8S and the 25S rRNA precursors occurs after cleavage at site C2 (Figure 1.2), 
but the factors involved in this are still unknown (Venema and Tollervey, 1995). Las1 
endonuclease was shown to be involved in this cleavage step (Gasse et al., 2015) and 
other factors and ribosomal proteins, such as RPL35 (Babiano and de la Cruz, 2010) 
are also important. Maturation of the 5.8S rRNA takes place after 3’ exonucleolytic 
processing (Figure 1.3) involving the exosome component RNA helicase Mtr4p (Jia et 
al., 2012) and the exonuclease Rrp6p (Briggs et al., 1998) in the nucleus, whereas the 
final 3’ processing by Ngl2p (Faber et al., 2006) occurs in the cytoplasm (Thomson and 
Tollervey, 2010). The exonuclease Rat1p and its cofactor Rai1p were also found to be 
involved in the 5’ end processing of the 5.8S rRNA (Fang et al., 2005). Maturation of 
the pre-25S rRNA LSU precursor occurs by exonucleolytic cleavage of the 5’ end 
(Figure 1.2) by Rat1p in the nucleus (El Hage et al., 2008), which is then exported to 
the cytoplasm (Geerlings et al., 2000), where it is further processed for the production 
of the mature 5.8S rRNA (Thomson and Tollervey, 2010). 
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Figure 1.2. Schematic representation of the rRNA processing pathway in yeast. 
processing pathway in humans. The small ribosomal subunit (SSU) precursor and 
mature rRNAs are shown in green and the large ribosomal subunit (LSU) rRNAs are 
shown in blue. The cleavage sites are indicated at the top. The enzymes and factors 
essential for each cleavage step are shown in red and the important ones in black. The 
nucleus and the cytoplasm are clearly indicated (Adapted from: (Henras et al., 2015)). 
 
In humans, the rRNA processing pathway is somewhat conserved, involving more than 
200 proteins (Henras et al., 2008). As opposed to yeast, most of the processing at 5’ 
ETS in humans occurs after ITS1 cleavage. An additional cleavage site A’ is found at 
the human 5’ ETS forming the 45S rRNA precursor, which is dependent on the UTP-
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A complex. The exonuclease XRN2 and the surveillance factor MTR4 are also 
important for this cleavage step (Figure 1.3) (Sloan et al., 2014). It was originally 
thought that the U3 snoRNA was also important for this cleavage step (Enright et al., 
1996), but it was recently shown that this is not the case (Sloan et al., 2014). 
Interestingly, the A’ cleavage step in humans can be bypassed either in the absence 
of XRN2 or naturally in the cells (Sloan et al., 2014). 
 
As opposed to yeast, there are two processing pathways in humans for the separation 
of the large and small subunit rRNA precursors and the processing of the LSU and 
SSU rRNA precursors (Sloan et al., 2013c, Rouquette et al., 2005, Mullineux and 
Lafontaine, 2012). The major pathway involves a single cleavage at site 2 of ITS1 by 
which leads to the production of 32S and 30S precursors of 28S and 18S respectively 
(Figure 1.3). The nuclease involved in this cleavage step is still unknown and the RNA 
binding protein RRP5 was shown to be important for this (Sloan et al., 2013c). The 
nucleolar protein NOL12, the ribosome biogenesis protein BOP1 and, in lesser extent, 
the RNA-binding protein RBM28, but not MRP RNase, are also involved in this 
cleavage event, which is comparable to A3 cleavage in yeast (Figure 1.3) (Sloan et al., 
2013c). Processing of the 30S SSU rRNA precursor towards site 2a involves a number 
of proteins, including the RRP6 exonuclease, and the MTR4 helicase (TRAMP 
complex component), which is required for full RRP6 activity (Sloan et al., 2013c). 
Moreover the exosome, the ribosomal protein RPS19 and the ribosome biogenesis 
proteins ENP1 and RCL1 are required for the production of the 18SE SSU rRNA 
precursor (Figure 1.3) (Sloan et al., 2013b). The mature 18S rRNA is produced by 
cleavage at site 3, presumably by NOB1 endonuclease, in the cytoplasm (Figure 1.3) 
(Henras et al., 2015). 
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 Figure 1.3. Schematic representation of the rRNA processing pathway in 
humans. The small ribosomal subunit (SSU) precursor and mature rRNAs are shown 
in green and the large ribosomal subunit (LSU) rRNAs are shown in blue. The cleavage 
sites are indicated at the top. The major pathway is indicated in black and the minor 
pathway is indicated in grey. The enzymes and factors essential for each cleavage 
step are shown in red and the factors important, but not essential, for the cleavages 
are shown in black. The nucleus and the cytoplasm are clearly indicated(Adapted from: 
(Sloan et al., 2013c)). 
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Processing of the 32S LSU rRNA precursor is less well-understood. Processing 
towards the 5’ end of 5.8S takes place by XRN2 exonuclease and other nucleases are 
likely to be involved (Figure 1.3) (Sloan et al., 2013c). Cleavage at site 4 results in the 
separation of the 12S rRNA precursor and the 28S precursor (Figure 1.3), but the 
factors involved in this step are still unknown. Presumably Las1 endonuclease might 
be involved in this cleavage step, similarly to yeast (Gasse et al., 2015). Processing of 
the 5’ end of the 12S rRNA precursor involves the exosome component RRP6 (Preti 
et al., 2013), the exosome associated-factors MTR4, C1D (Schilders et al., 2007) and 
MPP6 (Tafforeau et al., 2013), and the exonuclease ISG20L2 in the nucleus (Coute et 
al., 2008), and the exonuclease ERI1 (Ansel et al., 2008) in the cytoplasm, for the 
formation of the mature 5.8S rRNA. Processing of the pre-28S rRNA involves the 
exonuclease XRN2 in the nucleus (Wang and Pestov, 2011), and the mature 28S rRNA 
is then exported to the cytoplasm (Figure 1.3). 
 
The minor pathway for rRNA processing compensates if the major pathway is blocked 
(Figure 1.3) (Sloan et al., 2013c). It has been recently shown that UTP24 endonuclease 
is required for site 2 cleavage (Wells et al., 2016) and cleavage at site 2a is dependent 
upon RRP5 (Sloan et al., 2013c). The ribosomal proteins NOL12, RBM28, BOP1 and 
RNP1 were also shown to be involved in the minor pathway (Sloan et al., 2013c). In 
this case, the 36S precursor of the 28S rRNA is produced rather than the 32S, and the 
18SE precursor of the 18S is produced rather than the 30S (Figure 1.3). Further 
cleavage events take place as described above until the mature 18S, 28S and 5.8S 
are produced (Sloan et al., 2013c). 
 
The ribosomal proteins play an important role in the rRNA processing pathway (Henras 
et al., 2015). Some ribosomal proteins have been found to be required for rRNA 
processing, indicating another function in ribosomal proteins. For example, RPL26 
(Gazda et al., 2012) is necessary for SSU and LSU rRNA processing in humans. 
Furthermore, the association of the ribosomal proteins with the pre-rRNAs is important 
for the proper folding of the mature and stable ribosomal subunits in both prokaryotes 
(Chen and Williamson, 2013) and eukaryotes (Ferreira-Cerca et al., 2007, Ohmayer et 
al., 2013). Finally, the involvement of ribosomal proteins in several cleavage steps 
during rRNA processing is evident from depletion experiments mainly showing the 
requirement of almost half of the ribosomal proteins for processing of the 5’ ETS site 
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in yeast (Ferreira-Cerca et al., 2005, Ferreira-Cerca et al., 2007) and humans 
(O'Donohue et al., 2010), as well as other processing steps (Henras et al., 2015). 
 
1.2.4. Ribosomal protein production 
 
The genes encoding for ribosomal proteins are transcribed by RNA polymerase II and 
they have been found in the majority of chromosomes in humans, including the sex 
chromosomes X and Y (Kenmochi et al., 1998). This is in contrast to bacteria where 
the genes encoding for ribosomal proteins are organized in operons found under the 
control of a single promoter (Nomura et al., 1984). Most of the ribosomal proteins are 
encoded in 5’ TOP mRNAs, which have a Terminal OligoPyrimidine (TOP) tract at their 
5’ end. These mRNAs were discovered because they escaped rapamycin inhibition 
(Levy et al., 1991) and the mTOR pathway plays an important role in the translation of 
5’ TOP mRNAs in response to external stimuli and ribosome biogenesis defects 
(Gentilella et al., 2015). 
 
A number of proteins associate with mTOR, forming the mTOR complex 1 (mTORC1), 
including Raptor (Hara et al., 2002), PRAS40 (Oshiro et al., 2007), Rheb-GTPase, 
RAG (Groenewoud and Zwartkruis, 2013) and GβL (Kim et al., 2003). mTORC1 is 
important for cell growth and metabolism, and, therefore, controlled by various 
intracellular and extracellular stimuli, including growth factors, energy status and 
oxygen levels (Laplante and Sabatini, 2009b). mTORC1 is involved in a number of 
downstream pathways and plays an important role in transcription and translation (Hay 
and Sonenberg, 2004). mTORC1 is involved in regulating mRNA translation initiation 
and elongation, and pyrimidine biosynthesis, leading to activation of translation 
initiation (Plas and Thomas, 2009). Finally, mTORC1 promotes ribosome biogenesis 
by activation of rDNA transcription in the nucleolus and nucleoplasm. Interestingly, 
phosphorylation of the ribosomal protein S6, which is a part of the small ribosomal 
subunit (SSU), and activation of LARP1 (La ribonucleoprotein domain family, member 
1), a translational activator of 5’ TOP mRNAs, is induced by mTORC1 (Gentilella et al., 
2015). Taken together, activation of mTORC1 can affect ribosome biogenesis by 
regulation of both ribosomal protein and rRNA levels (Pende et al., 2004). 
 
Interestingly, there are two ribosomal proteins, RPS27a and RPL40, which are 
transcribed as ubiquitin-fusion ribosomal proteins (Kimura and Tanaka, 2010). Further 
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details on this pathway are discussed later on. Most of the ribosomal proteins are 
translated in the cytoplasm and transferred back in the nucleus, and, subsequently, to 
the nucleolus, where ribosome biogenesis takes place (Zemp and Kutay, 2007), 
whereas some of them bind the ribosomal complexes in the cytoplasm, such as RPL10 
(West et al., 2005). Ribosomal proteins produced in excess are unstable outside the 
ribosome and rapidly degraded by the proteasome (Lam et al., 2007). 
 
1.2.5. The 5S RNP 
 
The 5S RNP consists of the ribosomal proteins RPL5, RPL11 and the 5S rRNA, which 
is the smallest RNA in the ribosome. The 5S rRNA is transcribed in the nucleoplasm 
and contains 2-3 nucleotides on its 3’ site, which are cleaved for the production of the 
mature 5S rRNA in both yeast (van Hoof et al., 2000) and in humans (Sloan et al., 
2013c). In particular, the 3’ processing of 5S rRNA in humans is dependent on RPL5 
binding (Sloan et al., 2013a). In yeast, Rex1p, Rex2p and Rex3p exonucleases are 
essential for the 3’ processing of the 5S rRNA precursor (van Hoof et al., 2000). Unlike 
the 28S, 18S and 5.8S, the nucleotides of the 5S rRNA are not usually modified 
(Ciganda and Williams, 2011), and defective or excess 5S rRNA produced is 
polyadenylated and targeted for degradation by the exosome (Kuai et al., 2004). 
 
The secondary structure of the 5S rRNA is highly conserved amongst bacteria and 
eukaryotes, which consists of five helices, two hairpin loops, two internal loops and an 
internal hinge region (Szymanski et al., 2002). In lower organisms, such as X. leavis, 
the 5S rRNA is bound by the transcription factor TFIIIA, forming the 7S RNP (Layat et 
al., 2013, Sloan et al., 2013a). In humans, after transcription, the 5S rRNA is bound by 
the ribosomal protein RPL5, forming a pre-5S RNP complex, which is important for 5S 
rRNA stabilisation and for its localization in the nucleus. Furthermore, the levels of the 
5S rRNA are dependent on the levels of RPL5 (Deshmukh et al., 1993, Sloan et al., 
2013a), since the unbound 5S rRNA is highly unstable and gets degraded very rapidly. 
The 5S rRNA-RPL5 complex enters in the nucleolus where it is bound by the ribosomal 
protein RPL11, forming the mature 5S RNP (Sloan et al., 2013a), which is then 
integrated in the ribosome. 
 
 
11 
 
1.2.6. Recruitment of the 5S RNP in the large ribosomal subunit 
 
The 5S RNP gets integrated in the LSU in the nucleolus. The 5S rRNA is located in 
the central protuberance of the LSU. Interestingly, the 5S rRNA does not interact with 
any of the tRNAs in either the P or A site of the ribosome, and neither with any other 
factors during mRNA translation. However, its localization is important for connecting 
the tRNAs, elongation factors and peptidyl-transferase centre factors together 
(Dinman, 2005). Notably, mitochondria do not encode for a 5S rRNA and other factors 
are involved in the stabilisation of translation factors in the ribosome. It was, however, 
found that the 5S rRNA is imported from the nucleoplasm in the mitochondria 
(Magalhaes et al., 1998), but its functions during mitochondrial mRNA translation are 
still unknown. 
 
In yeast, the integration of the 5S RNP in the LSU is dependent upon the ribosome 
biogenesis factors Rrs1 and Rpf2p (Zhang et al., 2007). Using the yeast two-hybrid 
system, it was found that Rpf2p interact with RPL5 and RPL11 (Miyoshi et al., 2002, 
Morita et al., 2002). Furthermore, the structure of the Rrs1-Rpf2p complex was solved 
in the fungus Aspergillus nidulans, where it was shown that the Rrs1-Rpf2p complex 
interacts with the 5S rRNA-RPL5 complex, along with the ribosome biogenesis factor 
Rsa4, and that only Rpf2p interacts directly with the 5S rRNA, but not Rrs1 (Kharde et 
al., 2015). Similarly, in yeast, the Rrs1-Rpf2p complex contacts Rpl5, Rsa4 and the 
25S rRNA, which is important for the integration of the 5S RNP in LSU (Madru et al., 
2015). Furthermore, Symportin 1 (Syo1) also aids the recruitment of RPL5 and RPL11 
to the 5S rRNA in yeast (Calvino et al., 2015). RPL11 docks on helix 84 and the 5S 
rRNA interacts with Rpf2p, found in a complex with Rrs1, so that it is stabilised in the 
ribosome. These interactions result in the fixing of the 5S RNP in the pre-LSU 
complexes so that it does not rotate from the central protuberance in the mature LSU 
(Kharde et al., 2015). 
 
In humans, RRS1 and BXDC1 are the analogues of the Rrs1 and Rpf2p respectively. 
However, no interactions with the free 5S RNP were found after pull-down experiments 
(Sloan et al., 2013a). It was recently shown that RRS1 or BXDC1 knockdowns resulted 
in a reduction of RPL5 in the nucleolus, but only BXDC1 knockdown resulted in an 
altered RPL11 localization in the nucleolus. Furthermore, knockdowns of either RRS1 
or BXDC1 resulted in the accumulation of RPL5 and RPL11 in the nucleoplasm (Sloan 
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et al., 2013a). PICT1, a ribosome biogenesis factor, and RPL11 were shown to be 
required for the integration of the 5S RNP in the ribosome. Knockdowns of either PICT1 
or RPL11 resulted in a reduced incorporation of the 5S rRNA in the ribosome, whereas 
knockdowns of either RRS1 or BXDC1 had very little effect on the 5S rRNA ribosomal 
incorporation. Finally, knockdowns of PICT1, RPL11 or RRS1 resulted in a decreased 
LSU production, but only PICT1 and RPL11 knockdowns affected the 5S RNP 
recruitment to the ribosomal complexes (Sloan et al., 2013a). The exact functions of 
RRS1 and BXDC1 in humans are still unclear, whereas PICT1 is essential for the 
recruitment of the 5S RNP in the LSU (Sloan et al., 2013a). 
 
1.2.7. Small and large ribosomal subunit assembly and proofreading 
 
The majority of the ribosome assembly process takes place in the nucleus, with the 
first steps of ribosome biogenesis occurring in the nucleolus, and only the last 
maturation steps occurring in the cytoplasm. This ensures that no premature 
translation occurs in the cytoplasm before the ribosomes are formed correctly and 
efficiently (Zemp and Kutay, 2007). Furthermore, the binding of some ribosomal 
proteins on immature rRNAs is prevented by the association of ribosome biogenesis 
factors on the rRNA. For example, in yeast, Enp1 and Ltv1 ribosome biogenesis factors 
prevent the binding of ribosomal protein RPS10 on the 18S rRNA, and PNO1 prevents 
binding of RPS26 (Strunk et al., 2011). Surprisingly, these proteins do not show any 
sequence similarity to the SSU ribosomal proteins. Mrt4, another ribosome biogenesis 
factor, prevents binding of ribosomal protein P0 to 25S rRNA in yeast, by sequence 
homology. More specifically, Mrt4 is required for binding of P0 when the 25S rRNA is 
found at the right conformation, and P0 binding to the 25S rRNA triggers the release 
of Mtr4 (Rodriguez-Mateos et al., 2009). 
 
Thirdly, it was shown in yeast that the mature LSU is required for the last processing 
stages for the maturation of SSU in the cytoplasm (Lebaron et al., 2012, Lamanna and 
Karbstein, 2011). The mature 60S subunit is important for GTP hydrolysis of Fun12, 
the yeast homologue of the translation initation factor eIF5B. This is important for the 
binding of Nob1 endonuclease on the pre-SSU complexes, which cleaves the 20S 
rRNA, resulting in the production of the mature 18S rRNA. Blocking the binding of 
Fun12 to the LSU rRNA resulted in the inhibition of 20S rRNA cleavage (Lebaron et 
al., 2012). 
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In addition, the joining of the pre-60S and pre-40S subunits is blocked by ribosome 
biogenesis factors, until the mature complexes are formed. For example, Nmd3 
adaptor protein, which is required for nuclear export of the pre-60S complex (Sengupta 
et al., 2010) or Rei1 ribosome biogenesis factor, which is important for the maturation 
of the 60S complexes (Greber et al., 2016), prevent premature joining of the two 
subunits in yeast. Moreover, Tsr1 ribosome biogenesis factor fits in the 60S binding 
area of the pre-40S, blocking the association of the premature 60S (McCaughan et al., 
2016). Furthermore, Tif6p ribosome biogenesis factor binds to the 60S subunit surface 
in yeast, preventing 40S joining (Klinge et al., 2011). Release of Tif6p requires GTP 
hydrolysis, which is dependent on the GTPase Efl1p (Senger et al., 2001), with the aid 
of the guanine nucleotide exchange factor Sdo1 (Menne et al., 2007). The human 
homologue of Tif6p, eIF6, prevents joining of the human pre-60S and pre-40S 
complexes. The GTP hydrolysis-dependent release of eIF6 in humans is triggered by 
SBDS and EFL1 ribosome biogenesis factors (Finch et al., 2011). Finally, premature 
translation of cytoplasmic mRNAs is prevented by RIO2, TSR1 and NMD3 ribosome 
biogenesis factors in humans (Karbstein, 2013). 
 
1.2.8. Nuclear export 
 
The pre-60S and pre-40S complexes are exported from the nucleus to the cytoplasm 
via the nuclear pores by exportins. Exportin Crm1 (or XPO1) is necessary for the export 
of both pre-LSU and pre-SSU particles. Exportin 5 (Exp5) is also involved in the nuclear 
export of the pre-LSU, apart from Crm1 (Wild et al., 2010). Both Crm1 and Exp5 have 
a Ran GTP-dependent mechanism, where the nuclear export of the premature 
ribosomal subunits is catalysed by the hydrolysis of Ran-GTP to Ran-GDP (Johnson 
et al., 2002). 
 
The nuclear export of the pre-60S complexes is mainly dependent on Crm1, which 
binds to a nuclear export sequence (NES), consisting of a short leucine-rich motif 
(Hutten and Kehlenbach, 2007). However, no such signal is found on the pre-60S 
particles. For this reason, another protein, NMD3 (Nmd3p in yeast), is required for pre-
60S export (Sengupta et al., 2010). Nmd3p binds to the mature pre-60S subunit, which 
acts as an adaptor for Crm1 recruitment (Zemp and Kutay, 2007). Interestingly, Nmd3p 
does not bind to immature or misfolded pre-60S particles, providing an additional 
proofreading mechanism (Johnson et al., 2002). Another ribosome biogenesis protein, 
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called Arx1, also acts as an adaptor protein in yeast, like Nmd3p (Hung et al., 2008). 
Other proteins are also thought to be involved in the pre-60S export, but their exact 
roles are still unclear. For example, Rrp12p is a protein containing HEAT repeats, 
which are associated with nuclear export of other proteins and complexes (Schafer et 
al., 2003). It was proposed that Rrp12p is involved in nuclear export in yeast, since it 
was found to be bound on the pre-ribosomal complexes and depletion of Rrp12p 
resulted in nuclear export impairment (Oeffinger et al., 2004). Furthermore, Mtr2p, a 
protein involved in mRNA nuclear export, is thought to be involved in the nuclear export 
of pre-60S, since it was detected in these complexes (Nissan et al., 2002). 
 
Crm1 is the main exportin involved in the nuclear export of the pre-40S complexes as 
well. As with pre-60S, pre-40S particles also require protein adaptors, since no NES 
sequence was detected. However, Nmd3p was not found to be involved in pre-40S 
export. Instead, other proteins have been found to act as adaptors in yeast. Rio2p, a 
protein involved in the late maturation steps of SSU biogenesis (Vanrobays et al., 
2003), was predicted to act as a nuclear adaptor for pre-40S export (Zemp and Kutay, 
2007, Zemp et al., 2009), as it accumulated in the nucleus after Crm1 inhibition 
(Schafer et al., 2003). Furthermore, Dim2p and Ltv1p are two other potential protein 
adaptors found for pre-40S (Zemp and Kutay, 2007). Ltv1p is likely to facilitate the pre-
40S nuclear export, but it is non-essential for this (Seiser et al., 2006). Rrp12p is 
thought to be a potential adaptor protein for export of both subunits, since it was found 
to be associated with pre-40S and pre-60S complexes (Oeffinger et al., 2004). In 
humans, the main adaptor protein for pre-40S export is RIO2, since deletion of RIO2 
resulted in block of the final maturation and export of pre-40S because of recycling of 
trans-acting factors (Zemp et al., 2009), and TSR1 is also required (Carron et al., 
2011). Furthermore, late-binding ribosomal proteins, such as RPS15, RPS18, RPS5 
and RPS28, were also found to be involved in pre-40S nuclear export (Ferreira-Cerca 
et al., 2005). 
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1.3. Ubiquitin-ribosomal protein genes 
 
1.3.1. The importance of ubiquitin in the cell 
 
Ubiquitin (Ub) is a highly conserved, 76 amino acid-long peptide and highly abundant 
(Kimura and Tanaka, 2010), as it makes up 0.1-5% of all cellular protein (Ryu et al., 
2007). Ubiquitination is a reversible post-translational modification, which is essential 
for various cellular processes. The ubiquitin molecule is added on the substrate by E3 
ubiquitin ligases, where an isopeptide bond is formed between a lysine residue on the 
ubiquitin and a glycine residue on the protein (Pickart, 2001), which is cleaved by a 
group of proteases called de-ubiquitinases (Reyes-Turcu et al., 2009). Ubiquitin 
homeostasis is a tightly regulated process and it is estimated that mammals contain 
approximately 600 E3 ubiquitin ligases and 100 de-ubiquitinases (Li et al., 2008). 
 
The attachment of ubiquitin to other ubiquitin molecules or the protein substrate is 
dependent on ATP hydrolysis (Kimura and Tanaka, 2010). Firstly, the C-terminus of 
the ubiquitin molecule is activated by a formation of a Ub-adenylate intermediate, 
which then interacts with a cysteine residue of the E1 ubiquitin-activating enzyme 
forming a thiol-ester bond (Figure 1.4) (Pickart and Eddins, 2004). The ubiquitin is then 
transferred to a cysteine residue on the E2 ubiquitin-conjugating enzyme (Figure 1.4). 
Finally, the ubiquitin is attached to a specific lysine on the protein substrate by the 
facilitation of an E3 ubiquitin-ligase enzyme (Figure 1.4) (Pickart and Eddins, 2004). 
This takes place by binding of the E3 ligase to the ubiquitination signal on the substrate, 
followed by the ligation of the ubiquitin (Pickart, 2001). Interestingly, there is a huge 
number of the E3 ligases conferring substrate specificity (Hershko and Ciechanover, 
1998). Most E3 ligases contain a HECT (E6-AP carboxyl terminus) domain or a RING 
(really interesting new gene) domain (Pickart, 2001). 
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 Figure 1.4. Schematic representation of the ubiquitin transfer process. The 
ubiquitin molecule is indicated in yellow and the protein substrate is indicated in green. 
The E1 ubiquitin-activating enzyme is shown in dark grey, the E2 ubiquitin-conjugating 
enzyme in grey and the E3 ubiquitin-ligase in light grey. ATP hydrolysis is indicated by 
the release of AMP (Adapted from (Ardley and Robinson, 2005)). 
 
Mono-ubiquitination, the addition of one ubiquitin molecule on the protein substrate, is 
important for processes such as endocytosis and membrane trafficking (Ikeda and 
Dikic, 2008). For example, some transmembrane proteins are internalized in the cell 
after mono-ubiquitination (Miranda and Sorkin, 2007), such as some G-protein couple 
receptors (Tanowitz and Von Zastrow, 2002, Shenoy et al., 2001). Furthermore, mono-
ubiquitination has been found to be important in DNA damage repair pathways. For 
instance, lysine 63 on histone H2AX is ubiquitinated when DNA damage occurs, which 
is then recognized by DNA damage repair enzymes resulting in homologous-
recombination repair (Ikura et al., 2007). Moreover, ubiquitination of histones also 
affects gene regulation, since the chromatin structure is altered aiding in enhanced 
DNA transcription (Hammond-Martel et al., 2012). Finally, mono-ubiquitination was 
found to be important for cell-cycle regulation, by ubiquitination of cyclins, the cell cycle 
regulators (Teixeira and Reed, 2013), and apoptosis, by ubiquitination of the caspases 
involved in programmed cell death (Mukhopadhyay and Riezman, 2007, Huang et al., 
2000). 
 
On the other hand, poly-ubiquitination, the addition of multiple ubiquitin molecules on 
the substrate, is mainly involved in targeting the protein substrate for proteosomal 
degradation (Li and Ye, 2008). There are seven lysines on ubiquitin, where a poly-
ubiquitin chain is presumed to be formed by interaction with other ubiquitin molecules 
(Komander and Rape, 2012). The most well-studied is lysine 48 (K48), where poly-
ubiquitin chains are formed, consisting of at least four ubiquitins, leading to 
proteosomal degradation of the protein substrate (Hicke, 2001), which is important in 
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various cellular processes. Proteosomal degradation of a number of transcription 
factors or transcriptional activators leads to inhibition of gene transcription under 
certain physiological conditions (Lipford et al., 2005). Furthermore, proteins that are 
anomalously folded or damaged are targeted for proteosomal degradation (Lecker et 
al., 2006). For example, in cystic fibrosis, the mutant transmembrane protein CFTR is 
degraded and does not reach the cell membrane (Ward et al., 1995). Finally, poly-
ubiquitination is important for apoptosis, since the IAP protein family, which inhibits 
pro-apoptotic proteins (Deveraux and Reed, 1999), is targeted for proteosomal 
degradation leading to the activation of the apoptotic pathway (Lee and Peter, 2003). 
 
De-ubiquitinases are responsible for the cleavage of the peptide bond formed between 
ubiquitins or between the ubiquitin and the substrate, and they can be either cysteine 
proteases or zinc metalloproteases (Nijman et al., 2005). There are five classes of de-
ubiquitinases: the ubiquitin C-terminal hydrolases (UCHs), the ubiquitin-specific 
proteases (USPs), the ovarian tumour proteases (OTUs) and the Josephins, which are 
cysteine proteases, and the JAB1/MPN/MOV34 (JAMMs), which are zinc 
metalloproteases (Komander et al., 2009). The cysteine proteases contain three 
conserved amino acids for the nucleophilic attach of the catalytic cysteine residue to 
the peptide bond formed (Storer and Menard, 1994, Komander et al., 2009), whereas 
the zinc metalloproteases use two zinc ions for the recruitment and activation of a water 
molecule, which attacks the peptide bond (Sato et al., 2008). The de-ubiquitinases 
have diverse functions in the cell, including the processing of the ubiquitin precursors 
after translation, the recycling of ubiquitin and the removal of ubiquitin from the protein 
substrates for proteosomal degradation rescue (Komander et al., 2009). De-
ubiquitinases show some substrate specificity between the different types of 
ubiquitination and the type or structure of the different chain linkages (Komander et al., 
2009), but the exact mechanisms for this are still unclear. For instance, UCHs are 
known to cleave mono-ubiquitinated, but not poly-ubiquitinated chains (Pfoh et al., 
2015), and members of the UPS (Hu et al., 2005) and OTU (Edelmann et al., 2009) 
families have been described to be specific for K48 ubiquitinated chains (Komander et 
al., 2009). 
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1.3.2. RPRS27a- and RPL40-ubiquitin fusion ribosomal proteins 
 
In mammals, there are four Ub-encoding genes. Ubb and Ubc encode for a 4- and 9-
tandem repeat array of ubiquitin respectively, whereas RPS27a (Uba52 in mouse) and 
RPL40 (Uba80 in mouse) are produced as ubiquitin-ribosomal protein precursors, 
encoding for one ubiquitin (Redman and Rechsteiner, 1989). In humans, the majority 
of the ubiquitin pool is made up by the ubiquitins transcribed by Ubb and Ubc genes. 
In contrast, in yeast, only one gene, UBI4, encodes for a poly-ubiquitin chain, and the 
ubiquitin encoded by the ubiquitin-fusion ribosomal proteins genes UBI1, UBI2 and 
UBI3 make up the majority of the ubiquitin pool (Finley et al., 1987). The ubiquitin in 
the cell is not produced in excess, but the levels of the free ubiquitin are sufficient for 
the cellular functions (Kimura and Tanaka, 2010). 
 
RPS27a and RPL40 are produced as ubiquitin-ribosomal protein precursors 
throughout eukaryotes, which are then cleaved to separate the ribosomal proteins and 
ubiquitin component (Kimura and Tanaka, 2010), but their functions and significance 
remains unclear. RPS27a and RPL40 are part of the small and large ribosomal subunit 
respectively (Kimura and Tanaka, 2010), but they are not produced from 5’ TOP 
mRNAs as most of the ribosomal proteins (Levy et al., 1991). However, not much is 
known about their functions in humans or yeast. RPS27a was firstly identified as a 
ribosomal protein in 1989 (Redman and Rechsteiner, 1989) and the RPS27a protein 
was later found to be expressed in high levels in solid tumours, and up-regulated in 
patients with chronic myeloid leukaemia (CML) or acute myeloid leukaemia (AML). 
Confirming its role in CML, the expression of RPS27a in the CML cell line K562 was 
found to be elevated, which induced cell cycle and proliferation, while inhibiting 
apoptosis (Wang et al., 2014). Finally, RPS27a was found to be involved in the 
regulation of the tumour suppressor p53, which is normally targeted for proteosomal 
degradation by the E3 ubiquitin ligase MDM2. Upon ribosomal stress, RPS27a was 
found to directly interact with MDM2, inhibiting its activity, resulting in p53 activation 
(Sun et al., 2011). These studies indicate that RPS27a could be an important target for 
future anti-cancer treatment therapies. 
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1.4. Modifications of ribosomal RNA 
 
1.4.1. Pseudouridylation and methylation of rRNA  
 
The most prelavent rRNA modifications are the 2’-O-methylation and 
pseudouridylation. It is hypothesized that there are more than 100 2’-O-methylation 
sites and around 100 pseudouridines in human rRNAs (Maden, 1990). These 
modifications are mainly found in the well-conserved regions of the ribosome, such as 
the peptidyl-transferase centre and the decoding centre (Decatur and Fournier, 2002). 
Most individual modifications are not essential, but loss of the total 2’-O-methylation or 
pseudouridines is lethal (Higa-Nakamine et al., 2012, Decatur and Fournier, 2002) and 
clusters of modifications are important for the cell (Gigova et al., 2014, Esguerra et al., 
2008). 
 
2’-O-methylation involves the addition of a methyl group on the 2’ hydroxyl group of 
the ribose of the rRNA by methyltransferases (Figure 1.5A). This modification is 
important for the stability of single base pairs, since there are increased base-base 
interactions in the presence of a methyl group at 2’-OH, because of its ability to change 
the polarization of the bases (Agris, 1996). The stability of single base pairs is further 
aided by the presence of the methyl group, since it prevents hydrolysis from various 
nucleases because of chemical and steric block (Helm, 2006). Furthermore, 2’-O-
methylation encourages the formation of a thermodynamically stable RNA structure 
(Kierzek and Kierzek, 2003). Pseudouridylation involves the isomerization of uridine to 
pseudouridine (Ψ) by pseudouridine synthases (Figure 1.5B). Pseudouridine is less 
flexible than uridine due to its conformation (Charette and Gray, 2000). Furthermore, 
in uridine, the N1 atom of the uracil interacts with the the C1 atom of the ribose, 
whereas in pseudouridine the C5 atom of the uracil interacts with the C1 atom of the 
ribose (Figure 1.5B). This allows pseudouridine to form more stable interactions, 
because of the presence of an additional hydrogen donor of N1 atom (Charette and 
Gray, 2000). 
 
The 2’-O-methylation is catalyzed by the box C/D snoRNPs in eukaryotes, whereas 
pseudouridylation is catalyzed by the H/ACA snoRNPs (Watkins and Bohnsack, 2011). 
The crystal structures of the snoRNPs have been solved in archaea and the eukaryotic 
structures are predicted based on sequence similarities of the snoRNAs and proteins. 
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In bacteria, even though the rRNA modifcations are highly conserved, they are 
catalyzed by protein enzymes instead of snoRNP complexes (Bachellerie et al., 2002). 
Therefore, it is widely believed that the eukaryotic snoRNP complexes were most likely 
evolved from archaea, rather than bacteria, due to structural and mechanistical 
similarities (Bachellerie et al., 2002). 
Figure 1.5. Schematic representation of methylation and pseudouridylation. (A) 
The addition of a methyl group (shown in red) on the 2’ OH of the ribose by a 
methyltransferase. (B) The isomerization of uridine to pseudouridine (Ψ) by a 
pseudouridine synthase. The atom positions on the uracil rings and the Watson-Crick 
surface are indicated (Adapted from: (Kiss and Jady, 2004)). 
 
1.4.2. The Box C/D snoRNP 
 
The archaeal box C/D sRNP consists of the proteins L7Ae (NHPX or 15.5K in humans, 
Snu13 in yeast), Nop5 (Nop56, Nop58 in eukaryotes) and Fibrillarin (Nop1 in yeast) 
(Watkins and Bohnsack, 2011), as well as a sRNA component (Figure 1.6). Fibrillarin 
is a methyltransferase and it is essential for the catalysis of 2’-O-methyation of the 
rRNA (Watkins and Bohnsack, 2011). The archaeal and eukaryotic box C/D snoRNAs 
contain a conserved C/D box at the 5’ and 3’ ends of the RNA, and a C’/D’ box, which 
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is found in the middle of the RNA (Watkins and Bohnsack, 2011). A stem-loop 
structure, called the K-turn, is formed by the C/D motif, whereas another stem-loop 
structure, called the K-loop, is formed by the C’/D’ motif (Reichow et al., 2007). 
 
The archaeal box C/D sRNPs are thought to contain one copy of the sRNA, although 
there is some debate about this, and two copies of each of the box C/D proteins. After 
the crystal structure of the archaeal complex was solved (Bleichert et al., 2009), the 
two Nop5 molecules were found to interact forming a homo-dimer (Lin et al., 2011), 
providing the basis for the formation of the box C/D sRNP (Figure 1.6). The C-terminal 
of Nop5 interacts with L7Ae, which binds the K-turn motif of the sRNA, whereas the N-
terminal of Nop5 interacts with Fibrillarin, so that the active site of Fibrillarin is in close 
proximity to the substrate ribose (Lin et al., 2011) (Figure 1.6). It is the L7Ae that initially 
binds the K-turn motif of the sRNA (Kuhn et al., 2002), and the L7Ae-snoRNA complex 
is then recognized by the Nop5/Fibrillarin complex, which subsequently binds on the 
sRNA (Omer et al., 2002). The modification nucleotide is selected by base-pairing to 
the target site and the target nucleotide base pairs in a proximity of 5 base pairs from 
the D or D’ box (Kiss-Laszlo et al., 1996). 
 
 
 
 
 
 
 
Figure 1.6. Graphical representation of the 
archaeal box C/D sRNP. Nop5 is indicated in blue, 
Fibrillarin in orange and L7Ae in grey. The box C/D 
snoRNA is shown in black and the substrate RNA is 
shown in red. The target nucleotide in shown in 
yellow (From: (Watkins and Bohnsack, 2011)). 
 
 
The structure of the eukaryotic box C/D snoRNP has been recently solved and it was 
shown that it is highly similar to the archaeal complex (Kornprobst et al., 2016). In 
eukaryotes, the Nop56/Nop58 heterodimer is formed instead of the Nop5 homodimer, 
which is predicted to bind at the same positions on the snoRNA as the Nop5 dimer 
(Aittaleb et al., 2003). Nop56 is more often found to bind the C/D motif, whereas Nop58 
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most often binds the C’/D’ motif (Cahill et al., 2002) (van Nues et al., 2011). On the 
other hand, 15.5K in humans or Snu13 in yeast was initially found to bind the K-turn 
formed by the C/D motif (Szewczak et al., 2005), but not the K-loop. Recent data have 
indicated that Snu13 in yeast also binds the C’/D’ motif (Qu et al., 2011); hence, it is 
possible that Snu13 can stably bind the C/D motif and, in the presence of Nop56, the 
C’/D’ motif. Snu13 interacts with the snoRNA component first in eukaryotes (Rothe et 
al., 2014) (Dobbyn and O'Keefe, 2004) and it is predicted that Fibrillarin (Nop1 in yeast) 
is near the catalytic side, similarly to archaea. 
 
A number of box C/D snoRNAs are involved in rRNA methylation. For example, U16 
is involved in the methylation of the 18S rRNA, whereas U24 snoRNA is predicted to 
guide the methylation of nucleotides of the 28S rRNA (Kiss-Laszlo et al., 1996). 
Furthermore, some box C/D snoRNAs were found to be involved in both rRNA 
processing and methylation, such as U14 which is involved in 18S rRNA processing 
(Li et al., 1990, Enright et al., 1996) and methylation (Kiss-Laszlo et al., 1996) in yeast. 
Finally, a number of box C/D snoRNAs are solely involved in rRNA processing. U3 
snoRNA is involved in 18S rRNA processing in eukaryotes (Phipps et al., 2011) and 
U22 is involved in 18S rRNA in Xenopus oocytes (Tycowski et al., 1994), whereas U8 
is involved in 28S rRNA processing in Xenopus oocytes (Peculis and Steitz, 1993). 
Most of the box C/D snoRNAs contain complementary sequences to the rRNA 
substrate, which are important not only for guiding methylation, but also for rRNA 
processing and folding (Henras et al., 2008). Interestingly, there are more than 200 
box C/D snoRNAs, but only 100 2’-O-methylation sites (Jorjani et al., 2016). 
 
1.4.3. The H/ACA snoRNP 
 
The H/ACA sRNP complex consists of the proteins Dyskerin (Cbf5 in yeast and 
archaea), NOP10, NHP2, GAR1 and an RNA component (Figure 1.7) (Kiss et al., 2010, 
Watkins and Bohnsack, 2011). Dyskerin is the pseudouridine synthase of the complex, 
important for the isomerisation of uridine to pseudouridine (Lafontaine et al., 1998, 
Zebarjadian et al., 1999). All of the H/ACA RNAs have a similar structure and two very 
well conserved motifs: the ANANNA motif (called the H box), found in the hinge region 
(Balakin et al., 1996), and the ACA motif (Ganot et al., 1997b) found three positions 
downstream from 3’ end (Balakin et al., 1996, Meier, 2005). The H/ACA snoRNA forms 
a stem-loop structure where the nucleotide for catalysis is found, flanked by P1 and P2 
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stems, and a loop structure, called the K-loop or K-turn (Figure 1.7). Most of structural 
and biochemical studies on the H/ACA sRNP have been performed on archaeal 
proteins, where it was found that most H/ACA RNAs are found as a single hairpin 
structure and the eukaryotic complexes are thought to be similar (Watkins and 
Bohnsack, 2011). 
 
In archaea, it was found that the Cbf5, Nop10 and L7Ae (Nhp2) bind that H/ACA RNA 
directly, whereas Gar1 does not (Duan et al., 2009, Liang et al., 2009). Cbf5 binds the 
ACA motif and the P1 stem of the H/ACA RNA (Figure 1.7A), whereas L7Ae itneracts 
with the K-loop or K-turn formed at the top of the snoRNP (Baker et al., 2005, 
Rozhdestvensky et al., 2003). The P2 stem loop of the H/ACA RNA is bound by the 
surface formed after interactions between Cbf5, Nop10 and L7Ae (Figure 1.7A) (Li and 
Ye, 2006). In contrast, Gar1 does not bind the H/ACA RNA directly. Rather, it interacts 
with a conserved motif of Cbf5 called the thumb loop (Figure 1.7A). The interaction of 
Gar1 with the thumb loop of Cbf5 is important for keeping the substrate in place during 
catalysis and for the release of the final product (Duan et al., 2009). 
 
Based on the solved archaeal structure, the proposed model for the eukaryotic H/ACA 
snoRNP complex suggests that there are two copies of each of the proteins on the 
H/ACA RNA, where the two Dyskerin copies interact with each other (Figure 1.7B) 
(Watkins and Bohnsack, 2011). Furthermore, it was found that the eukaryotic H/ACA 
RNAs do not contain a K-turn motif and, therefore, NHP2 does not bind independently 
of Dyskerin, as in archaea. It is thought that binding of Dyskerin and NOP10 to the 
H/ACA RNA, and the protein-protein interactions between them are important for 
NHP2 binding in eukaryotes (Watkins and Bohnsack, 2011). In yeast, it was shown 
that the Cbf5-Nop10-Gar1 complex is structurally similar to the archaeal complex (Li 
et al., 2011), further confirming the proposed model. Similarly, in eukaryotes, GAR1 
interacts with Dyskerin but not with the H/ACA snoRNA, and is important for the 
organization of the complex to help keep the substrate in place during catalysis and for 
the release of the for the final product (Duan et al., 2009). 
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 Figure 1.7. Graphical representation of the H/ACA snoRNP. (A) The archaeal 
H/ACA snoRNP consists of Cbf5 (orange), Nop10 (green), L7Ae (grey) and Gar1 
(blue). The H/ACA snoRNA is shown in black and the ACA motif, the P1 and P2 loops 
are indicated. The substrate rRNA is shown in red and the target nucleotide is indicated 
by Ψ, showing pseudouridylation. (B) The human H/ACA snoRNP consists of Dyskerin 
(orange), NOP10 (green), NHP2 (grey) and GAR1 (blue). The H/ACA snoRNA is 
shown in black and the target rRNA is shown in red, with the target nucleotide to be 
marked with Ψ/ The H box is indicated by ANANNA sequence and the ACA motif is 
shown (From: (Watkins and Bohnsack, 2011)). 
 
Most H/ACA snoRNAs are required for rRNA modification. For example, U64 H/ACA 
snoRNA is required for pseudouridylation of the 28S rRNA, whereas U66 was found 
to be guide pseudouridylation of the 18S rRNA (Ganot et al., 1997a). However, some 
H/ACA snoRNAs were shown to be involved in rRNA processing rather than 
modification. For example, U17 (snR30 in yeast) is important in 18S rRNA processing. 
Depletion of U17 in frog oocytes caused the accumulation of the 20S rRNA precursor, 
indicating that it is required for the 5’ end processing for the production of the mature 
18S rRNA (Mishra and Eliceiri, 1997), which was similar to the phenotype shown in 
yeast (Morrissey and D.Tollervey, 1993, Atzorn et al., 2004). In particular, snR30 in 
yeast base pairs directly with 18S rRNA, and this interaction is essential for 18S rRNA 
processing and production (Fayet-Lebaron et al., 2009). Furthermore, the human U17 
H/ACA snoRNA has sequence similarity with its yeast homologue snR30 (Atzorn et al., 
2004) and was found to have direct interactions with 18S rRNA precursors (Rimoldi et 
al., 1993), indicating a role in 18S rRNA processing. Another example of a H/ACA 
snoRNA not involved in modification is snR10 in yeast, which was found to be involved 
in 18S rRNA processing (Tollervey, 1987). Most of the H/ACA snoRNAs have 
complementary sequences to rRNA, which are important for both the modification and 
processing of the substrate rRNA (Henras et al., 2008). 
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1.4.4. Other functions of the H/ACA RNP 
 
The H/ACA RNP is also a component of other RNP complexes in the cell and are 
predicted to be important for pre-mRNA splicing, by pseudouridylation of the small 
nuclear RNAs, and telomere maintenance, as well as ribosome biogenesis. It is also 
interesting that some H/ACA snoRNAs, called orphan snoRNAs, do not contain 
complementary sequences to any of the rRNA targets, as box C/D RNPs (Cavaillé et 
al., 2000). 
 
The H/ACA RNP guides the pseudouridylation of the small nuclear (sn)RNAs as a 
scaRNP, which are key players in pre-mRNA splicing for the production of the mature 
mRNA. The H/ACA scaRNP was found or predicted to be involved in the 
pseudouridylation of U1, U2, U4 and U5 snRNAs (Darzacq et al., 2002). For example, 
the U100 scaRNA is predicted to be important for the pseudouridylation of U54 in U2 
snRNA and U53 of U5 snRNA (Kiss et al., 2002, Schattner et al., 2006). Most scaRNAs 
contain H box and ACA motifs, such as U92 (Darzacq et al., 2002) and U93 (Kiss et 
al., 2002), which contain one and two H/ACA box domains respectively (Lestrade and 
Weber, 2006). However, some scaRNAs were also identified that contained both box 
C/D and H/ACA box domains, such as U85 (Jady and Kiss, 2001) and U87 (Darzacq 
et al., 2002), or only box C/D motifs, such as U90 and U91 (Darzacq et al., 2002). The 
H/ACA scaRNP complexes localize mainly to Cajal bodies, where the snRNPs are 
produced. This is achieved by binding of the Cajal body RNA chaperon protein TCAB1 
on the H/ACA scaRNP (Figure 1.8), which aids the localization of the complex in Cajal 
bodies (Tycowski et al., 2009). 
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 Figure 1.8. Schematic representation of the functions of the H/ACA RNP. The 
human H/ACA RNP consists of Dyskerin (orange), NOP10 (green), NHP2 (grey), 
GAR1 (blue) and an RNA component (black), and is involved in ribosome biogenesis, 
mRNA splicing and telomere maintenance. The Cajal-body chaperone protein TCAB1 
is shown in red and the protein component of telomerase (TERT) is show in light blue 
 
The H/ACA RNP is also part of the telomerase RNP and was found to have an 
important role in telomere maintenance (Figure 1.8) (Meier, 2005). Telomerase is a 
ribonucleoprotein enzyme, which is important for the addition of DNA sequence 
repeats at the telomeric ends. Telomerase consists of a protein component (hTERT) 
and an RNA component (hTR or TERC) which acts as a template (Feng et al., 1995). 
The RNA chaperone TCAB1 is associated with the telomerase complex for the 
localization of the H/ACA RNP complex on telomerase (Figure 1.8) (Stern et al., 2012). 
The H/ACA RNP and the Shelterin complex, which consists of six proteins (TRF1, 
TRF2, POT1, RAP1, TIN2, TPP1) (Xin et al., 2008), are important for the assembly 
and the stability of the telomerase complex (Meier, 2005, Podlevsky et al., 2008). 
Furthermore, Dyskerin may also play a functional role in telomere assembly, since 
mutations in Dyskerin were shown to cause a decreased accumulation of TERC 
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leading to telomere defects (Brault et al., 2013), which were restored after the addition 
of the catalytic domain of Dyskerin (Machado-Pinilla et al., 2012). 
 
1.4.5. The pseudouridine synthase Dyskerin 
 
Dyskerin (Cbf5 in yeast, NOP60B in Drosophila melanogaster), the pseudouridine 
synthase of the H/ACA RNP, is a 58kD evolutionary conserved protein (Angrisani et 
al., 2014). Cbf5 in yeast (Cadwell et al., 1997) and NOP60B in Drosophila (Giordano 
et al., 1999) were the first to be identified in being involved in rRNA processing and 
pseudouridylation. Later on, mutations on the human DKC1 gene, which encodes for 
Dyskerin, were identified in X-linked Dyskeratosis Congenita (DC) patients, a rare 
genetic disease (Podlevsky et al., 2008). Dyskerin is a highly conserved protein 
evolutionarily, especially the aspartic acid residue important for its catalytic activity. 
Furthermore, mutations on the yeast Cbf5 gene were rescued by expression of either 
the Drosophila (Phillips et al., 1998) or rat (Yang et al., 2000) Dyskerin, also underlying 
its high conservation. In addition, the protein levels of Dyskerin were found to be 
elevated in different neuroblastoma cell lines independently of the telomerase 
functions, showing that Dyskerin might also have functions outside the H/ACA RNP 
(O'Brien et al., 2016a). 
 
Dyskerin consists of multiple domains: the nuclear localization signals, the Dyskerin-
specific domain, the TruB and the PUA domain. There are two nuclear localization 
signals (NLS), one at the N-terminus and one at the C-terminus of the protein (Figure 
1.9), to ensure the nuclear, and nucleolar, localization of Dyskerin. In humans, there is 
a small extension of approximately 30 amino acids in the N-terminal NLS, which is not 
found in yeast Cbf5 (Angrisani et al., 2014). This indicates that the N-terminal NLS may 
have additional roles in humans, which is further supported by the identification of a 
few mutations in this domain, giving rise to X-linked DC (Podlevsky et al., 2008). 
 
Dyskerin contains a Dyskerin-specific domain (Figure 1.9), which is conserved 
amongst the Dyskerin protein family, but its functions are still unknown (Angrisani et 
al., 2014). Mutations in this domain have been identified in DC patients (Podlevsky et 
al., 2008), showing that it might be important for the function or structure of Dyskerin. 
In addition, TruB is the catalytic domain of Dyskerin (Figure 1.9) important for its 
pseudouridylation activity (Angrisani et al., 2014). A highly conserved aspartic acid is 
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found in this domain (D125 in humans, D96 in yeast) (Figure 1.9), required the 
isomerization of uridine to pseudouridine (Cerrudo et al., 2014). Inactivation of the 
catalytic activity of Dyskerin by mutation of D125 site does not support growth in yeast 
(Zebarjadian et al., 1999). Finally, Dyskerin contains a PUA domain (Figure 1.9), which 
recognizes and binds the H/ACA snoRNA component of the H/ACA RNP (Angrisani et 
al., 2014). Interestingly, a few mutations in the PUA domain have been linked with X-
linked DC, whereas only two mutations, S121G and R158W, in the TruB domain have 
been identified in X-linked DC patients (Figure 1.9) (Podlevsky et al., 2008). It is likely 
that many mutations in the TruB domain of Dyskerin completely block the activity of 
Dyskerin, resulting in cell death and, therefore, cannot be identified. 
Figure 1.9. Schematic representation of the domains of Dyskerin. The nuclear-
localization signals (NLS) are shown in grey, the Dyskerin-specific domain in green, 
the TruB catalytic domain in red and the PUA RNA-binding domain in light blue. The 
conserved catalytic aspartic acid is indicated (D125 in humans), as well as the 
mutations S121G and R158W found in X-linked DC patients (Adapted from: (Angrisani 
et al., 2014)). 
 
1.5. Ribosomopathies 
 
1.5.1. Introduction 
 
Ribosomopathies are rare genetic diseases caused by mutations on genes encoding 
ribosomal proteins or ribosome biogenesis factors (Narla and Ebert, 2010). There are 
18 ribosomopathies characterized, including Diamond-Blackfan Anaemia (DBA), 5q 
syndrome, Treacher-Collins (TC) syndrome, Dyskeratosis Congenita (DC), 
Shwachman-Diamond Syndrome (SDS), Cartilage Hair Hypoplasia (CHH) and Bowen-
Conradi syndrome (Table 1.1). Ribosomopathies arise due to mutations in genes 
encoding for SSU ribosomal proteins (Lipton and Ellis, 2010, Ebert et al., 2008b), LSU 
ribosomal proteins (Cmejla et al., 2009) or ribosome biogenesis factors, such as 
TCOF1 (Gonzales et al., 2005, Weiner et al., 2012), Dyskerin (Heiss et al., 1998, 
Knight et al., 2001, Angrisani et al., 2014) or SBDS (Boocock et al., 2003). 
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Table 1.1. Clinical representation of Ribosomopathies. The table presents the most 
well-studied Ribosomopathies Diamond-Blackfan Anaemia, 5q syndrome, Treacher-
Collins syndrome, Dyskeratosis Congenita, Shwachman-Diamond Syndrome, 
Cartilage Hair Hypoplasia and Bowen-Conradi syndrome. The prevalence, the genes 
mutated, the clinical manifestations, the cancer risk and the p53 involvement in each 
ribosomopathy are shown (Adapted from: (Narla and Ebert, 2010)). 
 
Interestingly, even though mutations in genes encoding for different proteins involved 
in different stages of ribosome biogenesis result in ribosomopathies, most patients 
present with similar phenotypes. These include macrocytic anaemia, skeletal defects 
and pre-disposition to cancer, especially acute myeloid leukaemia (AML) (Table 1.1) 
Ribosomopathy Prevalence Gene 
defect 
Clinical 
manifestations 
Cancer risk p53 
involvement 
Diamond-
Blackfan anaemia 
1:100,000 to 
1:200,000 
live births 
RPS19, 
RPS24, 
RPS17, 
RPS7, 
RPS15, 
RPS27A, 
RPL36, 
RPL35A, 
RPL5, 
RPL11 
Hypoplastic 
macrocytic 
anaemia 
Skeletal, 
urogenital and 
cardiac defects 
Short stature 
AML 
MDS 
osteosarcoma 
p53-
dependent 
anaemia 
5q syndrome Less than 1 
in 200,000 
RPS14 Macrocytic 
anaemia 
MDS 
AML 
p53-
dependent 
anaemia 
Treacher-Collins 
Syndrome 
1 in 50,000 
live births 
TCOF1, 
POLR1C, 
POLR1D 
Craniofacial 
anomalies 
Hearing 
difficulties 
None reported p53-
dependent 
craniofacial 
defects 
Dyskeratosis 
Congenita 
1 in 1million 
people 
DKC1, 
NOP10, 
NHP2, 
TERT, 
TERC, 
TINF2 
Cytopenias 
Anaemia 
Skin 
hyperpigmentati
on 
Nail dystrophy 
Oral leukoplakia 
AML 
Head and 
neck tumours 
p53-
dependent 
anaemia 
Shwachman-
Diamond 
Syndrome 
1 in 50,000 
births 
SBDS Exocrine 
pancreatic 
insufficiency 
Neutropenia 
Neurocognitive 
impairment 
Liver 
abnormalities 
MDS 
AML 
p53-
dependent 
hematopoieti
c defects 
Cartilage Hair 
Hypoplasia 
1 in 1,300 
(Old Older 
Amish), 1 in 
20,000 
(Finnish 
descent)  
RMRP Short stature 
Bone 
deformities 
Hair growth 
abnormalities 
Non-Hodgkin 
Lymphoma 
Basal cell 
carcinoma 
p53-
dependent 
symptoms 
Bowen-Conradi 
syndrome 
1 in 355 
births 
(Hutterite 
population) to 
1 in 1million 
EMG1 Growth 
retardation 
Early childhood 
death 
None reported None 
reported 
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(Narla and Ebert, 2010). Despite the fact that all tissues require an efficient ribosome 
biogenesis pathway, it is clear that ribosome biogenesis defects mostly affect the 
haematopoietic cells after embryonic development, as seen by ribosomopathy patients 
as well as animal models (Yelick and Trainor, 2015). Furthermore, the tumour 
suppressor p53 was found to be involved in the development of some of the 
phenotypes in animal models (Amsterdam et al., 2004, Jaako et al., 2015) (Table 1.1), 
which is directly regulated by ribosome biogenesis defects (Golomb et al., 2014), as 
discussed later on. Surprisingly, not much is known about the levels of p53 in 
ribosomopathy patients, as most of our knowledge on p53 involvement comes from 
cell and animal models. 
 
1.5.2. Diamond-Blackfan Anaemia 
 
Diamond-Blackfan Anaemia is a congenital bone marrow failure syndrome, which 
presents with macrocytic anaemia and, sometimes, short stature (Delaporta et al., 
2014), that is estimated to affect 4-5 cases per million births (Narla and Ebert, 2010). 
Approximately 30-50% of the patients present with craniofacial and limb abnormalities, 
similar to TC syndrome patients (Yelick and Trainor, 2015). Diamond-Blackfan 
anaemia is caused by mutations in genes encoding for SSU or LSU ribosomal proteins; 
indeed rRNA processing defects are used for DBA diagnosis (Ellis, 2014). The main 
therapeutic strategy for DBA is the use of steroids (Khanna-Gupta, 2013). However, 
this cannot be maintained in most cases, hence regular blood transfusions are needed, 
and bone marrow transplantation is frequently needed (Vlachos et al., 2001). 
 
Diamond-Blackfan anaemia patients often have a family history and most cases in an 
autosomal dominant manner (Narla and Ebert, 2010). The most commonly mutated 
gene is RPS19 (Lipton and Ellis, 2010), but mutations on other genes encoding for the 
SSU proteins RPS24, RPS17, RPS7 and RPS15, or LSU proteins RPL35A, RPL5, 
RPL11 and RPL36 have also been identified (Cmejla et al., 2009, Lipton and Ellis, 
2010). Patients with mutations on RPL5 were found to have higher frequency of 
physical abnormalities, and patients with RPL11 mutations were found to have more 
thumb abnormalities than those with RPS19 mutations (Gazda et al., 2008). Hence, 
mutations in different genes may cause different phenotypes in DBA patients. 
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DBA presents with an increased risk of development of myelodysplastic syndrome 
(MDS), AML or osteosarcoma (Table 1.1). In mouse models resembling DBA 
phenotypes, some symptoms were found to be dependent on the levels of the tumour 
suppressor p53. More specifically, the development of anaemia in these models was 
shown to be dependent upon the interaction of the ribosome assembly intermediate 
5S RNP with MDM2, the main p53 suppressor in the cell (discussed later) (Jaako et 
al., 2015), suggesting that ribosome biogenesis defects are linked to cancer 
development in these patients. 
 
1.5.3. 5q- syndrome 
 
5q- syndrome has been characterized as a subtype of myelodysplastic syndrome 
(MDS) (Narla and Ebert, 2010) and it is caused by a deletion on the long arm of 
chromosome 5 (Van den Berghe et al., 1974). 5q- syndrome is characterized by severe 
macrocytic anaemia and it is presented with a lower rate of progression to AML in 
comparison to other MDS patients (Vardiman et al., 2002). The 5q-syndrome 
symptoms can be effectively managed with the drug Lenalidomide (List et al., 2006), 
which promotes erythropoiesis for production of healthy blood cells (Ebert et al., 2008a, 
Narla and Ebert, 2010, Wei et al., 2009). 
 
5q- syndrome was identified to be caused by haploinsufficiency of RPS14 gene (Ebert 
et al., 2008b), which encodes for the small ribosomal protein RPS14. 
Haploinsufficiency of RPS14 was shown to cause defective SSU biogenesis and 
impaired erythropoiesis, probably due to ribosome biogenesis defects (Ebert et al., 
2008b). As with DBA syndrome, the tumour suppressor p53 was found to be involved 
in 5q- syndrome as well. There was a high expression of p53 in erythroid cells of 5q-
syndrome patients, where the p53 pathway was found to be deregulated (Pellagatti et 
al., 2010). Finally, p53 gene inactivation in mice models having RPS14 
haploinsufficiency rescued the erythroid defects observed (Yelick and Trainor, 2015). 
 
1.5.4. Treacher-Collins syndrome 
 
Treacher-Collins (TC) syndrome is an autosomal dominant disorder and it is presented 
once every 50,000 live births (Posnick and Ruiz, 2000). Patients with TC syndrome 
have no haematological abnormalities, but they present with craniofacial defects as 
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well as problems with brain development and hearing (Narla and Ebert, 2010). These 
craniofacial abnormalities can be managed by doctors with a series of surgeries and 
speech development therapies (Sakai and Trainor, 2009). 
 
Mutations on TCOF1 gene, which encodes for treacle protein, have been found to 
cause the development of Treacher-Collins syndrome (Weiner et al., 2012). Treacle is 
involved in ribosome biogenesis, in the methylation of the rRNA precursors, as well as 
transcription of the rDNA. Furthermore, it was found to be localized in the nucleolus 
along with the upstream binding factor (UPF) and RNA polymerase I (Gonzales et al., 
2005, Valdez et al., 2004). Mutations on the RNA polymerase I and III subunits were 
also found to cause TC syndrome (Yelick and Trainor, 2015). 
 
The p53 tumour suppressor was found to be involved in TC syndrome pathogenesis. 
Mouse models with the TC phenotype were found to have an upregulated p53, 
resulting in the apoptosis of almost 25% of the neuronal crest cells (NCC) when TCOF1 
was mutated (Dixon et al., 2006). Furthermore, inhibition of p53 in TCOF1-deficient 
mice prevented the development of craniofacial defects (Jones et al., 2008), further 
providing a link between p53 and ribosomopathies. 
 
1.5.5. Dyskeratosis Congenita 
 
Dyskeratosis Congenita (DC) is a rare genetic disorder with clinical manifestations 
including bone marrow failure, nail dystrophy, immune deficiencies, tumours (Mason 
and Bessler, 2011). Hoyeraal-Hreidarsson Syndrome is a more severe variant of DC 
(Yaghmai et al., 2000), which is characterized by intra-uterine growth retardation, 
microcephaly, mental retardation, mucocutaneous lesions and a higher mortality rate 
(Ohga et al., 1997, Yaghmai et al., 2000). DC patients present with shortened 
telomeres, which is detected by clinical testing (Savage, 2009). 
 
DC is acquired with different modes of inheritance (Table 1.2). X-linked DC arises due 
to mutations in DKC1 gene (Table 1.2), which encodes of Dyskerin, the pseudouridine 
synthase of the H/ACA snoRNP complex (Heiss et al., 1998, Knight et al., 1998). 
Mutations in the genes encoding for the other H/ACA proteins NOP10 (Walne et al., 
2007) and NHP2 (Vulliamy et al., 2008) give rise to the autosomal recessive form of 
DC (Table 1.2). No mutations in the gene encoding for GAR1 have been identified so 
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far. The autosomal dominant form of DC arises due to mutations in the genes encoding 
for the protein (TERT) (Armanios et al., 2005) or the RNA (TERC) (Vulliamy et al., 
2001) component of the telomerase complex (Table 1.2). Furthermore, mutations in 
the gene encoding for the Cajal body-localization protein TCAB1, which is associated 
with telomerase, result to the autosomal recessive form of the disease (Table 1.2) 
(Mason and Bessler, 2011). 
 
The exact cause of DC is still unclear. It was initially thought that DC arises because 
of telomere defects, since telomere shortening is observed in all forms (Mason and 
Bessler, 2011). Nevertheless, there are a few problems with this theory. Firstly, the DC 
phenotype is similar to the one observed in other ribosomopathies, such as DBA, 
especially the anaemia and increased cancer risk (Narla and Ebert, 2010). Secondly, 
clinical features of the disease were seen in mice (Ruggero et al., 2003, Gu et al., 
2008) and zebrafish models (Ying Zhang et al., 2012), before any telomere defects 
were observed. These studies show that DC might not be caused by telomere defects, 
but rather, be due to ribosome biogenesis defects. This was further confirmed in a 
recent study, where the authors showed that Dyskerin levels were elevated in 
neuroblastoma patients, which were independent of the telomerase functions in these 
cells (O'Brien et al., 2016a). 
 
 
Dyskeratosis Congenita 
Complexes Mutations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Telomerase 
Genes  Inheritance  Presentation  
Dyskerin  X-linked recessive  X-linked recessive Dyskeratosis 
Congenita  
Hoyeraal Hreidarsson syndrome  
NOP10  Autosomal recessive  Autosomal recessive 
Dyskeratosis Congenita  
NHP2  Autosomal recessive  Autosomal recessive 
Dyskeratosis Congenita  
TCAB1  Autosomal recessive  Autosomal recessive 
Dyskeratosis Congenita  
TERT  Autosomal dominant  Idiopathic pulmonary fibrosis  
Aplastic anaemia  
Autosomal recessive 
Dyskeratosis Congenita  
TERC  Autosomal dominant  Aplastic anaemia  
Pulmonary fibrosis  
Dyskeratosis Congenita  
Table 1.2. Clinical presentation of Dyskeratosis Congenita. 
H/ACA 
snoRNP 
 
H/ACA 
snoRNP 
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As with other ribosomopathies, the levels of the tumour suppressor p53 were found to 
be de-regulated in DC as well. Depletion of Dyskerin in mice (Ge et al., 2010b) or 
zebrafish (Ying Zhang et al., 2012) resulted in an increase in p53 levels. Finally, 
suppression of Dyskerin in neuroblastoma human cells was shown to lead to a p53-
dependent cell cycle arrest due to ribosome biogenesis defects, but not telomerase 
defects (O'Brien et al., 2016a). These studies suggest that DC is most likely due to 
ribosome biogenesis defects rather than telomere defects. 
 
1.5.6. Ribosomes, Ribosomopathies and cancer 
 
Most ribosomopathies appear with increased cancer risk, especially for AML, which is 
likely to be linked with anaemia (Orsolic et al., 2015). DC patients from a National 
Cancer Institute cohort presented an 11-fold higher ratio of observed to expected 
cancers as compared to general population (Alter et al., 2009). Patients with SDS have 
an estimated cancer risk of 19% at 20 years old, which reaches 36% at the age of 30 
years old, according to the French Severe Chronic Neutropenia Registry (Donadieu et 
al., 2005). In the case of DBA, the situation is less clear, but patients were found to 
develop AML and, in some cases, osteosarcoma, as well as other types of tumours 
(Vlachos et al., 2012). 
 
It is thought that the tumour development in ribosomopathy patients is directly linked 
to ribosome biogenesis defects. Mutations in genes encoding for either ribosome 
biogenesis factors or ribosomal proteins are the main cause of ribosomopathies (Yelick 
and Trainor, 2015). A study in 2004 have used zebrafish cell lines which were 
heterozygous for a recessive embryonic lethal mutation. An elevated cancer incident 
was observed in 12 cell lines, 11 of which had a mutation in a gene encoding for 
ribosomal proteins (Amsterdam et al., 2004). Furthermore, the transcription factor 
RUNX1 was found to be involved in the development of AML, MDS (Behrens et al., 
2016) as well as breast cancer (Browne et al., 2015), and its depletion in hematopoietic 
stem and progenitor cells was found to cause an inhibition of ribosome biogenesis (Cai 
et al., 2015). Mutations in NPM1 gene, encoding for nucleophosmin, a nucleolar 
protein involved in ribosome biogenesis, are found in approximately 30% of AML 
patients (Federici and Falini, 2013). Furthermore, It was found that translocation or 
heterozygous deletion of NPM1 gene is commonly found in hematopoietic cancers, 
such as APL (acute promyelocytic anaemia) or MDS (Lindstrom, 2011). 
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1.6. The tumour suppressor p53 
 
1.6.1. p53 
 
p53 was identified by three independent studies in 1979 (DeLeo et al., 1979, Lane and 
Crawford, 1979, Linzer and Levine, 1979) and it was firstly thought to be an oncogene, 
whilst later it became clear that it acts as a tumour suppressor (Levine, 1989). p53 is 
found as a monomer or as a homotetramer in the cell (McLure and Lee, 1998). The 
TP53 gene, which encodes for p53, consists of 11 exons, and the p53 protein contains 
5 domains: the N-terminal transactivation domain (TAD), the proline-rich domain 
(PRD), the central DNA binding domain (DBD), the tetramerization domain (TD) and 
C-terminal basic domain (BD) (Figure 1.10) (Kamada et al., 2015). The transactivation 
domain (TAD) is involved in the transcriptional activity of p53, as well as interactions 
with other proteins (Kamada et al., 2015). The proline-rich domain is important for p53 
stability and activity (Green and Kroemer, 2009). The DNA-binding domain binds 
directly on DNA consensus sequences for p53 binding (Zhao et al., 2001). The binding 
of DBD on the DNA is regulated by the C-terminal basic domain. Finally, the 
tetramerization domain is important for p53 tetramerization, which is required for DNA 
binding, post-translational modifications and interactions with other proteins (Kamada 
et al., 2015). 
Figure 1.10. Schematic representation of the domains of p53. The N-terminal 
transactivation domain (TAD) is shown in green, the proline-rich domain (PRD) in 
yellow, the DNA-binding domain (DBD) in red, the tetramerization domain (TD) in light 
blue and the C-terminal basic domain (BD) in light grey (Adapted from: (Kamada et al., 
2015)). 
 
Other members of the p53 family include p63 and p73 transcription factors, which have 
similar structure, but a longer C-terminal on their tetramerization domain. In p63 and 
p73, this forms a helical structure, which is, presumably, involved in stabilisation 
(Joerger et al., 2009). The DNA binding nucleotide recognition motif is conserved 
amongst the p53 family members (Brandt et al., 2009) and hetero-tetramers of p53, 
p63 or p73 have been found in cells involved in transcriptional regulation of cell cycle 
and development (Joerger et al., 2009). Finally, p63 and p73 have been shown to have 
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p53-independent roles in the cells, such as epithelial or neuronal development (Dotsch 
et al., 2010). 
 
1.6.2. p53 regulation and activation 
 
p53 is a transcription factor and the major tumour suppressor in humans, widely known 
as the “guardian of the genome”. Mutations in the gene encoding for p53 or 
deregulation of p53 levels have been reported in a variety of cancers (Wade et al., 
2013), as well as other diseases including ribosomopathies (Drygin et al., 2014). The 
levels of p53 are mainly controlled by the ubiquitin ligase MDM2 (or HDMX) (Momand 
et al., 1992), which homodimerizes via its RING domain (Fang et al., 2000) and binds 
to p53 (Wade et al., 2013). This leads to p53 ubiquitination so that it is targeted for 
proteosomal degradation (Vogelstein et al., 2000). Furthermore, p53 activity is also 
inhibited by MDM2. The p53-binding domain of MDM2 binds on the transactivation 
(TAD) domain of p53 (Poyurovsky et al., 2010) and the central domain of MDM2, 
including the acidic domain and zinc finger domain, binds on the transactivation 
domain of p53 (Ma et al., 2006) (Cross et al., 2011). This results in p53 inhibition 
(Figure 1.11). A positive feedback loop mechanism exists between MDM2 and p53, 
where MDM2 expression is activated by p53 (Wu and Levine, 1997), ensuring that the 
p53 levels remain low in unstressed cells.  
Figure 1.11. The inhibition of p53 by MDM2. The p53 binding domain (BD), the acidic 
domain (AD), the Zinc-finger domain (Zn) and the RING domain of MDM2 are shown 
in orange. The transactivation domain (TAD) and DNA-binding domain (DBD) of p53 
are shown in green. 
 
Apart from MDM2, a related MDM protein called MDMX (or HDM4) was found to be 
another important regulator of p53 levels in human cells (Linares et al., 2003). MDMX 
does not have a ubiquitin-ligase activity like MDM2 (Linares et al., 2003). However, 
MDM2-MDMX hetero-dimers are formed via interaction between their RING domains, 
which provides a stronger inhibition mechanism for p53 regulation (Uldrijan et al., 
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2007). Finally, inhibition of p53 by the MDM2-MDMX heterodimer was found to be 
particularly important during embryonic development (Pant et al., 2011), and a lot of 
targeted cancer treatments are now focused on MDM2 and MDMX (Wade et al., 2013). 
 
Activation of p53 in the cell after stress responses (Brown et al., 2009) takes places by 
various mechanisms. Firstly, phosphorylation of p53 leads to p53 activation due to a 
block in MDM2-p53 interaction (Momand et al., 2000). For example, phosphorylation 
of serine 15 is the main mechanism for p53 activation after DNA damage responses 
(Meek and Anderson, 2009). Furthermore, phosphorylation of MDM2 can also take 
place, blocking the MDM2-p53 interaction, which leads to p53 stabilisation (Momand 
et al., 2000). Finally, oligomerization of p53 can also lead to p53 activation by blocking 
the MDM2-p53 interaction due to post-transcriptional modifications on p53, such as 
phosphorylation or acetylation (Meek and Anderson, 2009). 
 
A number of upstream pathways, both intrinsic and extrinsic, result in p53 activation 
(Figure 1.12) (Brown et al., 2009). DNA damage responses, which result in double 
strand breaks, lead to the activation of ATM (ataxia telangiectasia mutated) kinase, 
whereas UV irradiation leads to the activation of ATR kinase (serine/threonine kinase) 
or Casein Kinase II (Vogelstein et al., 2000) (Figure 1.12). ATM, ATR or Casein Kinase 
II kinases activate Chk2 kinase, which in turns phosphorylates p53 on serine 20 (Hirao 
et al., 2000). This modification prevents MDM2 binding, resulting in p53 stabilisation. 
Furthermore, growth signals also result in p53 activation. Oncogenic signals, such as 
expression of Ras or Myc oncogenes (Sherr and Weber, 2000), result in activation of 
the tumour suppressor p14ARF, an alternative reading frame protein of CDKN2A locus 
(Stott et al., 1998). p14ARF inhibits the proteosomal degradation of p53 by preventing 
its ubiquitination by MDM2 (Xirodimas et al., 2001), leading to p53 activation (Figure 
1.12), via the 5S RNP complex (discussed later) (Sloan et al., 2013a). 
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Figure 1.12. The activation of p53 after DNA breaks, UV irradiation and oncogene 
over-expression. Activation of downstream targets is indicated with an arrow and 
inhibition of downstream targets is indicated by a line. p53 is shown in green, MDM2 
in orange and ATM (ataxia telangiectasia mutated), ATR (serine/threonine kinase) and 
ARF are indicated in light grey (Adapted from: (Brown et al., 2009)). 
 
1.6.3. Cell cycle regulation by p53 
 
p53 has a variety of functions in the cell for maintenance of the genome integrity 
(Bieging et al., 2014), including cell cycle control, apoptosis and DNA damage repair. 
 
The cell cycle consists of interphase, which contains the G1, S and G2 phase, and 
mitosis, which contains the prophase, metaphase, anaphase and telophase. During 
G1 phase, the cell is prepared for DNA replication, which takes places during S phase, 
whereas the cell prepares for mitosis during G2 phase (Schafer, 1998). The cell cycle 
is mainly regulated by the cyclin-dependent serine/threonine kinases (CDKs) along 
with cyclins (Nigg, 1995), by activating enzymes required for progression to the next 
cell cycle phase and inhibiting enzymes that prevent this. In brief, Cdk4 or 6 along with 
cyclin D (Bates et al., 1994) are required for the progression of cell cycle through G1 
phase, whereas Cdk2-cyclin E (Dulic et al., 1992) complex is required for the 
progression from G1 to S phase. Cdk2-cyclin A complex (Tsai et al., 1991) is necessary 
for progression of cell cycle from S phase to G2 phase and, finally, Cdk1-cyclin B 
complex (Nurse, 1990) is required for progression to mitosis (Schafer, 1998). 
 
Activation of p53 promotes the expression of p21 (p21WAF1/CIP1) (Figure 1.13), which 
results in inhibition of several CDKs (Karimian et al., 2016), apart from Cdk1 
presumably (Harper et al., 1995). Cdk4/6-cyclin D complex activate transcription 
factors important for the expression of genes involved in G1 to G2 phase promotion. 
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Active p21 binds cyclins, preventing the activation of downstream transcription factors 
(Hall et al., 1995a), resulting in G1 cell cycle arrest (Figure 1.13). Furthermore, p53 
activation results in G1 cell cycle arrest by activation of a DNA damage checkpoint 
(Bakalkin et al., 1995), which prevents the progression of cell cycle to the S phase. 
Activation of p53 also results in G2/M cell cycle arrest in some cases (Vogelstein et al., 
2000). Active p53 promotes the expression of the 14-3-3σ protein, especially in 
epithelial cells. 14-3-3σ blocks Cdk1-cyclin B complex, required for the transition of G2 
phase to mitosis, thus resulting in G2 cell cycle arrest (Figure 1.13) (Laronga et al., 
2000). 
Figure 1.13. Schematic representation of the cell cycle regulation by p53. 
Activation of downstream targets is shown by an arrow and inhibition of downstream 
targets is shown by a line. p53 is shown in green, p21 and 14-3-3σ in white. 
Cdk1=cyclin-dependent kinase 1 (Adapted from: (Brown et al., 2009)). 
 
1.6.4. p53 function in apoptosis 
 
Apoptosis is a programmed cell death which takes place normally for maintenance of 
cell numbers in tissues, or as a defence mechanism under stress conditions (Elmore, 
2007). Caspases, cysteine-aspartic proteases, are the key players in apoptosis, which 
cleave polypeptide chains upon activation, resulting in cell death (Goodsell, 2000). 
Activation of apoptosis occurs by the intrinsic, mitochondrial pathway, or the extrinsic, 
death receptor pathway. Intracellular signals, such as toxin accumulation or hypoxia, 
result in changes in mitochondria and the opening of the mitochondria permeability 
transition (MPT) pore (Chalah and Khosravi-Far, 2008). This leads to the release of 
several proteins, forming the apoptosome, resulting in activation of caspase-9, which, 
in turn, activates the execution caspase-3 (Elmore, 2007). On the other hand, the 
extrinsic pathway is activated by the association of extracellular ligands with the 
transmembrane death receptors, such as TNF (Locksley et al., 2001). Activation of 
death receptors results in the formation of a death-inducing signalling complex (DISC), 
resulting in the activation of caspase-8, which leads to the activation of the execution 
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caspase-3 (Fuchs and Steller, 2011). In both cases, caspase-3 activates other 
caspases, proteases and endonucleases, leading to apoptosis (Elmore, 2007). 
 
p53 has been found to act as pro-apoptotic transcription factor, leading to the induction 
of apoptosis, mainly via the activation of the intrinsic pathway. p53 leads to the 
transcriptional activation of various pro-apoptotic proteins of the Bcl-2 protein family 
(Fridman and Lowe, 2003), such as Bax (Figure 1.14) (Miyashita et al., 1994). Upon 
activation, Bax binds on the mitochondrial membrane in association with other pro-
apoptotic proteins (Gross et al., 1998), leading to the release of cytochrome c and 
caspases, which form the apoptosome, resulting in apoptosis (Figure 1.14) (Weng et 
al., 2005). Other pro-apoptotic proteins that are transcriptionally activated by p53 
include PUMA (Nakano and Vousden, 2001) and NOXA (Figure 1.14) (Oda et al., 
2000). Furthermore, p53 activation can also result in the activation of the extrinsic 
pathway. p53 was found to activate PIDD protein (Figure 1.14), which contains a death-
domain and resembles other death-signal receptors, like TNF and Fas (Lin et al., 
2000). Finally, p53 plays a non-transcriptional role in apoptosis (Fridman and Lowe, 
2003), potentially by interactions with the mitochondrial membrane for cytochrome c 
release (Figure 1.14) (Mihara et al., 2003). 
 
 
 
 
 
 
 
Figure 1.14. Schematic 
representation of the regulation of 
apoptosis by p53. Activation of 
downstream targets is indicated by an 
arrow, p53 is shown in green and the 
proteins PUMA, NOXA, PIDD and Bax 
are show in white (Adapted from: 
(Brown et al., 2009)). 
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1.6.5. p53 function in DNA damage repair  
 
DNA damage occurs for a number of reasons and various mechanisms exist in the cell 
for DNA damage repair. In outline, DNA damage caused by reactive oxygen species 
(ROS) or X-rays results in the formation of base oxidation or single strand breaks, 
which is repaired by the Base Excision Repair (BER) machinery. Errors during DNA 
replication may lead to insertions, deletions or mismatches, which is repaired by 
Mismatch Repair (MMR), whereas bulk DNA adducts caused by UV light are repaired 
by Nucleotide Excision Repair (NER) enzymes. Finally, double strand breaks caused 
by ionizing radiation or anti-tumour drugs are repaired by Homologous Recombination 
(HR) or Non-Homologous End Joining (NHEJ) (Sancar et al., 2004). 
 
Active p53 can lead to the transcriptional activation of downstream targets involved in 
DNA damage repair (Figure 1.15). For example, p53 is responsible for induction of 
GADD45α (Figure 1.15), which is involved in recruiting DNA damage repair enzymes 
(Carrier et al., 1999). GADD45α has been found to interact with PCNA (proliferating 
cell nuclear antigen) (Hall et al., 1995b), which binds on DNA and recruits other 
enzymes involved in BER (Shivji et al., 1992) and homologous recombination (Pfander 
et al., 2005). Furthermore, p53 results in activation of XPC (Figure 1.15), which senses 
DNA bulky adducts during nucleotide excision repair (NER) (Adimoolam and Ford, 
2002). 
Figure 1.15. Schematic representation of the regulation of DNA damage repair 
by p53. Activation of downstream targets is indicated by an arrow, p53 is shown in 
green and the proteins GADD45α, PCNA (proliferating cell nuclear antigen) and XPC 
in white. BER=base-excision repair, HR=homologous recombination, 
NER=nucleotide-excision repair (Adapted from: (Brown et al., 2009)). 
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1.6.6. The 5S RNP-MDM2 pathway for p53 regulation and ribosomopathies 
 
Ribosome biogenesis was shown to be directly linked to the regulation of the levels of 
p53 (Freed et al., 2010a, Narla and Ebert, 2010). The 5S RNP, consisting of the 
ribosomal proteins RPL5, RPL11 and the 5S rRNA, is normally integrated in the large 
ribosomal subunit (Sloan et al., 2013a). However, ribosome biogenesis defects result 
in the accumulation of the free 5S RNP in the nucleoplasm, since it can no longer be 
integrated in the large ribosomal subunit. This results in the binding of the 5S RNP to 
MDM2, inhibiting its function in ubiquitinating p53, leading to p53 stabilisation (Figure 
1.16) (Pelava et al., 2016). It was recently found that all three components of the 5S 
RNP are required for its binding to MDM2 (Sloan et al., 2013a, Donati et al., 2013). 
Furthermore, the structures of the MDM2-RPL11 and ribosome-bound 5S RNP have 
shown that the same binding site on RPL11 is used for binding of the 5S RNP complex 
to either MDM2 or the ribosome (Zheng et al., 2015). Finally, it is believed that the 
interaction of the 5S RNP with MDM2 prevents the association of MDMX in the 
complex, leading to p53 activation (Figure 1.16) (Li and Gu, 2011). It is of particular 
interest that other ribosomal proteins have also been shown to bind to MDM2 in vivo, 
including RPL23 (Dai et al., 2004), RPS3 (Yadavilli et al., 2009) and RPS27a (Sun et 
al., 2011), suggesting that there are multiple pathways regulation p53 levels after 
ribosome biogenesis defects. 
 
Figure 1.16. Schematic representation of the stabilisation of p53 via the 5S RNP-
MDM2 interaction. MDM2 (orange), with MDMX (brown), binds and ubiquitinates p53 
(green), targeting it for proteosomal degradation. The free 5S RNP (blue) binds and 
inactivates MDM2, causing p53 stabilisation, which leads to metabolic changes, cell 
cycle arrest, and apoptosis. 
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Defects in LSU production have been shown to cause the accumulation of the 5S RNP 
in the nucleoplasm, which results in p53 stabilisation by binding MDM2 (Donati et al., 
2013, Marechal et al., 1994, Sloan et al., 2013a, Dai and Lu, 2004, Horn and Vousden, 
2008). However, defects in SSU production have also been linked with the stabilisation 
of p53 via the 5S RNP-MDM2 pathway (Fumagalli et al., 2009, Fumagalli et al., 2012, 
Dutt et al., 2011), but the mechanism for this is still unclear. It was recently proposed 
that defects in SSU production are linked with the levels of the tumour suppressor p53 
by the up-regulation of the ribosomal protein mRNAs (Fumagalli et al., 2012). In this 
paper, the authors propose that defects in 40S synthesis result in an up-regulation of 
translation of the ribosomal proteins (Fumagalli et al., 2012). This results in the 
production of more 5S RNP to bind MDM2 in order to compete the requirement of the 
60S subunit for the RPL11 protein as part of the 5S RNP. However, when both the 40S 
and the 60S synthesis are co-impaired, it is predicted that there is both an up-regulation 
on 5S RNP production and a block in 5S RNP integration into the 60S, leading to p53 
supra-induction (Fumagalli et al., 2012). 
 
The 5S RNP has been implicated in other signalling pathways in the cell as well. Firstly, 
RPL5 and RPL11, presumably as a part of the 5S RNP, were shown to bind p73, 
blocking its interaction with MDM2, leading to p73 activation (Zhou et al., 2015). 
Furthermore, it was found that the 5S RNP might be important for the regulation of the 
levels and stability of the proto-oncogene c-Myc. RPL11 binds c-Myc after ribosome 
biogenesis defects, resulting in the suppression of its transcriptional activity. 
Additionally, RPL5 and RPL11 were shown to recruit the RNA-induced silencing 
complex (RISC) for c-Myc mRNA degradation (Liao et al., 2014). Finally, it was shown 
that RPL11 also binds the tumour suppressor p14ARF, forming the 
RPL11/p14ARF/MDM2/p53 complex, leading to p53 stabilisation because of MDM2 
inhibition (Dai et al., 2012). It was recently found that RPL5 and the 5S rRNA, 
presumably as part of the 5S RNP complex, are also important for this process, since 
depletion of RPL5 or RPL11 in cells overexpressing p14ARF eliminated the p53 
response (Sloan et al., 2013a). 
 
To date, there is no evidence on how ribosome biogenesis defects lead to 
ribosomopathies, but it is widely thought that p53 plays an important role in this process 
(Narla and Ebert, 2010), even though not much research has been carried out using 
patient tissues. The main hypothesis so far is that p53 levels are up-regulated in 
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ribosomopathy patients via the 5S RNP-MDM2 pathway after ribosome biogenesis 
defects as described, leading to cell cycle arrest and apoptosis, which, subsequently, 
results in anaemia (McGowan et al., 2008, Fumagalli et al., 2009). Another possibility 
is that the defective ribosome biogenesis causes a delay in translation of globin mRNA, 
leading to the accumulation of excess heme, which results in cell-specific apoptosis 
due to oxidative stress and, therefore, anaemia (Keel et al., 2008). Lastly, it was 
suggested that abnormal translation might occur due to defective ribosome production, 
leading to the phenotypes observed (Blazquez-Domingo et al., 2005). 
 
1.7. Aims and Objectives 
 
Ribosome biogenesis is an essential cellular process, which is down-regulated during 
cell division and differentiation, and controlled by various stimuli, such as DNA 
damage, hypoxia and oncogene expression (Gentilella et al., 2015). Defects in 
ribosome biogenesis are associated with ribosomopathies, and the ribosome 
biogenesis pathway was found to be up-regulated in a variety of cancers (Orsolic et 
al., 2015). Ribosome biogenesis is directly linked with the regulation of the tumour 
suppressor p53 via the 5S RNP-MDM2 pathway (Pelava et al., 2016), and most of the 
previous and current anti-cancer chemotherapeutic treatments target ribosome 
biogenesis (Burger et al., 2010), highlighting its importance in cancer development. 
 
The work in this PhD thesis covers three key areas of ribosome biogenesis and p53 
regulation: 
 
1) Ribosomopathies, a set of rare genetic diseases, arise due to mutations in 
genes encoding for ribosomal proteins or ribosome biogenesis factors. X-linked 
Dyskeratosis Congenita (DC) arises due to mutations in the gene encoding for 
Dyskerin, which is important for the pseudouridylation of rRNAs as part of the H/ACA 
snoRNP (Knight et al., 2001). However, very little is known about its function in 
humans, since most studies have been performed in yeast, where the H/ACA snoRNP 
is only involved in SSU biogenesis (Atzorn et al., 2004, Henras et al., 2004, Lafontaine 
et al., 1998). The catalytic activity of Dyskerin was shown to be essential for rRNA 
processing and modification in yeast (Zebarjadian et al., 1999), but not in mice, where 
it is more likely that pseudouridines are important for rRNA stability (Gu et al., 2013). 
In humans, the importance of Dyskerin in H/ACA snoRNP formation and rRNA 
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processing is yet to be determined. Furthermore, zebrafish (Ying Zhang et al., 2012) 
and mice models (Ge et al., 2010b, Gu et al., 2008) of X-linked DC were presented 
with elevated p53 levels when Dyskerin was depleted, presumably due to ribosome 
biogenesis defects. Despite its high important in X-linked DC and, possibly, cancer 
development in these patients, not much is known about the role of Dyskerin in p53 
regulation in humans. 
 
2) Diamond-Blackfan Anaemia (DBA), another ribosomopathy, arises due to 
mutations in genes encoding for either LSU or SSU ribosomal proteins (Ellis, 2014). 
As with most ribosomopathies, DBA patients present with an increased cancer risk, 
where de-regulation of p53 levels is thought to be important. This is supported by DBA 
mouse models where most of the symptoms were dependent on p53, and the anaemia 
development was dependent on the interaction of the 5S RNP and MDM2 (Jaako et 
al., 2015). It is known for a few years that defects in LSU production lead to the 
accumulation of the free 5S RNP, leading to MDM2 binding and inhibition, and, 
subsequently, p53 activation (Pelava et al., 2016, Sloan et al., 2013a, Nicolas et al., 
2016). Surprisingly, various studies have shown that defects in SSU production also 
lead to p53 accumulation via the 5S RNP-MDM2 pathway (Fumagalli et al., 2009, 
Fumagalli et al., 2012, Golomb et al., 2014). However, it still remains unclear how 
defects in the SSU feedback to the recruitment of the 5S RNP in the LSU, with no 
obvious defects in LSU production. Furthermore, ribosome biogenesis takes place in 
different compartments in the cell with a number of ribosomal proteins and ribosome 
biogenesis factors to be involved. Depletion of LSU or SSU ribosomal proteins 
(Fumagalli et al., 2009, Fumagalli et al., 2012, Golomb et al., 2014) or depletion of 
ribosome biogenesis factors important for LSU production (Sloan et al., 2013a) was 
shown to result in p53 activation via the 5S RNP-MDM2 pathway. Whether defects in 
early or late stages of either LSU or SSU production affect the regulation of p53 via the 
same pathway is unclear. 
 
3) The majority of ribosomal proteins are transcribed by 5’-TOP mRNAs (Levy et 
al., 1991). Instead, RPS27a and RPL40 are transcribed as ubiquitin-ribosomal protein 
precursors (Kimura and Tanaka, 2010), which are then processed for the release of 
the ubiquitin and the ribosomal protein. Yet, there is not much information on when this 
processing step occurs. It is known that RPS27a and RPL40 are part of the SSU and 
LSU respectively (Finley et al., 1989, Redman and Rechsteiner, 1989), but their role 
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in ribosome biogenesis during rRNA processing is still unclear. Interestingly, RPS27a 
is up-regulated in a variety of cancers and leukaemia (Wang et al., 2014) and was 
described as a potential new regulator of p53 by binding and inhibiting MDM2 when 
over-expressed (Sun et al., 2011). However, not much is known about the function of 
RPS27a or RPL40 in p53 homeostasis. 
 
Therefore, this PhD project aimed to: 
• Investigate the functions of Dyskerin in human ribosome biogenesis and p53 
regulation 
• Explore how defects on different stages of SSU or LSU production affect p53 
regulation 
• Study the processing of RPS27a and RPL40, and their function in human 
ribosome biogenesis and p53 regulation 
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2. Chapter Two. Materials and Methods 
 
2.1 DNA methods 
 
2.1.1 Construct introduction 
 
The open reading frame (ORF) of Dyskerin, Ubiquitin-RPS27a or Ubiquitin-RPL40 was 
cloned in a pcDNA5/FRT/TO vector as described below (Figure 2.1). The 
pcDNA5/FRT/TO vector contained a FLAG-tag sequence so that all the proteins were 
expressed with a FLAG-tag on the N-terminus. For RPS27a- and RPL40- ubiquitin 
fusion ORFs, an HA tag was added to the C-terminus. 
 
2.1.2 Polymerase Chain Reaction (PCR) for cloning 
 
The ORF of each construct was amplified by Polymerase-Chain Reaction (PCR) using 
the Phusion DNA Polymerase (New England Biolabs) in order to create PCR products 
with blunt-ends. A cDNA library of the total mRNA, made using a reverse-transcription 
(RT) PCR (discussed later), was used as a template in all cases. A final concentration 
of 1x HF (High-Fidelity) Phusion Buffer (New England Biolabs) was used in a 50 µl 
reaction, along with 200 µM dNTPs, 1 µM of each of the Forward and Reverse primers 
(Table 2.1), approximately 100 ng of the template DNA and 0.5 µl of the Phusion 
Polymerase (New England Biolabs). 
 
 
The PCR conditions (Table 2.2) were according to the manufacturer’s instructions, 
where the annealing temperature was 3°C below the primer melting temperature (Tm). 
Name Forward primer (5’ to 3’) Reverse Primer (5’ to 3’) 
Dyskerin CGCGAGATCTATGGCGGATGCGG
AAGTAAT 
CGCGCTCGAGTCACTCAGAAACCAATTCT
ACC 
RPS27a GATCGGATCCATGCAGATTTTCGT
GAAAACCCTTAC 
1:GGATAGCCCGCATAGTCAGGAACATCG
TATGGGTACTTGTCTTCTGGTTTGTTGAAA
CAGTAAGTCAG 
2:GCCGTCGACTCATGCATAGTCCGGGAC
GTCATACGGATAGCCCGCATAGTCAGGA
AC 
RPL40 GATCGGATCCATGCAGATCTTTGT
GAAGACCCTCAC 
1:GGATAGCCCGCATAGTCAGGAACATCG
TATGGGTATTTGACCTTCTTCTTGGGACG
C 
2:GCCCTCGAGTCATGCATAGTCCGGGAC
GTCATACGGATAGCCCGCATAGTCAGGA
AC 
Table 2.1. Primers used for cloning. 
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2.1.3 DNA visualization and extractions 
 
The PCR products were diluted in 6x DNA loading buffer (0.4 % orange G, 0.03 % 
bromophenol blue, 0.03 % xylene cyanol FF, 15 % Ficoll400, 10 mM Tris-HCl pH 7.5, 
50 mM EDTA pH 8.0), to a final concentration of 1x. Products bigger than 500kb were 
loaded on a 1% agarose gel, whereas products smaller than 500kb were loaded on a 
2% agarose gel. The agarose gels were made in 1x TBE solution (TRIS/Borate/EDTA: 
90 mM Tris-HCl, 90 mM Boric acid, 2 mM EDTA, pH 8.0) with the addition of 1x 
SYBRSafe dye (Life Technologies). Gels were visualized using a UV transilluminator 
and the GelDoc system or a Typhoon Phosphorimager. For cloning, DNA was 
extracted from the agarose gel using the Wizard® SV gel and PCR Clean-Up System 
Kit (Promega), according to the manufacturer’s instructions. To remove any excess 
ethanol from the sample after extractions, the samples were dried using the speed-vac 
for 30minutes. 
 
2.1.4 Ligation in pJET1.2 vector 
 
1 µl of the DNA PCR product (approximately 10 ng) was added to 0.5 µl of pJET1.2 
vector (approximately 50 ng) (Promega), with 0.5 µl of T4 DNA ligase (Promega) and 
5 µl of 2x Ligase Reaction Buffer (Promega). The mixture was incubated at room 
temperature for 30 minutes, before being transformed in DH5α E. coli competent cells. 
 
2.1.5 Transformations in Escherichia coli and DNA extractions  
 
Plasmid DNA was transformed into DH5α E. coli competent cells, which were prepared 
based on the Inoue Method (Brown et al., 2009).Up to 100 ng of plasmid DNA or up to 
10 µl of the ligation mixture was added to 100 µl of DH5α E. coli competent cells and 
placed on ice for 30 minutes. The cells were then heat-shocked at 42°C for 1 minute 
Phusion PCR 
Step Temperature (°C) Time (sec) Cycles 
Initial activation 98 30 1 
Denaturation 98 10 
20-25 Annealing Tm - 3 30 
Extension 72 15/kb 
Final Extension 72 600 1 
Table 2.2. PCR conditions using the Phusion DNA polymerase for cloning. 
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before they were placed on ice for 1 minute. 1 ml of Luria Broth (LB) (15.5 g LB / 1 L 
water) medium was added and the cells were incubated at 37°C for 1 hour while 
shaking. The cells were then centrifuged at 3,000rpm on a benhctop centrifuge for 2 
minutes and 900 µl of the LB medium was removed. The cells were resuspended in 
the remaining LB medium and placed on ampicillin-containing plates overnight at 37°C. 
One colony was picked up from each plate and added to 3 ml of ampicillin-containing 
LB medium, which was grown overnight at 37°C. DNA was extracted from the cells 
using the GeneJet Plasmid Miniprep Kit (ThermoScientific) according to the 
manufacturer’s instructions. 
 
2.1.6 DNA sequencing 
 
The identity of the plasmids was confirmed by DNA sequencing at GATC Biotech or 
Source Biosciences. The primers used for DNA sequencing corresponded to the vector 
sequences upstream and downstream the open reading frame. 
 
2.1.7 Restriction Digest 
 
The cDNA of interest was released, using restriction digest, from pJET1.2 vector for its 
cloning in the pcDNA5/FRT/TO vector. Approximately 2 µg of DNA was digested with 
10 U of the relevant restriction enzymes and buffers (Promega) according to the 
manufacturer’s instructions, producing sticky-ended products. Table 2.3 summarizes 
the restriction enzymes used for each of the constructs. 
 
 
 
 
 
ORF Restriction Enzyme 1 Restriction Enzyme 2 
Dyskerin BglII XhoI 
RPS27a BamHI SalI 
RPL40 BamHI XhoI 
Table 2.3. Restriction enzymes used for construct digestion. 
50 
 
2.1.8 Ligation in pcDNA5/FRT/TO vector 
The cDNAs were cloned into a modified pcDNA5/FRT/TO vector (Andrew Knox, Nick 
Watkins, personal communication) (Figure 2.1). A 5:1 molar ration (DNA insert:vector) 
was used along with 0.3 U of T4 DNA ligase (Promega) in 1x T4 DNA ligase Buffer 
(Promega). The samples were incubated at 18°C overnight and transformed in DHA5α 
E. coli competent cells. DNA was extracted as described above and the samples were 
sent for DNA sequencing in order to confirm the construct sequence. 
 
Figure 2.1. The modified pcDNA5/FRT/TO vector used for cloning. Two repeats of 
FLAG-tag sequence and six copies of the His-tag sequence were found upstream the 
cloned cDNA, which was under a tetracycline promoter. On the pcDNA5/FRT/TO 
vector are shown in order: the CMV promoter, the multiple cloning sites, the BGH 
reverse priming site and polyadenylation signal (pA), the Flp recombination site (FRT), 
the Hygromycin-resistance gene, the SV40 early polyadenylation (pA) signal, the pUC 
origin and Ampicillin resistance gene (From A.A Knox). 
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2.1.9 Site-directed mutagenesis 
 
Site-Directed mutagenesis was used to introduce mutations in the pcDNA5/FRT/TO-
cloned Dyskerin. 200 ng DNA, 1x Pfu Turbo Buffer (Stratagene), 100 ng of each primer 
(Forward and Reverse) (Table 2.4), 200 nM dNTPs and 2.5 U Pfu Turbo (Stratagene) 
were added to the reaction, which was performed according to the manufacturer’s 
instructions. Next, the PCR products were digested with DpnI (Promega) for 1 hour at 
37°C in order to remove the template DNA, since DpnI digests the methylated DNA. 5 
µl out of the 100 µl reaction were transformed in 50 µl of DHA5α E. coli competent 
cells. Cells were grown and DNA was purified as described above. 
 
 
 
The PCR conditions used were according to the manufacturer’s instructions as 
described in Table 2.5. 
 
 
 
 
 
 
 
 
2.2 Human Cell Culture methods 
 
2.2.1 Human Cell lines 
 
HEK293 (human embryonic kidney) cells Flp-In™ T-REX™-293 (Invitrogen), HeLa 
human cell line SS6 (cervical carcinoma) and U2OS (human osteosarcoma) Flp-InTM 
cells (gift from Dr Laurence Pelletier, Samuel Lunenfeld Research Institute, Toronto, 
Dyskerin Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’) 
RNAi resistant GATTGGGGACTATATCAGGACA
GGTTTCATTAATCTTGACAAGCC
CTCTAACCCCTC 
GAGGGGTTAGAGGGCTTGTCAA
GATTAATGAAACCTGTCCTGATA
TAGTCCCCAATC 
D125A GGAGAAGACAGGGCACAGTGGT
ACTCTGGACCCCAAGGTGACTG
GTTGTTTAATCG 
CGATTAAACAACCAGTCACCTTG
GGGTCCAGAGTACCACTGTGCC
CTGTCTTCTCC 
Table 2.4. Primers used for site-directed mutagenesis. 
Pfu Turbo PCR 
Step Temperature (°C) Time (sec) Cycles 
Initial activation 95 30 1 
Denaturation 95 10 
17 Annealing 55 60 
Extension 72 60/kb+60 
Table 2.5. PCR conditions using the Pfu Turbo DNA polymerase. 
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Canada) were cultured using Dulbecco’s Modified Eagles Medium (DMEM) containing 
4500 mg/L glucose, L-glutamine and sodium bicarbonate, without pyruvate (Sigma 
Aldrich) with additional 10 % Fetal Bovine Serum (FBS) (Sigma Aldrich) and 1 % 
Penicillin/Streptomycin (Sigma Aldrich). MCF7 (human breast cancer) cells were 
cultured using Gibco™ DMEM/F12 media with Glutamax (Life Technologies) with the 
addition of 10 % FCS (Sigma Aldrich). LNCaP prostate cancer cells (from Neil Perkins) 
were grown in RPMI 1640 (Lonza) with L-Glutamine and 25 mM HEPES, 
supplemented with 10 % Fetal Bovine Serum (FBS) (Sigma Aldrich). All cells were 
grown as a monolayer in a humidified incubator at 37°C with 5 % CO2. When 70-80 % 
confluent, the cells were passaged using 1x Trypsin-EDTA (Sigma Aldrich) in sterile 
Phosphate Buffer Saline (PBS) (Sigma Aldrich) for 5 minutes at 37°C and re-seeded 
with the appropriate medium. LNCaP cells were centrifuged at 3,000 g for 2-3 minutes 
after trypsinization, in order to remove any leftover trypsin, and re-seeded with the 
appropriate medium.  
 
HEK293 Flp-In™ T-REX™-293 and U2OS Flp-In™ cells both contain an integrated 
pFRT/lacZeo vector which provides a Flp-In Recombinase site (FRT). They also 
contain a pcDNA6/TR vector which provides a tetracycline-regulated gene, where the 
ORF of each gene of interest was cloned. This allowed for the control of the expression 
of the gene of interest with different concentrations of tetracycline. Finally, they contain 
a Blasticidin-S resistant sequence, whereas the pcDNA5/FRT/TO vector contain a 
Hygromycin B resistance gene upstream the ORF of the gene of interest cloned. These 
cells were therefore used to generate tetracycline-inducible stable cell lines (details 
below) by selection with 100 µg/ml Hygromycin B every passage and 10 µg/ml 
Blasticidin S every third passage. 
 
Cell stocks were prepared using a Freezing Media made by the corresponding media 
for each cell line with the addition of 20 % FBS and 10 % DMSO. Approximately 4x106 
cells were resuspended in the freezing media and the cell stocks were cooled to -80°C 
before being stored in liquid nitrogen. Reviving of cell stocks was performed by thawing 
of cells at 37°C and washing the cells in 5 ml of the corresponding media before 
resuspending them in 10 ml of media for normal growth. 
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2.2.2 Cell harvesting by trypsinization 
 
Cells were harvested by trypsinization, followed by centrifugation at 800rpm for 3 
minutes (swing bucket centrifuge) or 3,000rpm for 5 minutes (benchtop 
microcentrifuge). 
 
2.2.3 Actinomycin D and MG132 treatments 
 
Low levels of actinomycin D (ActD) block RNA polymerase I, resulting in ribosome 
biogenesis inhibition (Casse et al., 1999), whereas MG132 was used for inhibition of 
the proteasome (Guo and Peng, 2013). The cells were treated with 5 ng/µl ActD (in 
ethanol) or 25 µM of MG132 (in ethanol) (Lam et al., 2007) for approximately 18 hours. 
 
2.2.4 siRNA transfections 
 
Knockdowns were performed using the lipid transfection method for reverse 
transfection of siRNA duplexes. The Lipofectamine RNAiMAX transfection Reagent (5 
µl for a 6-well plate or 1 µl for a 24-well plate) (Life Technologies) and Optimem I (500 
µl for a 6-well plate or 100 µl for a 24-well plate) (Invitrogen) were incubated along with 
the siRNA for 15 minutes at room temperature. The different concentrations of siRNAs 
used are described on Table 2.6. Note that 5 times less siRNA was used when a 24-
well plate was used. Approximately 3x105 cells (6-well plate) or 5x104 cells (24-well 
plate) in antibiotic-free media were added to each well. siRNA transfections were 
performed for 48 hours unless otherwise stated. 
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2.2.5 DNA transfections for stable cell lines 
 
Stable cell lines were created using the Flp-In recombination system (Life 
Technologies, (Sauer, 1994)). The open reading frame of the protein of interest was 
cloned in a pcDNA5/FRT/TO plasmid as described previously, which contains an FRT 
recombination site. Both the HEK293T and U2OS cells also contain an FRT specific 
recombination site in the chromatin (Figure 2.2). pOGG44 vector, which was co-
transfected with the pcDNA5/FRT/TO plasmid, contains the Flp-In recombinase. 
Expression of the recombinase results in the homologous recombination of the two 
FRT sites on the vector and host cell line, so that the gene of interest is integrated in 
the host (Figure 2.2). The gene of interest is cloned downstream a tetracycline 
siRNA Source Reference Sequence (5' to 3') µM 
µl (6-
well)  
Control Eurofins MWG 
Elbashir et 
al., 2001 CGUACGCGGAAUACUUCGAdTdT 20 7.5 
DKC-2 EUROGENTEC  N/A GGACAGGUUUCAUUAAUCUdTdT 20 20 
PICT1 Eurofins MWG N/A GAAGAAGUCACUGCUUCUCdTdT 20 10 
PNO1 Eurofins MWG N/A CAGUCCCAGCUAACAGAUATT 20 10 
RIO2 Eurofins MWG N/A GGAUCUUGGAUAUGUUUAAdTdT 20 7.5 
RPL18 
ThermoScientific 
Pharmacon N/A 
GAGGCUGUUGGUCAAGU 
UAUACAGGdTdT  2 1 
RPL21 
Dharmacon 
Smartpool N/A N/A 2 1 
RPL40 
Dharmacon 
Smartpool 
Sun et al., 
2011 N/A 20 7.5 
RPL5 Eurofins MWG N/A GGUUGGCCUGACAAAUUAUdTdT 20 7.5 
RPL7 
ThermoScientific 
Pharmacon N/A N/A 2 7.5 
RPL7a Eurofins MWG 
Fumagalli 
et al., 2009 CACCACCTTGGTGGAGAACAAdTdT 20 7.5 
RPS19 Eurofins MWG 
Idol et al., 
2007 GAUGGCGGCCGCAAACUGAdTdT 20 7.5 
RPS27a Eurofins MWG 
Sun et al., 
2011 
CAGACATTATTGTGGCAAAdTdT 
20 7.5 
RPS6 Eurofins MWG 
Fumagalli 
et al., 2009 TTGTAAGAAAGCCCTTAAATAdTdT 20 7.5 
Table 2.6. The siRNA sequences used for siRNA transfections. 
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promoter, so that its expression can be induced. The host cell line contains a 
Hygromycin B resistance gene, so that selection with Hygromycin B was performed to 
identify the transfected cells (Figure 2.2). 
 
Cells were plated on a 6-well plate for 18-24 hours, aiming for 30-60 % confluence. 1.8 
µg of pOGG44 were added to 0.6 µg of pcDNA5/FRT/TO plasmid, for each well, in a 
microcentrifuge tube. In the meantime, 9 µl of FuGene 6 (Promega) were added to 91 
µl Optimem I (Life Technologies) for each well, in a separate microcentrifuge tube, and 
incubated at room temperature for 5 minutes. The DNA mixture containing both the 
pOGG44 and pcDNA5/FRT/TO vectors was added to the Optimem mixture and 
incubated at room temperature for 15 minutes. The whole mixture was added to the 
cells in each well in a drop-wise manner. The cells were left to grow for 72h before 
transferred in a T75 flask (Sarstedt). Selection with Hygromycin B and Blasticidin S 
was performed as described above, to select for stable transformants. 
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 Figure 2.2. Schematic representation of the FlpIn recombination system for 
stable cell line generation. Homologous recombination between the Flp 
recombination (FRT) sites of the pcDNA5/FRT/TO vector and the HEK293T host cell 
line is shown by the dotted line and the Flp-In recombinase needed is encoded by the 
pOGG44 vector. Addition of tetracycline results in the expression of the FLAG-tagged 
gene of interest. In order, the following are shown on the figure: the SV40 
polyadenylation signal, the ATG initiation codon, the Flp recombination site (FRT), the 
Hygromycin-resistance gene, the pUC origin, the ampicillin-resistance gene, the CMV 
promoter, the tetracycline promoter, the FLAG-tag, the cloned cDNA of the gene of 
interest (GOI) and the lacZ fused with zeocin resistance gene (lacZ-zeocin) (based on 
a figure from Invitrogen, adapted from K.E. Sloan). 
 
2.2.6 Flow cytometry for cell cycle analysis 
 
Cells were harvested by trypsinization and centrifuged at 3,000rpm on a bench-top 
centrifuge for 5 minutes. The cell pellet was washed with 500 µl of PBS/0.1 % FCS 
before centrifuged again at 3,000rpm on a bench-top centrifuge for 5 minutes. Cells 
were fixed using 1 ml of ice-cold 70 % ethanol and incubated on ice for 30 minutes. 
Cells were centrifuged again at 3,000rpm on a bench-top centrifuge for 5 minutes and 
the cell pellet was resuspended in 50 µl of 100 µg/ml of RNase A diluted in water. 
Addition of 200 µl of propidium iodide to a final concentration of 50 µg/ml (diluted in 
PBS) took place before incubation of cells in the dark at 4°C for 20 minutes. The 
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samples were transferred to Flow Cytometry tubes and analysed using the FACS 
Canto II software (BD Biosciences). 
 
2.2.7 Immunofluorescence 
 
Cells were plated on coverslips in a 24-well plate and treated as stated in each 
experiment. U2OS, but not HEK293T, cells were washed once with Phosphate Buffer 
Saline (PBS). 200 µl of 4 % parafolmadehyde in PBS was added to the cells for 20 
minutes in room temperature, for fixing the cells on the coverslip. The cells were 
washed once with PBS before the addition of 200 µl of PBS/0.1 % Triton for 15 minutes, 
followed by 4 washes with 500 µl of PBS. The cells were blocked for 1-2 hours using 
PBS/0.1% Triton/10% fetal calf serum (FCS) solution before being transferred to a 
clean well for the addition of 50 µl of the primary antibody (Table 2.7), which was diluted 
in the blocking solution, for 1-2 hours. The coverslip was transferred back to the original 
well for the cells to be washed 3 times with 500 µl of PBS followed by three 10-minute 
washes with 500 µl PBS. The coverslip was transferred to the second well to be probed 
with 50 µl of the secondary antibody, which was also diluted in the blocking solution 
(Table 2.7), for 1-2 hours in the dark. The coverslip was again transferred to the original 
well to be washed three times with PBS followed by one 10-minute wash with PBS, 
one 10-minute wash with DAPI (0.1 µg/ml, Sigma) diluted in PBS (1 in 10,000 dilution) 
and a final 10-minute wash with PBS. All washes after the addition of the secondary 
antibody were performed in the dark. The coverslip was then immerged 5 times in 
water and 5 times in ethanol, air-dried and mounted on a glass slide using Moviol. The 
cells were visualized using a Zeiss Axiovert 200M inverted microscope and analysed 
using the Axiovert software. 
Antibody Source Reference # number Dilution 
α-Fibrillarin Mouse SantaCruz G2808 1 in 200 
α-FLAG Rabbit Sigma 
F7425-
2MG 1 in 100 
α-HA Mouse 
Perkeley Antibody 
Company N/A 1 in 200 
α-Rabbit Alexa Fluor 555 Donkey Invitrogen N/A 1 in 500 
α-Mouse Alexa Fluor 647 Donkey Invitrogen N/A 1 in 500 
 
 
Table 2.7. The primary and secondary antibodies used for 
immunofluorescence. 
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2.2.8 Pulse chase labelling 
 
Cells were plated on a 6-well plate and treated as described in each experiment. They 
were then incubated at 37°C/5 % CO2 for 1 hour with Phosphate-Free Media (Life 
Technologies) for phosphate depletion before being incubated for 1 hour with 
Phosphate-Free Media with added 32P-orthophosphate (0.5 µl per ml) at 37°C/5 % 
CO2. Incubation with normal DMEM media (Sigma Aldrich) followed for 3 or 4 hours 
(chase) as stated in each experiment. RNA was extracted using Tri-reagent and loaded 
on a glyoxal-agarose gel as described below. The membrane was exposed to a 
phosphorimager screen before visualization of RNA using a Typhoon Phosphorimager 
(Life Technologies). ImageQuant software was used for quantitation of RNA bands and 
each RNA value was normalized against the loading control as stated in each 
experiment. 
 
2.3 Protein Methods 
 
2.3.1 Western Blotting 
 
Cells were harvested by trypsinization and centrifuged at 3,000rpm on a benchtop 
centrifuge for 2-5 minutes. The pellet was resuspended in 2x Protein Loading Dye (74 
mM Tris-HCl pH 6.8, 1.25 mM EDTA, 20 % glycerol, 2.5 % SDS, 0.125 % bromophenol 
blue, 50 mM DTT) and mixed, before incubated at 95°C for 5-10 minutes. The sample 
was loaded on an SDS polyacrylamide (PAGE) gel, consisting of 13 % separating gel 
(4.33 ml 30 % acrylamide (37.5:1), 2.5 ml 4x resolving gel buffer (1.5 M Tris pH 8.8, 
0.4% SDS), 33 µl 10% ammonium persulfate, 33 µl TEMED, water up to 10 ml) and 4 
% stacking gel (1.7 ml 30 % acrylamide (37.5:1), 2.5 ml 4x stacking gel buffer (0.5 M 
Tris pH 6.8, 0.4 % SDS), 100 µl 10% ammonium persulfate, 10 µl TEMED, water up to 
10 ml). Electrophoresis was carried out for 40 minutes at 200V in 1x Protein Running 
Buffer (25 mM Tris-HCl pH 8.3, 250 mM glycine, 0.1 % SDS (w/v)) in a BioRad Western 
Electrophoresis tank. The samples were transferred on a nitrocellulose membrane 
(Protran, GE Healthcare) for 1,5 hour at 65V in Western Transfer Buffer (25 mM Tris-
HCl pH 8.3, 150 mM glycine, 10 % methanol) in a BioRad Western Transfer tank. The 
membranes were stained with Ponceau S solution (Sigma) confirming efficient transfer 
of the sample. Next, the membranes were blocked, in order to avoid any unspecific 
antibody binding, using 2 % non-fat milk (Marvel) in 1x Phosphate Buffer Saline 
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(PBS)/0.1 % Triton for 1-2 hours at room temperature. The membranes were then 
probed with the primary antibodies diluted in blocking solution (Table 2.8) overnight at 
4°C before washed for 5-10 minutes for 3 times with 1x PBS/0.1 % Triton. 
 
 
The membranes were subsequently probed with the secondary antibodies diluted in 
blocking solution (Table 2.9) for 1-2 hours at room temperature before washed again 
for 5-10 minutes for 3 times with 1x PBS/0.1 % Triton. 
Antibody Source Reference # number Dilution 
Donkey α-Goat HRP conjugated Donkey SantaCruz sc-2020 1 in 10,000 
Donkey α-Mouse CD800 Donkey LICOR 926-32212 1 in 10,000 
Donkey α-Mouse HRP conjugated Donkey SantaCruz sc-2314 1 in 10,000 
Donkey α-Rabbit CD680 Donkey LICOR 926-60073 1 in 10,000 
Donkey α-Rabbit HRP conjugated Donkey SantaCruz sc-2313 1 in 10,000 
 
 
The membranes probed with Horseradish Peroxidase (HRP)-conjugated secondary 
antibodies were developed on an ECL film (GE Healthcare) using the Automatic 
Developer after the addition of ECL solution (Thermo Scientific). The membranes 
Antibody Source Reference # number Dilution 
α-CSL4 Rabbit 
Watkins Lab, raised against 
peptides, ref: 1390 1390 1 in 500 
α-Dyskerin Rabbit SantaCruz sc-48794 1 in 1,000 
α-FLAG Rabbit Sigma F7425-2MG 1 in 1,000 
α-HA Mouse Perkeley Antibody Company N/A 1 in 5,000 
α-Karyopherin Rabbit SantaCruz SC-11367 1 in 1,000 
α-p21 Rabbit SantaCruz sc-397 1 in 200 
α-p53 Mouse SantaCruz sc-126 1 in 500 
α-PICT1 Goat SantaCruz sc-46615 1 in 500 
α-PNO1 Rabbit 
Watkins Lab, raised against 
peptides N/A 1 in 500 
α-RIO2 Goat SantaCruz E-14 E-14 1 in 200 
α-RPL5 Rabbit SantaCruz A0912 1 in 5,000 
α-RPL7 Rabbit Abcam ab72550 1 in 2,000 
α-RPS19 Rabbit 
P. Mason (Idol et al, 2007), 
Sloan et al, 2013 (JCB) N/A 1 in 1,000 
α-Tubulin Mouse Cell Signalling 3873 1 in 1,000 
Table 2.8. The primary antibodies used for Western Blotting. 
Table 2.9. The secondary antibodies used for Western Blotting. 
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probed with fluorescently-labelled secondary antibodies (CD680 or CD800) were 
visualized using the Odyssey-LICOR system (LICOR). Quantitation of the western 
blots was performed using the ImageQuant software (GE Healthcare), followed by 
normalization against the loading control. 
 
2.3.2 Luciferase assay 
 
U2OS cells expressing luciferase under the control of a p53-regulated promoter (kindly 
provided from Dr Neil Perkins, Newcastle University) were plated on a 24-well plate 
(approximately 5x104 cells) and treated appropriately before washed once with 
Phopshate Buffer Saline (PBS) (Sigma Aldrich). The cells were harvested using 1x 
Lysis Buffer (Promega) and the luciferase reaction was carried out according to the 
manufacturer’s instructions using the Promega Luciferase Kit. Measurements of the 
luciferase intensity were taken using the Lumat 100 Luminometer (Berthold). Bradford 
assay was also performed in order to identify differences in cell numbers, where 10 µl 
of cell extract was added to 790 µl of water (800 µl of water was used as a blank 
control) before the addition of 200 µl of Bradford Reagent. The samples were incubated 
for 5 minutes at room temperature before the Optimal Density (OD) was measured at 
595 nm using a Spectrophotometer (Ultrospec 2000). In order to calculate the fold 
difference in p53 activity, the luciferase intensity values were normalized against the 
OD values from the Bradford assay for each sample. 
 
2.3.3 Glycerol gradients 
 
10-40 % glycerol gradient (v/v) were prepared by adding approximately 2 ml of 10 % 
Glycerol solution (10 % Glycerol, 0.15 M KCl, 20 mM HEPES pH 8, 1.5 mM MgCl2, 1 
mM DTT, 0.2 % Triton X-100) to an Ultra-Clear Centrifuge Tube (Beckman). Using a 
long needle, 40 % Glycerol solution (40 % Glycerol, 0.15 M KCl, 20 mM HEPES pH 8, 
1.5 mM MgCl2, 1 mM DTT, 0.2 % Triton X-100) was under the 10% gradient solution. 
A rubber lid was placed at the top and the gradients were rotated at 83° angle for 1 
minute and 10 seconds at 22rpm on a BioComp Gradient master (BioComp), before 
being stored in the fridge for 1h. In the meantime, approximately 5-7x106 cells were 
resuspended in 0.5 ml of Gradient Buffer E (20 mM HEPES pH 8, 150 mM KCl, 0.5 
mM EDTA, 0.1 mM DTT, 5 % Glycerol) on ice. The cells were disrupted by sonication 
twice for 15sec with a 30sec interval at 20 % amplitude/0.3sec pulse. 0.2 % Triton-X 
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100 was added to the samples before centrifuging for 10min at 4°C at 13,000rpm to 
remove any insoluble material. 400 µl were removed from the top of the gradient, which 
was then placed on a pre-cooled swTi60 bucket, where 400 µl of the extract were 
loaded. 40 µl of the sample before centrifugation were stored in -20⁰C, representing 
the 10 % total sample. The buckets were then balanced using Gradient Buffer E. 
Centrifugation took place in a swTi60 rotor (Beckman L7-80) for 1,5h at 52,000rpm at 
4°C with brakes to slow acceleration. Each gradient was then fractionated using 200 
µl from top to bottom and frozen in liquid nitrogen before being stored in -80°C. For 
Western Blot analysis, 20 µl of each fraction was added to 5 µl of 5x Protein Loading 
Dye and 5 µl of the total sample was added to 5 µl of 2x Protein Loading Dye, before 
loaded on an SDS-PAGE gel and analysed as described above. 
 
2.4 RNA methods 
 
2.4.1 RNA extractions 
 
RNA was extracted for total cell pellets using Tri-Reagent. 1 ml of Tri Reagent (Ambion) 
was added to whole cell pellet from a 6-well plate and incubated for 5 minutes at room 
temperature. 200 µl of chloroform were added and the samples were vortexed for 
approximately 15 seconds until mixed. The samples were incubated at room 
temperature for 2 minutes before being centrifuged at 12,000g for 15 minutes for 
separation of RNA (top layer), DNA (middle layer) and protein (bottom layer). The RNA 
(top layer) was transferred to a clean microcentrifuge tube and 500 µl of isopropanol 
(Sigma Aldrich) were added. The sample was vortexed for 1-2 seconds and incubated 
at room temperature for 5 minutes before being centrifuged at 12,000g for 10 minutes. 
The supernatant was discarded and the RNA pellet was washed with 1 ml of 75 % 
ethanol before centrifuged for 5 minutes at 13,000rpm. The supernatant was again 
discarded and the RNA pellet was dried using the speed-vac for 1 minute. The RNA 
pellet was diluted in 12-13 µl of water and incubated at 55°C for 10 minutes. The RNA 
was stored at -20°C until needed. 
 
2.4.2 Reverse-Transcription (RT)-PCR  
 
RT-PCR was performed in order to identify the levels of the mRNAs where no 
antibodies were available either commercially or in the lab. RNA was extracted from 
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the cells using Tri-reagent as described above. DNase treatment followed in order to 
remove any DNA that was potentially left in the sample, where 8 µl of the total RNA 
were added to 8 µl of water before the addition of 2 µl of DNase Turbo 
(ThermoScientific) and 2 µl of DNase Turbo Buffer (ThermoScientific). The samples 
were incubated at 37°C for 1 hour followed by incubation at 80°C for 5 minutes to 
denature the DNase. Next, reverse transcription was carried out, where 1 µl of the 
DNase-treated RNA (approximately 400 ng) was added to 9 µl of water before the 
addition of 1 µl of 2 µM of an oligo-dT primer and 1 µl of 10 mM dNTPs. The samples 
were incubated at 65°C for 5 minutes and in ice for 1 more minute. After the addition 
of 4 µl of 5x First-Strand (FS) Buffer (ThermoScientific), 2 µl of 0.1 M DTT 
(ThermoScientific) and 1 µl of rRNAsin (Promega), the samples were gently mixed and 
incubated at 42°C for 2 minutes. 1 µl of Superscript III Reverse Transcriptase 
(ThermoScientific) was added to the mixture, whereas 1 µl of water was added as a 
negative control. The samples were incubated at 42°C for 50 minutes, followed by 
incubation at 70°C for 15 minutes. The primers used for the final PCR step are 
described on table 2.10. 
 
 
GoTaq D2 DNA polymerase was used for the final PCR according to the 
manufacturer’s instructions (Table 2.11). 
 
 
 
 
 
 
 
 
Name Forward primer (5’ to 3’) Reverse Primer (5’ to 3’) 
GAPDH GTCGTATTGGGCGCCT 
GGTCACCC 
ACACCCATGACGAACATGGGGGC 
RPL18 CTACCTGAGGCTGTTGG 
TCAAG 
CGAAATGCCGGTACACCTCTC 
RPL21 GGAAAGAGGAGAGGC 
ACCCG 
GCTGGCGCTTTAGTTGAACC 
RPL40 GATCGGATCCATGCAGATCTT
TGTGAAGACCCTCAC 
GGATAGCCCGCATAGTCAGGAACATCGTATGGGTA
TTTGACCTTCTTCTTGGGACGC 
RPS27a GATCGGATCCATGCAGATTTT
CGTGAAAACCCTTAC 
GGATAGCCCGCATAGTCAGGAACATCGTATGGGTA
CTTGTCTTCTGGTTTGTTGAAACAGTAAGTCAG 
Table 2.10. Primers used for RT-PCR. 
GoTaq G2 (RT-PCR) 
Step 
Temperature 
(°C) Time (min) Cycles 
Initial activation 95 5 1 
Denaturation 95 1 
20-25 Annealing Tm - 3 1/kb 
Extension 72 2 
Final Extension 72 5 1 
Table 2.11. The PCR conditions using Go-Taq D2 DNA polymerase 
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2.4.3 Northern Blotting 
 
RNA was extracted from the cells and diluted in 1x Glyoxal Loading Buffer (61.2 % 
DMSO (v/v), 20.4 % glyoxal (v/v), 12.2 % 1x BPTE buffer (28.7 mM Bis-Tris, 9.9 mM 
PIPES, 1 mM EDTA) (v/v), 4.8 % glycerol (v/v), and 0.02 mg/ml ethidium bromide), 
before being incubated at 55°C for 1 hour. The sample was loaded on a glyoxal-
agarose gel consisting of 1.2 % Agarose (Melford) in 1x BPTE (30 mM Bis-Tris free 
acid pH 7.0, 10 mM PIPES free acid, 1 mM EDTA) diluted in 1x BPTE buffer. The RNA 
was separated for 3,5 hours at 185V in 1x BPTE buffer and visualized using a UV light 
or the Typhoon Phosphorimager. The gel was then washed once with 75 mM NaOH 
at room temperature for 20 minutes, twice with Tris-Salt pH 7.4 (0.5 mM Tris-HCl pH 
7.4, 1.5 M NaCl) at room temperature for 15 minutes and once with 6x SSC (1 M NaCl, 
0.1 M Na3C6H5O7) at room temperature for 20 minutes. The RNA was transferred on 
a Hybond N membrane (Amersham) in 6x SSC overnight at room temperature using 
the capillary action method. The RNA was then cross-linked on the membrane using 
the auto-crosslinking option on the Stratalinker UV Crosslinker (Stratagene). 
 
Alternatively, RNA was extracted and diluted in 1x RNA loading dye (40 % formamide, 
0.5 mM EDTA, 50 µg/ml bromophenol blue, 50 µg/ml xylene cyanol). The sample was 
incubated for 2-5 minutes at 95°C and loaded on an 8 % Acrylamide/7 M Urea gel. 
Electrophoresis was performed for approximately 1 hour at 400V in 1x TBE solution, 
following RNA transfer on a Hybond N membrane (Amersham) in 0.5x TBE solution 
for 1,5 hour at 65V in a transfer tank. The RNA was cross-linked on the membrane 
using the auto-crosslinking option the Stratalinker UV Crosslinker (Stratagene). 
 
The RNA membranes were pre-hybridized using 10 ml of SESI buffer (0.5 M sodium 
phosphate pH 7.2, 7 % SDS (w/v), 1 mM EDTA) for 5’-oligo probes for 30 minutes at 
37°C. After pre-hybridization, the membranes were incubated with the respective 
probes for 1-2 days at 37°C. After decanting of the 5’-oligo labelled probes, the 
membranes were washed for 20 minutes twice at 37°C using 1x SSC/0.1 % SDS 
solution before exposed to a phosphorimager screen. Alternatively, hybridization (Pre-
Hyb) buffer (25 mM NaPO4  pH 6.5, 6x SSC, 5x Denhardts, 0.5 % SDS (w/v), 50 % 
deionised formamide, 100 μg/ml denatured salmon sperm DNA) was used for random-
prime labelled probes, where the membrane was incubated for 2 hours at 42°C. After 
pre-hybridization, the membranes were incubated with the respective probes for 1-2 
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days at 42°C. After decanting of the random-prime labelled probes, the membranes 
were washed twice for 5 minutes at 42°C with 2x SSC/0.5 %SDS, twice for 5 minutes 
at 42°C with 2x SSC/0.1 % SDS and finally for 20 minutes at 50°C with 2x SSC/0.1 % 
SDS, before exposed to a phosphorimager screen and visualized using a Typhoon 
Phosphorimager. 
 
2.4.4 32P-Labelled probes for Northern Blotting 
 
Oligo probes (Table 2.12) were labelled using a 32P-labelled γ-ATP (Perkin Elmer), by 
adding 1 µl of the oligo-primer (10 µM), 1 µl of Polynucleotide Kinase Buffer (New 
England Biolabs), 2-3 µl of 32P-labelled γ-ATP and 1 µl of T4 Polynucleotide Kinase 
(New England Biolabs) in 10 µl reaction. The mixture was incubated at 37°C for 45 
minutes before the addition of 40 µl of water. Any excess radioactive material was 
removed using a G50 column (Life Technologies) by centrifugation of the mixture at 
3,000rpm for 2 minutes on a benchtop centrifuge. The probe was incubated at 95°C 
for 2 minutes before added to the SESI buffer for membrane hybridization. 
Name Sequence 
18S GGGCGGTGGCTCGCCTCGCG 
28S TGGTCCGTGTTTCAAGACGGGT 
5’-ITS1 CCTCGCCCTCCGGGCTCCGTTAATGATC 
ITS1 AGGGGTCTTTAAACCTCCGCGCCGGAACGCGCTAGGTAC 
ITS2 GCGCGACGGCGGACGACACCGCGGCGTC 
pre-5.8S ATTGATCGGCAAGCGAC 
 
 
 
Random-primed labelled probes (Table 2.13) were made using a random hexamer 
mix. 25-50 ng of template DNA, which was PCR-amplified from a plasmid template 
(Madhumalar et al., 2009), was placed in a microcentrifuge tube and water was added 
to a final volume of 9 µl. The mixture was incubated at 95°C for 5 minutes and then 
placed on ice for 1 minute. Next, 3 µl random hexamer mix (250 mM Tris pH 7.5, 50 
mM MgCl2, 5 mM DTT, 500 µM dATP, 500 µM dGTP, 500 µM dTTP), 2 µl of 32P-
labelled dCTP (Perkin Elmer) and 1 µl of Klenow Polymerase (Promega) were added 
to the sample. The mixture was incubated at 37°C for 30 minutes before the addition 
of 35 µl of water. Similarly to the oligo-labelled probes, the excess radioactive material 
was removed using a G50 column (Life Technologies), by centrifugation of the sample 
at 3,000rpm for 2 minutes on a benchtop centrifuge. The probe was finally incubated 
at 95°C for 2 minutes before added to the Pre-Hyb Buffer for membrane hybridization. 
Table 2.12. The oligo rRNA probes used for Northern Blotting. 
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 2.5 Other assays 
 
2.5.1 Immunoprecipitation 
 
Approximately 2x107 cells were harvested by trypsinization and centrifuged at 800rpm 
(swing bucket centrifuge) for 3 minutes. 2 ml of Gradient Buffer E (150 mM KCl, 20 mM 
HEPES pH 8.0, 0.5 mM EDTA, 0.1 mM DTT) was added to each sample before 
vortexing for a few seconds until the cell pellet was dissolved. The samples were kept 
on ice throughout the whole procedure. The samples were sonicated at 20 % 
amplitude/0.3sec pulse/1sec off, 3x 20 sec on-20 sec off intervals before the addition 
of 100 µl of 20 % Triton-X (final concentration of 0.2 %), 222 µl of 87 % Glycerol (final 
concentration of 10 %) and 3 µl of 1 M MgCl2 (final concentration of 1.5 mM). The 
samples were mixed gently and divided into two microcentrifuge tubes before 
centrifugation at 12,000g for 10 minutes at 4°C. The supernatant was transferred to a 
clean microcentrifuge tube. 100 µl of sample was stored in -20⁰C representing the 5 % 
of the total sample. 
 
The beads were prepared the day before using 10 µl of Protein G-sepharose beads 
(GE Healthcare) for each reaction by washing them 3 times in 1 ml of ice-cold 
immunoprecipitation (IP) buffer (10 % Glycerol, 0.15 M KCl, 20 mM HEPES pH 8.0, 
1.5 mM MgCl2, 1 mM DTT, 0.2 % Triton X) and resuspending them in 1 ml of IP buffer 
before the addition of 2 µl of α-FLAG antibody (Sigma Aldrich) per sample. The 
antibody was bound on the Protein G-sepharose beads by gently rotating the mixture 
overnight at 4°C. Control beads were used, which contained no antibody. Both control- 
and FLAG-beads were again washed 3 times in 1 ml of ice-cold IP buffer and 
resuspended in 1 ml of ice-cold IP buffer. 100 µl of the beads were added in a 
Name Vector Forward Primer (5’ to 3’) Reverse primer (5’ to 3’) 
U1 pUC18 GGGGAAAGCGCGAACGCAGdTdT TACTTACCTGGCAGGGGAGd
TdT 
U17 pBS+HU17  T7 T3 
U64 pUC19 ACTCTCTCGGCTCTGCATAGTTGCd
TdT 
GCCTGTTTGCACCCCTCAAG
GdTdT 
U19 N/A ATCCAGCGGTTGTCAGCTATCCdTd
T 
AATTGTTTGCACCCAGACTAG
GdTdT 
U70 N/A CCGCAGCCAATTAAGCCGACdTdT GCCTGTCTCCAAGGTCCCTT
AGAGCdTdT 
Table 2.13. The PCR products used for random-prime labelling of rRNA probes 
for Northern Blotting. 
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microcentrifuge tube for each reaction. 1 ml of the lysate was added to either the α-
FLAG or the control beads and the mixture was gently rotated for 2 hours at 4°C. The 
samples were centrifuged at 3,000rpm at 4°C for 1 minute and washed 3 times using 
1 ml of ice-cold IP buffer, before diluted in 1ml of ice-cold IP buffer and transferred to 
a clean microcentrifuge tube. 
 
RNA was extracted by adding 180 µl of Homogenization Buffer (1 % SDS, 50 mM Tris, 
50 mM NaCl, 0.5 mM EDTA) to each sample and 200 µl of Phenol/Chloroform (Sigma 
Aldrich). The samples were vortexed for 2-3 minutes and centrifuged at 13,000rpm for 
5 minutes. The RNA was transferred to a clean microcentrifuge tube, where 1 µl of 20 
mg/ml Glycogen Blue (Fisher Scientific), 12.5 µl of 3 M NaOAc pH 5.3 (final 
concentration of 1 in 10) and 500 µl of 100 % ethanol (final concentration of 2.5x) were 
added. The samples were incubated at -80°C for 1 hour or -20°C overnight before 
being centrifuged at 12,000g for 20 minutes at 4°C. The RNA pellet was washed in 1 
ml of ice-cold 75 % ethanol and further centrifuged at 12,000g for 20 minutes at 4°C. 
The RNA pellet was air-dried before resuspended in 8 µl of water. RNA analysis was 
performed using Northern Blotting as described above.  
 
2.5.2 Statistical Analysis 
 
Statistical analysis took place using Microsoft Excel, where the T-test function was 
used. Unpaired t-test using a two-tailed distribution was performed. 
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3. Chapter Three. The role of Dyskerin in human ribosome 
biogenesis and p53 regulation 
 
3.1 Introduction 
 
Ribosome biogenesis is a tightly regulated pathway that involves more than 200 
proteins, including nucleases and helicases (Henras et al., 2008). The 28S, 18S and 
5.8S rRNAs are transcribed as a single (47S) rRNA precursor by RNA polymerase I in 
the nucleolus, whereas the 5S rRNA is transcribed by RNA polymerase III in the 
nucleoplasm (Granneman and Baserga, 2004). The mature rRNAs are produced after 
a series of cleavage events and they incorporate a number of modifications necessary 
for their stability and function. One of the main rRNA modifications is the conversion of 
uridine to the isomer pseudouridine (Figure 3.1A). This process is catalysed by 
pseudouridine synthases. A conserved aspartic acid residue found in all pseudouridine 
synthases acts as a nucleophile (Ramamurthy et al., 1999) and interacts with the uracil 
to promote a break in the glycosyl bond between the uracil and the ribose, followed by 
the rotation of the uracil before being attached back on the ribose (Boschi-Muller and 
Motorin, 2013). In uridine, the C1 atom of the ribose interacts with the N1 atom of the 
uracil via the formation of a glycosyl bond. In contrast, in pseudouridine the C1 atom 
of the ribose interacts with the C5 atom of the uracil (Figure 3.1A). This C-C bond in 
pseudouridine allows for an increased rotation ability and for additional base pairing 
with other molecules by interactions with the N1 atom, so that more stable structures 
are formed when pseudouridine is present (Charette and Gray, 2000). 
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Figure 3.1. The pseudouridylation and the H/ACA snoRNP. (A) Schematic 
representation of the differences between uridine and pseudouridine. The atom 
positions on the uracil rings and the Watson-Crick surface is indicated in each case. 
Ψ=pseudouridine. (B) Schematic representation of the functions of the H/ACA RNP. 
The H/ACA RNP consists of Dyskerin (orange), NOP10 (green), NHP2 (grey), GAR1 
(blue) and an RNA component (black), and is involved in ribosome biogenesis, mRNA 
splicing and telomere maintenance. The Cajal-body chaperone protein TCAB1 is 
shown in red and the protein component of telomerase (TERT) is show in light blue. 
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The process of pseudouridylation is catalysed by the H/ACA small nucleolar 
(sno)RNPs, which consist of the pseudouridine synthase Dyskerin (Cbf5 in yeast and 
archaea), the core proteins NOP10, NHP2 (L7Ae in archaeal) and GAR1, and a 
snoRNA component (Figure 3.1B) (Watkins and Bohnsack, 2011). The structure of the 
H/ACA snoRNP has been solved in archaea, where the H/ACA snoRNA consists of 
one stem loop, containing the ACA motif at the bottom, the P1 and P2 stems and a K-
turn at the top (Watkins and Bohnsack, 2011). Cbf5 interacts with the H/ACA snoRNA, 
by binding on the ACA motif (Baker et al., 2005), L7Ae binds the K-turn 
(Rozhdestvensky et al., 2003) and the surface between the P2 stem and the K-turn is 
bound by the Cbf5-Nop10-L7Ae complex. Gar1 does not interact directly with the 
H/ACA snoRNA and it binds the thumb loop of Cbf5 (Watkins and Bohnsack, 2011). 
In eukaryotes, the structure of the H/ACA snoRNP is yet to be solved, but the 
similarities between the H/ACA snoRNAs and proteins (Reichow et al., 2007) indicate 
that the eukaryotic complex shows structural similarity to the archaeal complex. 
Indeed, it was shown in yeast that the Cbf5-Nop10-Gar1 complex is structurally similar 
to the archaeal complex (Li et al., 2011). It is thought that the eukaryotic H/ACA 
snoRNAs consist of two stem loops instead of one (Figure 3.1B) (Ganot et al., 1997b) 
which are important for the formation and function of the H/ACA RNP. Presumably, the 
two Dyskerin molecules interact with each other (Figure 3.1B) (Watkins et al., 1998) 
and binding of Dyskerin to NOP10 is required for the recruitment of NHP2 to the 
complex because of the lack of a K-turn in eukaryotic H/ACA snoRNAs (Watkins and 
Bohnsack, 2011). GAR1 interacts with Dyskerin but not with the H/ACA snoRNA, and 
is important for the organization of the complex to help keep the substrate in place 
during catalysis and for the final product to be released (Duan et al., 2009). 
 
Most H/ACA snoRNAs interact with the RNA substrate by base-complementarity 
(Henras et al., 2008), which is important for both the modification and the positioning 
of the rRNA substrate during catalysis (Henras et al., 2008). The majority of H/ACA 
snoRNAs are involved in LSU or SSU rRNA pseudouridylation. For example, the U64 
H/ACA snoRNA is important for pseudouridylation of U4975 of the 28S rRNA, whereas 
the U66 H/ACA snoRNA guides the pseudouridylation of U119 of the 18S rRNA in 
humans (Ganot et al., 1997a). Notably, a number of H/ACA snoRNAs have been found 
to be involved in rRNA processing rather than modification, such as U17/E1 (snR30 in 
yeast) (Enright et al., 1996, Morrissey and D.Tollervey, 1993, Mishra and Eliceiri, 1997) 
and snR10 (Tollervey, 1987), both of which have been shown to be important for 18S 
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rRNA processing. U17 depletion in frog oocytes resulted in a decrease of mature 18S 
rRNA and an accumulation of the 18S rRNA precursors (Mishra and Eliceiri, 1997), 
which was similar to the phenotype shown in yeast after snR30 depletion (Morrissey 
and D.Tollervey, 1993). Furthermore, it was shown that snR30 base pairs directly with 
18S pre-rRNA sequences in yeast, which is important for its processing resulting in the 
production of the mature 18S rRNA (Fayet-Lebaron et al., 2009). Similarly, the human 
U17 H/ACA snoRNA was found to interact directly with 18S rRNA precursors (Rimoldi 
et al., 1993, Atzorn et al., 2004), suggesting that it might be involved in SSU 
processing. Depletion of snR10 was also shown to affect 18S rRNA processing in yeast 
(Tollervey, 1987) and it is likely that base pairing of snR10 with the precursor rRNA is 
required for processing (Liang et al., 2010). To date, no H/ACA snoRNAs were found 
to be solely involved in LSU rRNA processing in higher eukaryotes that resemble the 
mechanism of action of U17/snR30 or snR10. TB11Cs2C2 snoRNA in Trypanosoma 
brucei, a protozoan parasite, was suggested to have specific roles in LSU rRNA 
processing (Gupta et al., 2010) and bioinformatics analysis of the snoRNAs in 
Leishmania major, another protozoan parasite, suggested that some snoRNAs might 
be involved in both SSU and LSU rRNA processing (Eliaz et al., 2015). For example, 
LM35Cs3C5, a L.major-specific snoRNA, is likely to be involved in LSU rRNA 
processing and SSU rRNA modification (Eliaz et al., 2015). Whether this is the case 
with some H/ACA snoRNAs in higher eukaryotes remains to be demonstrated. 
 
Apart from its role in human ribosome biogenesis, the H/ACA RNP has additional roles 
in the cell. Firstly, it is involved in mRNA splicing, by pseudouridylation of small nuclear 
(sn)RNAs (Figure 3.1B) (Darzacq et al., 2002, Karijolich and Yu, 2011, Fernandez et 
al., 2013). The H/ACA proteins bind to the H/ACA small Cajal (sca)RNAs, forming the 
H/ACA scaRNP, which was found or predicted to be involved in the pseudouridylation 
of U1, U2, U4, U5 and U6 snRNAs involved in mRNA splicing (Darzacq et al., 2002). 
For example, U93 H/ACA scaRNA was predicted to be important for pseudouridylation 
of both U2 and U5 snRNAs (Kiss et al., 2002, Schattner et al., 2006). The localization 
of the H/ACA scaRNP complex to the Cajal body, a nuclear sub-organelle, is aided by 
the binding of the chaperone protein TCAB1 (Tycowski et al., 2009). Furthermore, the 
H/ACA snoRNP is an essential part of telomerase and important for telomere 
maintenance (Figure 3.1B). Telomerase is a ribonucleoprotein complex consisting of 
a protein (TERT) and an RNA (TERC) component, which adds DNA sequence repeats 
at the ends of telomeres (Feng et al., 1995). The H/ACA snoRNP part of telomerase is 
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important for both the assembly and stability of the telomerase complex (Meier, 2005). 
The involvement of the H/ACA snoRNP in ribosome biogenesis, splicing and telomere 
maintenance may provide a regulatory link between these three processes. 
 
A number of genetic diseases, called ribosomopathies, arise because of mutations in 
genes encoding for ribosomal proteins or ribosome biogenesis factors. Examples of 
these diseases include Diamond-Blackfan anaemia, Dyskeratosis Congenita and 5q 
syndrome (Freed et al., 2010b). Dyskeratosis Congenita (DC) is a rare genetic disorder 
characterized by bone marrow failure, nail dystrophy, immune deficiencies and tumour 
development (Mason and Bessler, 2011). DC is presented with different modes of 
inheritance. X-linked DC is caused by mutations in DKC1 gene, which encodes for 
Dyskerin (Heiss et al., 1998, Knight et al., 1998), whereas autosomal recessive DC is 
caused by mutations in NOP10 (Walne et al., 2007) or NHP2 (Vulliamy et al., 2008) 
genes. Interestingly, autosomal dominant DC arises because of mutations in genes 
encoding for TERT (Armanios et al., 2005) or TERC (Vulliamy et al., 2001) component 
of human telomerase. A more severe form of DC, called Hoyeraal-Hreidarsson 
syndrome, presents with a higher mortality rate (Yaghmai et al., 2000). Several 
mutations in DKC1 gene were found to cause Hoyeraal-Hreidarsson syndrome, such 
as P10L, found in the Dyskerin-specific domain of Dyskerin (Figure 3.2) (Vulliamy et 
al., 2006). Interestingly, mutations found on domain encoding for the catalytic TruB 
domain of Dyskerin all result in both X-linked Dyskeratosis Congenita and Hoyeraal-
Hreidarsson syndrome (Podlevsky et al., 2008). More specifically, S121G (Knight et 
al., 1999) and R158W (Knight et al., 2001) mutations found in the catalytic site of 
Dyskerin (Figure 3.2) were identified in DC patients. 
 
It was originally thought that DC arises due to telomere defects, since telomere 
shortening is observed in all forms (Podlevsky et al., 2008). This idea was enforced 
after the discovery of mutations in the genes encoding for TERT (Armanios et al., 2005) 
Figure 3.2. Schematic representation of the domain organization of DKC1 gene 
and the site of mutations. The nuclear localization signals (NLS) are shown in grey, 
the Dyskerin-specific domain is shown in green, the RNA-binding domain (PUA) is 
shown in light blue and the catalytic domain (TruB) is shown in red. The P10L, S121G 
and R158W mutations found in DC patients are clearly indicated. 
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or TERC (Vulliamy et al., 2001) that were shown to cause DC. However, clinical 
features of the disease, such as anaemia, are common to other ribosomopathies, 
similar to Diamond-Blackfan Anaemia and 5q syndrome (Narla and Ebert, 2010). The 
DC phenotype has been found to present before telomere shortening in mouse models 
(Ruggero et al., 2003, Gu et al., 2008) and in zebrafish (Ying Zhang et al., 2012), 
supporting the theory that ribosome biogenesis defects might be responsible for DC 
as well as telomere shortening. Furthermore, a recent study showed that increased 
cell proliferation in neuroblastoma patient samples was due to Dyskerin-related 
ribosome biogenesis defects but independent of telomerase inhibition (O'Brien et al., 
2016a). 
 
Most ribosomopathies, including DC, present with a high risk of developing cancer, 
especially Acute Myeloid Leukaemia (AML) (Narla and Ebert, 2010). In mice and 
zebrafish models of ribosomopathies, the clinical symptoms of some of these diseases 
were shown to be dependent on the tumour suppressor p53 (Yelick and Trainor, 2015). 
Ribosome biogenesis is directly involved in the regulation of p53 in the cell (Pelava et 
al., 2016). p53 is controlled by MDM2, an E3 ubiquitin ligase, which binds and 
ubiquitinates p53, targeting it for proteosomal degradation (Figure 3.3) (Meek, 2015). 
MDM2 was found to be regulated by the 5S RNP, an LSU intermediate complex 
consisting of the ribosomal proteins RPL5 and RPL11 along with the 5S rRNA (Donati 
et al., 2013, Sloan et al., 2013a, Nishimura et al., 2015). Under normal conditions, the 
5S RNP is integrated in the large ribosomal subunit during ribosome biogenesis. Under 
stress conditions, ribosome biogenesis is blocked, resulting in an increase in the levels 
of the free 5S RNP in the nucleoplasm, since it can no longer be integrated into the 
large ribosomal subunit. The free 5S RNP, but not the individual RPL5, RPL11 or 5S 
rRNA (Sloan et al., 2013a), binds and inactivates MDM2, resulting in p53 stabilization 
(Figure 3.3) (Sloan et al., 2013a, Dai and Lu, 2004, Dai et al., 2008, Sun et al., 2010, 
Zhang et al., 2003, Lu, 2006, Nishimura et al., 2015). Being a major transcription factor 
in the cell, stabilization of p53 leads to transcriptional activation of downstream targets, 
such as p21, which is involved in cell cycle arrest, and Bax, which is involved in 
apoptosis (Brown et al., 2009). 
 
As with most ribosomopathies, p53 was found to be involved in models of X-linked DC 
where Dyskerin levels were significantly reduced. In zebrafish models, it was found 
that Dyskerin knockdown resulted in p53 activation, which led to the development 
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hematopoietic defects (Ying Zhang et al., 2012). Furthermore, depletion of Dyskerin in 
mouse livers was shown to cause an induction of p53, leading to cell cycle arrest (Ge 
et al., 2010b). On another study, hemizygous male mice carrying a mutation in the 
gene encoding for Dyskerin (DKC1) were shown to present with an induction in the 
p53-dependent DNA damage repair pathway (Gu et al., 2008). 
 
It is clear that Dyskerin plays a key role in the development of DC. In order to 
understand the exact causes of DC and how tumour development might occur, it is of  
vital importance to study the functions of Dyskerin in human cells. In yeast, it was 
shown that the H/ACA snoRNPs are mainly involved in the biogenesis of the small 
ribosomal subunit (Atzorn et al., 2004, Henras et al., 2004, Lafontaine et al., 1998). 
However, not many studies have been performed in human cells exploring the role of 
Dyskerin in ribosome biogenesis. Furthermore, mutations in the catalytic domain of 
Dyskerin result in the development of Hoyeraal-Hreidarsson syndrome and the 
presentation of severe clinical symptoms of X-linked Dyskeratosis Congenita 
(Podlevsky et al., 2008). These mutations only affect the pseudouridine synthase 
activity of Dyskerin, which was shown to be essential for both rRNA processing and 
modification in yeast (Zebarjadian et al., 1999) but, presumably, only for rRNA stability 
in mouse embryonic fibroblast cells (Gu et al., 2013). Therefore, I aimed to investigate 
Figure 3.3. Schematic representation of the regulation of p53 levels by the 5S 
RNP-MDM2 pathway. MDM2 (orange) binds and ubiquitinates p53 (green), targeting 
it for proteosomal degradation. The free 5S RNP (blue) binds and inactivates MDM2, 
causing p53 stabilisation, which leads to metabolic changes, cell cycle arrest, 
senescence and apoptosis. 
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the functions of Dyskerin in human ribosome biogenesis pathway and to identify 
whether the catalytic activity of Dyskerin is essential for rRNA processing in humans. 
Finally, since ribosome biogenesis defects are linked with the regulation of the p53 
tumour suppressor via the 5S RNP-MDM2 pathway (Pelava et al., 2016), I investigated 
whether p53 levels were affected when Dyskerin was knocked-down or inactive. 
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3.2 Results 
 
3.2.1 Dyskerin is likely to be essential for H/ACA snoRNP accumulation in 
HEK293T cells  
 
In order to study the functions of Dyskerin in human cells, a knockdown system was 
established in HEK293T human embryonic kidney cells using reverse transfection of 
siRNA complexes. The knockdown efficiency was evaluated by Western Blotting, after 
the whole cell extract was loaded on an SDS-PAGE gel. The levels of Dyskerin were 
analysed using an α-Dyskerin antibody and the exosome component CSL4 was used 
as a loading control (Figure 3.4A). Even though the lane with the Dyskerin knockdown 
was under-loaded, the siRNA treatment resulted in a reduction of the Dyskerin levels 
by approximately 60% (Figure 3.4A), as shown after quantitation using the 
ImageQuant software, and often worked more efficiently (see later). 
 
In yeast, Cbf5 is essential for the accumulation of the H/ACA snoRNP, since its loss 
results in a decrease in snoRNA levels (Zebarjadian et al., 1999). It was, therefore, 
expected that knockdown of Dyskerin in human HEK293T cells would also result in a 
reduction of the levels of the H/ACA snoRNAs. To confirm this, knockdown of Dyskerin 
was performed for 48h, and RNA was extracted and loaded on an 8% Acrylamide/7M 
Urea gel. The RNA was transferred on a Hybond N membrane, which was incubated 
with radiolabelled (32P) probes against the U17, U64, U19 and U70 H/ACA snoRNAs, 
with the U1 snRNA used as a loading control (Figure 3.4B). U17 is involved in SSU 
rRNA processing (Atzorn et al., 2004), U64 and U19 are involved in LSU modification 
(Ganot et al., 1997a) and U70 is involved in SSU rRNA modification (Ganot et al., 
1997a). In comparison to the control, knockdown of Dyskerin resulted in a reduction of 
the levels of all four H/ACA snoRNAs tested (Figure 3.4B). These data demonstrated 
that the Dyskerin-knockdown system in HEK293T showed the expected phenotype 
with Dyskerin being required for the accumulation of the H/ACA snoRNAs in humans. 
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 3.2.2 Dyskerin is required for ribosome biogenesis in HEK293T cells 
 
In yeast, it was shown that the H/ACA snoRNPs are required for biogenesis of the 
small ribosomal subunit (Lafontaine et al., 1998, Girard et al., 1992). Having 
established a knockdown system in HEK293 cells, I next investigated the function of 
Dyskerin in human ribosome biogenesis. Pulse-chase labelling was used to 
characterize the newly-synthesized rRNAs, after Dyskerin knockdown. HEK293T cells 
were incubated in phosphate-free media for 1h, followed by the addition of 
radiolabelled phosphate (32P) for 1h. The cells were then grown in normal media for 3h 
or 4h (chase) (Figure 3.5A). RNA was extracted, loaded on a 1.2% agarose-glyoxal 
gel and transferred on a Hybond N membrane. The ethidium bromide staining (UV) of 
the 28S rRNA was used as a loading control (Figure 3.5A). 
 
 
Figure 3.4. Dyskerin knockdown results in a reduction in the levels of the H/ACA 
snoRNAs tested. siRNA-mediated knockdown using Control or Dyskerin (DKC-2) 
siRNAs was performed in HEK293T cells for 48h. (A) Whole cell extracts were loaded 
on an SDS-PAGE gel, analyzed by Western Blotting and visualized using ECL. The 
antibodies, used to detect the levels of Dyskerin, and CSL4, used as a loading control, 
are indicated on the left of the panel. (B) RNA was extracted, separated on an 8% 
Acrylamide/7M Urea gel, and analyzed by Northern Blotting. Radiolabelled (32P) 
probes, indicated on the left of the panel, were used to detect the levels of U17, U64, 
U19 or U70 H/ACA snoRNAs. The U1 snRNA was used as a loading control. 
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 At 3h of chase after Dyskerin knockdown, there was an approximately 15% decrease 
in the 47/45S rRNA precursor levels and a 35% decrease in the levels of the 32S rRNA 
precursor as compared to the control (Figure 3.5A, B, 3h chase). Furthermore, the 
levels of the newly-synthesized 28S rRNA were decreased by approximately 50% after 
Dyskerin knockdown as compared to the control, whereas the levels of the newly-
synthesized 18S rRNA were decreased by approximately 70% (Figure 3.5A, B, 3h 
chase). By comparison, 4h of chase after Dyskerin knockdown, not much difference 
Figure 3.5. Dyskerin knockdown results in defects in both large and small 
ribosomal subunit biogenesis in HEK293T cells. (A) 48h after knockdowns using 
control or Dyskerin (DKC-2) siRNAs, the cells were incubated in a phosphate-free 
media for 1h. Addition of radiolabelled phosphate (32P) took place for 1h before the 
cells were left to grow under normal conditions for 3h or 4h (chase). RNA was extracted 
and loaded on a glyoxal-agarose gel, before being transferred on a Hybond N 
membrane and visualized using a Phosphorimager. The 28S rRNA levels after 
ethidium bromide staining (UV) were used as a loading control. (B) ImageQuant was 
used for quantitation of the rRNAs and the data were normalized against the loading 
control (28S UV). The graph represents the averages of two experimental repeats, and 
the rRNA levels after Dyskerin knockdown (DKC-2) were normalized to the rRNA levels 
using the control siRNA for 3h or 4h of chase. The dotted line represents the rRNA 
precursor levels in control cells. (C) Schematic representation of the rRNA processing 
intermediates seen in pulse labelling experiments in humans. The SSU precursors and 
mature rRNA are shown in green and the LSU precursors and mature rRNA are shown 
in blue. The cleavage sites are shown on the top (Adapted from (Sloan et al., 2013c)). 
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was observed in the levels of the 47/45S rRNA precursor as compared to the control 
(less than 10% decrease), but the levels of the 32S rRNA precursor were decreased 
by approximately 35% (Figure 3.5A, B, 4h chase). Similarly to the 3h chase, the levels 
of the newly-synthesized 28S and 18S were decreased by approximately 50% and 
60% respectively when Dyskerin was knocked down as compared to the control, after 
4h of chase (Figure 3.5A, B, 4h chase). 
 
Taken together, these data indicate that Dyskerin knockdown results in defects in the 
biogenesis of both the large and small ribosomal subunit, as opposed to yeast where 
Dyskerin plays an important role in small ribosomal subunit biogenesis (Lafontaine et 
al., 1998). 
 
Since Dyskerin knockdown surprisingly affected both the LSU and SSU newly-
synthesized rRNAs, I used Northern blotting to investigate the effects of Dyskerin 
knockdown on pre-rRNA processing. Dyskerin was knocked down for 48h in HEK293T 
cells before RNA was extracted. The RNA was loaded on a glyoxal-agarose gel and 
analysed by Northern Blotting. Radiolabelled (32P) probes against the Internal 
Transcribed Spacer 1 (ITS1) and 2 (ITS2) (Sloan et al., 2013c) regions were used in 
order to analyse the levels of the precursor rRNAs (Figure 3.6A). The 5’-ITS1 probe 
identifies the 18SE rRNA precursor, the ITS1 probe identifies the 47/45S, 41S, 30S, 
26S and 21S precursors whereas the ITS2 probe identifies the 47/45S, 32S and 12S 
precursors (Figure 3.6A) (Sloan et al., 2013c). 
 
Dyskerin knockdown resulted in a significant decrease in the levels of 41S, 26S, 21S 
and 18SE rRNA precursors as compared to the control, but no significant difference 
were observed in the levels of 30S rRNA precursor after Dyskerin knockdown as 
compared to the control (Figure 3.6B, D). Furthermore, the 32S rRNA precursor levels 
were significantly increased after Dyskerin knockdown as compared to the control, but 
no significant difference was observed on the levels of the 12S rRNA precursor (Figure 
3.6 C, D). Taken together, these data show that Dyskerin contributes to pre-rRNA 
processing for both large and small ribosomal subunit biogenesis. This agrees with the 
previous data showing that Dyskerin knockdown results in a decreased accumulation 
of both 28S and 18S rRNAs in pulse-chase labelling experiments (Figure 3.5). 
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 3.2.3 Dyskerin knockdown results in p53 accumulation via the 5S RNP-MDM2 
pathway in U2OS cells 
 
Defects in ribosome biogenesis result in the accumulation of the tumour suppressor 
p53 (Freed et al., 2010b) via the 5S RNP-MDM2 pathway. The 5S RNP, an LSU 
intermediate consisting of the ribosomal proteins RPL5, RPL11 and the 5S rRNA, 
Figure 3.6. Dyskerin knockdown results in both LSU and SSU early rRNA 
processing defects. (A) Schematic representation of the rRNA precursors in humans. 
The SSU precursors and mature 18S rRNA are shown in green and the LSU precursors 
and mature 28S rRNA are shown in blue. The cleavage sites are shown at the top and 
the ITS1 and ITS2 sites recognized by the radiolabeled (32P) probes are marked in red 
(Adapted from (Sloan et al., 2013c) (B-C) RNA was extracted 48h after siRNA 
transfection using control or Dyskerin (DKC-2) siRNAs in HEK293T. The RNA was 
separated on a 1.2% glyoxal-agarose gel and analyzed by Northern blotting. The 
membranes were incubated with 32P-labelled-oligo probes against ITS1 or 5’ITS1 
(18SE) (B) and ITS2 (C) The ethidium bromide staining of 28S rRNA (UV) was used as 
a loading control. The rRNA precursors are indicated on the left of each panel. (D) 
ImageQuant software was used for quantitation of the rRNA levels, which were 
normalized to the loading control (28S UV). The levels of the rRNA precursors were 
normalized to control and to the 47/45S rRNA levels. The graphs represent the 
averages of three experimental repeats and the error bars show the standard error (+/-
SEM). Statistical analysis was performed using an unpaired t-test. The unmarked bars 
indicate non-significant differences as compared to the control and the dotted line 
represents the rRNA precursor levels in control cells. *p value < 0.05, **p value < 0.01, 
***p value < 0.001. 
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accumulates in the nucleoplasm when ribosome biogenesis is defective. The free 5S 
RNP binds the ubiquitin ligase MDM2, which normally binds and inhibits p53, targeting 
it for proteosomal degradation. Upon 5S RNP binding, the function of MDM2 is 
inhibited, leading to p53 stabilisation (Pelava et al., 2016). Since Dyskerin knockdown 
resulted in defects in both LSU and SSU ribosome biogenesis, I wanted to investigate 
whether Dyskerin knockdown had an effect on p53 levels in the cell. For this, U2OS 
human osteosarcoma cells were used instead of HEK293T, because HEK293T cells 
do not contain an active p53 due to their transformation method with adenovirus E1A 
and E1B, as E1B inhibits activation of transcription of p53 by decreasing its DNA-
binding capacity (Lin et al., 2014, Steegenga et al., 1996). Knockdown of Dyskerin was 
performed in U2OS cells for 48h and the whole cell extract was loaded on an SDS-
PAGE gel before analysed by Western Blotting using α-p53 and α-p21 antibodies. The 
p21 gene is a target of p53 and provides an indication of p53 activity. It is worth noting 
that p21 levels can be regulated post-translationally (Jung et al., 2010) and p21 mRNA 
levels were not checked here, neither were other downstream targets of p53 (Gottlieb 
and Vousden, 2010). Karyopherin was used as a loading control (Figure 3.7A). 
 
Dyskerin knockdown resulted in an almost 2-fold significant increase in p53 levels 
(Figure 3.7A, B) and to an increase in p21 protein levels. In order to investigate whether 
the p53 increase observed after Dyskerin knockdown was a result of MDM2 inhibition 
by the 5S RNP, RPL5 was co-depleted with Dyskerin to block p53 activation by the 5S 
RNP (Donati et al., 2013). Note that expression levels of Dyskerin or RPL5 were not 
checked after the double knockdowns, so less efficient depletion of the targets might 
have occurred. After co-depletion of RPL5, p53 was at similar levels to the control and 
significantly decreased as compared to the p53 levels after Dyskerin knockdown 
(Figure 3.7A, B). Furthermore, the p21 levels were also decreased as compared to the 
single Dyskerin knockdown (Figure 3.7A) which was consistent in all experimental 
repeats. Finally, RPL5 knockdown resulted in a 60% decrease in RPL5 levels (Figure 
3.7C), although this decrease was often bigger. RPL5 knockdown alone did not result 
in a significant change in p53 levels as compared to the control, as expected (Figure 
3.7A, B) (Donati et al., 2013, Sloan et al., 2013a). In conclusion, these data indicate 
that defects in ribosome biogenesis caused by Dyskerin knockdown result in p53 
accumulation via the 5S RNP-MDM2 pathway. 
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 3.2.4 Creation of RNAi resistant stable cell lines of Dyskerin WT and D125A 
catalytic mutant in HEK293T and U2OS cells 
 
I have shown that Dyskerin knockdown results in defects in both large and small 
ribosomal subunit biogenesis, which leads to p53 accumulation via the 5S RNP-MDM2 
pathway. In yeast, the catalytic activity of Dyskerin is important for rRNA processing 
and modifications (Zebarjadian et al., 1999), but not in mouse embryonic fibroblasts 
where it was shown it affects rRNA stability rather than processing (Gu et al., 2013). 
Therefore, I next wanted to investigate whether the catalytic activity of Dyskerin is 
Figure 3.7. Dyskerin knockdown results in an induction of p53 via the 5S RNP-
MDM2 pathway. (A) Knockdowns of control, Dyskerin (DKC-2) or RPL5 were 
performed in U2OS cells for 48h. The whole cell extract was loaded on an SDS-PAGE 
gel and analyzed by Western Blotting using α-p53 and α-p21 antibodies (shown on 
the left of the panel). Karyopherin (Karyop.) was used as a loading control. The 
membranes were visualized using the LICOR system. (B) The ImageQuant software 
was used for quantitation of the Western blots. The graphs represent the averages 
from three experimental repeats and the error bars show the standard error (+/-SEM). 
Statistical analysis was performed using an unpaired t-test. The unmarked bars 
indicate non-significant differences as compared to the control. *p value < 0.05. (C) 
siRNA treatment was performed in U2OS cells for 48h. The whole cell extract was 
loaded on an SDS PAGE gel and analysed by Western Blotting using the antibodies 
shown on the left of the panel. Karyopherin (Karyop.) was used as loading control and 
Western blots were visualized using ECL. 
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important for ribosome biogenesis in humans. HEK293T and U2OS cells that stably 
expressed Dyskerin were created using the Flp-In recombination system (Life 
Technologies). The open reading frame (ORF) of Dyskerin was mutated so that it 
would be resistant to the siRNA sequence (DKC-2) with no change in the amino acid 
sequence (Figure 3.8D). Furthermore, the ORF of Dyskerin was mutated to inactivate 
the catalytic activity of Dyskerin by replacing the aspartic acid essential for Dyskerin 
activity with an alanine (D125A) (Figure 3.8A). This mutation was shown to cause rRNA 
processing or stabilisation defects in yeast and mouse models due to inactivation of 
Dyskerin (Gu et al., 2013, Zebarjadian et al., 1999). The aspartic acid at position 125 
is a well-conserved residue found at the catalytic domain of Dyskerin (TruB) amongst 
species (Figure 3.8B) and it is also conserved in four classes of pseudouridine 
synthases (Gu et al., 2013). The expressed protein contained a FLAG-tag sequence 
on the N-terminus and was under the control of a titratable tetracycline promoter. 
Figure 3.8. Dyskerin domains and mutagenesis. (A) Schematic representation of 
the domain organization of Dyskerin. The nuclear localization signals (NLS) are shown 
in grey, the Dyskerin-specific domain is shown in green, the RNA-binding domain 
(PUA) is shown in light blue and the catalytic domain (TruB) is shown in red. The 
position of the catalytic mutant D125A is marked. (B) Sequence alignment of the 
conserved catalytic site of Dyskerin in 13 species: human (H. sapiens), budding yeast 
(S. cerevisiae), rat (R. rattus), mice (M. musculus), chicken (G. gallus), fission yeast 
(S. pombe), fish (D. danglia), cow (B. taurus), chimpanzee (P. troglodytes), orangutan 
(P. pygmaeus), giant panda (A. melanoleuca), frog (X. leavis) and archaea (P. 
furiosus). The conserved aspartate necessary for the catalytic activity of Dyskerin is 
indicated with an asterix. (C) Structure of the H/ACA snoRNP. Dyskerin is shown in 
orange, NOP10 in green, NHP2 in dark grey and GAR1 in blue. The H/ACA snoRNA 
is shown in light grey and the rRNA substrate in red. The position of the D125 catalytic 
nucleotide is shown in pink (indicated by the arrow). (D) Outline of the mutations on 
the Dyskerin ORF for creation of the RNAi resistant plasmids. The nucleotide and 
amino acid sequences are clearly marked on the sequence. 
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The cells were grown in normal media and induction of the FLAG-tagged protein was 
performed for 48h using a range of tetracycline concentrations (0-1000 ng/µl). Whole 
cell extract was then loaded on an SDS-PAGE gel and analysed using Western 
Blotting. The levels of both the endogenous and FLAG-tagged Dyskerin were 
determined using an α-Dyskerin antibody and the levels of the FLAG-tagged Dyskerin 
were revealed using an α-FLAG antibody. The exosome complex protein CSL4 was 
used as a loading control (Figure 3.9).  
 
Expression of the FLAG-tagged proteins was optimised to result in an equal or slightly 
higher levels to that seen for the endogenous. The expression of the RNAi resistant 
WT FLAG-tagged Dyskerin in HEK293T was optimal using 100ng/µl tetracycline 
(Figure 3.9A, top panel), whereas expression of the RNAi resistant D125A mutant 
FLAG-tagged Dyskerin in HEK293T cells was optimal using 1000ng/µl tetracycline 
(Figure 3.9A, bottom panel). It is not clear why this difference in tetracycline 
concentrations was seen in HEK293T cells. In U2OS cells expressing the RNAi 
resistant WT or the D125A mutant FLAG-tagged Dyskerin, 1000ng/µl tetracycline was 
used for optimal expression of the FLAG-tagged protein (Figure 3.9B). It was expected 
that expression of the FLAG-tagged Dyskerin would result in a slight decrease in the 
levels of the endogenous protein, since the cells would compensate for the over-
expression of Dyskerin. 
 
Dyskerin localizes to the nucleolus, where ribosome biogenesis takes place, and in the 
nucleoplasm, in humans (Heiss et al., 1999) and in yeast (Bertrand et al., 1998). 
Immunofluorescence was performed to confirm that the RNAi resistant FLAG-tagged 
Dyskerin was localized as normal in cells expressing either the WT or the D125A 
mutant Dyskerin (Figure 3.9C). HEK293T cells expressing the RNAi resistant WT or 
D125A mutant FLAG-tagged Dyskerin were grown in normal media for 48h with the 
addition of 100ng/µl or 1000ng/µl tetracycline respectively. The cells were then fixed 
on a coverslip using 4% paraformaldehyde and incubated with α-FLAG antibody for 
visualization of the FLAG-tagged protein expressed. The nucleolus was stained using 
α-Fibrillarin antibody and HEK293T cells were used as a control. The RNAi resistant 
WT FLAG-tagged Dyskerin was found to mainly localize to the nucleolus and, to a 
lesser extent, to the nucleoplasm, as expected (Figure 3.9C, WT panel). Similarly, the 
RNAi resistant D125A FLAG-tagged Dyskerin also localized to the nucleolus and, to a 
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lesser extent, to the nucleoplasm (Figure 3.9C, D125A panel). The RNAi resistant WT 
or D125A mutant FLAG-tagged Dyskerin, therefore, localized as expected. 
 
 
 
Figure 3.9. Expression of the WT or D125A Dyskerin in HEK293T and U2OS cells. 
(A-B) The cells were grown in normal media in addition to different concentrations of 
tetracycline (0-1000 ng/µl) in HEK293T (A) or U2OS (B) cells stably expressing the 
RNAi resistant WT or D125A mutant Dyskerin. Whole cell extracts were loaded on an 
SDS-PAGE gel and analysed by Western Blotting, visualized by ECL. α-Dyskerin 
antibody was used to detect the levels of the endogenous and the FLAG-tagged 
protein, whereas α-FLAG antibody was used to detect the levels of the FLAG-tagged 
protein only. CSL4 was used as a loading control. The antibodies used are indicated 
on the left of the panels and the FLAG-tagged or endogenous Dyskerin are indicated 
on the right of the panels. (C) Immunofluorescence was performed after 48h of 
induction of HEK293T cells expressing the RNAi resistant (RNAiR) WT or the D125A 
mutant FLAG-tagged Dyskerin using 100ng/µl or 1000ng/µl tetracycline respectively. 
Plain HEK293T cells were used as a control. The FLAG-tagged Dyskerin is shown by 
the α-FLAG antibody (red). Nucleolar staining was performed using the α-Fibrillarin 
(Fib) antibody (green), whereas the DNA was stained with DAPI (blue). Visualization 
of the cells was performed using the Zeiss Axiovision inverted microscope and 
software. 
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Next, the RNAi rescue system was tested, where the siRNA duplexes were transfected 
for 48h in HEK293T or U2OS cells expressing the RNAi resistant WT or D125A mutant 
FLAG-tagged Dyskerin for 48h, with the addition of tetracycline. Whole cell extracts 
were loaded on an SDS-PAGE gel and analysed by Western Blotting. In HEK293T 
cells containing the empty pcDNA5 vector, the Dyskerin knockdown resulted in 
approximately 70% decrease in the levels of the endogenous protein compared to the 
control, taking in mind the differences in loading as seen by the CSL4 levels (Figure 
3.10A). Two bands were visible in these cells when the α-Dyskerin antibody was used, 
but there was no visible band when the α-FLAG antibody was used. It is not clear why 
this was sometimes seen. Dyskerin knockdown in HEK293T cells expressing either 
the RNAi resistant WT or the D125A mutant FLAG-tagged Dyskerin resulted in an a 
90% and 95% reduction of the endogenous protein respectively as compared to the 
control knockdown (Figure 3.10A, B). However, no reduction was observed in the 
levels of the FLAG-tagged protein in HEK293T expressing the RNAi resistant WT 
FLAG-tagged Dyskerin (Figure 3.10A), showing that the endogenous protein was 
mostly replaced by the FLAG-tagged Dyskerin. Even though an increase was observed 
in the levels of the FLAG-tagged protein in HEK293T cells expressing the RNAi 
resistant D125A mutant FLAG-tagged Dyskerin (Figure 3.10A), this was not always 
seen, indicating that the D125A mutant protein replaced the endogenous one. 
 
In U2OS cells containing the empty pcDNA5 vector, the knockdown of Dyskerin 
resulted in an efficient 70% decrease in the levels of the endogenous protein, as 
expected (Figure 3.10C). Even though there were differences in loading, Dyskerin 
knockdown in U2OS cells expressing either the RNAi resistant WT or D125A mutant 
FLAG-tagged Dyskerin resulted in a 40% and 30% reduction of the endogenous 
protein levels respectively, but not in any reduction in the levels of the FLAG-tagged 
protein (Figure 3.10C, D). Even though the reduction in the levels of the endogenous 
Dyskerin in U2OS cells expressing the RNAi resistant WT or D125A mutant was not 
as high as expected, the cells contained the RNAi resistant FLAG-tagged protein while 
the endogenous Dyskerin was decreased, which allowed us to study the effects of the 
inactivation of Dyskerin nevertheless. The minor increase in the levels of the RNAi 
resistant D125A FLAG-tagged Dyskerin was not always seen and it might be an 
experimental variation (Figure 3.10C, D). 
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Taken together, these data indicated that the RNAi rescue system enabled the 
replacement of the endogenous Dyskerin with the FLAG-tagged protein in both 
HEK293T and U2OS cells. 
 
 
Figure 3.10. The RNAi rescue system in HEK293T and U2OS cells. (A, C) 
HEK293T (A) or U2OS (C) cells containing the empty pcDNA5 vector (marked as 
“Vector”) or expressing the RNAi resistant WT or D125A mutant FLAG-tagged 
Dyskerin were treated with control or Dyskerin (DKC-2) siRNAs for 48h. 100ng/µl 
tetracycline was used for 48h in WT-expressing cells and 1000ng/µl tetracycline was 
used in pcDNA5-containing and D125A-expressing cells. The whole cell extract was 
loaded on an SDS-PAGE gel and analysed by Western Blotting, visualized by ECL. α-
Dyskerin antibody was used to detect the levels of the endogenous and the FLAG-
tagged Dyskerin, whereas α-FLAG antibody was used to detect only the FLAG-tagged 
protein. CSL4 was used as a loading control. The antibodies used are shown on the 
left of the panels and the endogenous and FLAG-tagged Dyskerin are indicated on the 
right of the panels. (B, D) ImageQuant software was used for quantitation of the levels 
of the endogenous and FLAG-tagged Dyskerin in HEK293T (B) or U2OS (D) cells 
expressing the RNAi resistant (RNAiR) WT or D125A mutant Dyskerin, which were 
normalized to the loading control (CSL4). 
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3.2.5 The catalytic activity of Dyskerin is not required for accumulation of the 
H/ACA snoRNP 
 
Dyskerin knockdown resulted in a decrease in the levels of U17, U64, U19 and U70 
H/ACA snoRNAs (Figure 3.4B). It was shown that mutations in the catalytic domain of 
the yeast Cbf5 resulted in a decreased accumulation of the H/ACA snoRNAs 
(Zebarjadian et al., 1999). I, therefore, wanted to investigate whether this was also the 
case in humans. Knockdowns of control and Dyskerin (DKC-2) were performed for 48h 
in HEK293T cells expressing the RNAi resistant WT or D125A mutant FLAG-tagged 
Dyskerin, or in HEK293T cells containing pcDNA5 vector. RNA was extracted and 
separated on an 8% acrylamide/7M Urea gel, and the membranes were incubated with 
radiolabelled (32P) probes specific for the U17, U64, U19 or U70 snoRNAs and the U1 
snRNA, which was used as a loading control (Figure 3.12A). 
 
In HEK293T cells containing the empty pcDNA5 vector, the levels of all four H/ACA 
snoRNAs were decreased by approximately 80% after Dyskerin knockdown (Figure 
3.11A, B), consistent with earlier results (Figure 3.4B). Expression of the RNAi resistant 
WT FLAG-tagged Dyskerin resulted in more than 90% rescue of U17, U64 and U70 
after Dyskerin knockdown as compared to the control knockdown, and in 
approximately 70% rescue of U19 H/ACA snoRNA (Figure 3.11A). This further 
confirmed that the RNAi rescue system worked as expected and that the FLAG-tagged 
Dyskerin can function in snoRNP biogenesis as normal. Expression of the RNAi 
resistant D125A catalytic mutant FLAG-tagged Dyskerin also rescued all four H/ACA 
snoRNAs, even though there was a slight increase in U64, U19 and U70 snoRNA 
levels (Figure 3.11A). These results indicated that the catalytic activity of Dyskerin is 
not required for the accumulation of H/ACA snoRNAs in human cells. Analysis of 
further H/ACA snoRNAs, such as U66, U69 and U72, will be performed in the future in 
order to understand the involvement of Dyskerin and its catalytic activity in the 
accumulation of other H/ACA snoRNAs. 
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 To further investigate the importance of the Dyskerin catalytic domain mutants on 
H/ACA snoRNP formation, I determined the association of the FLAG-tagged proteins 
with the snoRNAs using immunoprecipitation. The endogenous protein was replaced 
by the WT or D125A mutant FLAG-tagged Dyskerin as described previously and the 
whole cell extract was lysed using sonication. Sepharose beads containing the α-FLAG 
antibody were used for the pull down and beads containing no antibody were used as 
a control. RNA was extracted from the beads and loaded onto an acrylamide gel, 
transferred on a membrane and probed with radiolabelled (32P) probes for U17 and 
U64 (Figure 3.11C). Both WT and D125A mutant FLAG-tagged proteins efficiently 
Figure 3.11. Dyskerin, but not its catalytic activity, is required for the 
accumulation of the H/ACA snoRNAs in HEK293T cells. (A) Knockdowns using 
Control or Dyskerin siRNA (DKC-2) were performed for 48h in HEK293T cells 
containing the empty pcDNA5 vector, or expressing the RNAi resistant WT or the 
D125A mutant FLAG-tagged Dyskerin for 48h. 100ng/µl tetracycline was used in WT-
expressing cells and 1000ng/µl tetracycline was used in pcDNA5-containing and 
D125A-expressing cells. RNA was extracted and loaded on an acrylamide gel and 
analysed by Northern Blotting. Radiolabelled (32P) probes specific for U17 and U64 
H/ACA snoRNAs and U1 snRNA were used, as indicated on the left of the panel. The 
U1 snRNA was used as a loading control. (B) Quantitation of two experimental repeats 
was performed using the ImageQuant Software and the levels U17 and U64 H/ACA 
snoRNAs were normalized against the loading control levels (U1 snRNA). The graphs 
represent the averages from two experimental repeats and the dotted line represents 
the snoRNA levels in control cells. (C) Knockdowns using Dyskerin siRNA (DKC-2) 
were performed for 48h in HEK293T cells expressing the WT or the D125A mutant 
FLAG-tagged Dyskerin. Immunoprecipitation followed, where α-FLAG beads were 
used for pull down of complexes associated with Dyskerin, and control beads, 
containing no antibody, were used as a control. RNA was extracted using the phenol-
chloroform method and loaded on an 8% acrylamide/7M Urea gel before analysed by 
Northern Blotting. Radiolabelled (32P) probes were used to detect the levels of U17 
and U64 H/ACA snoRNAs (shown on the left of the panel). T=total, IP=α-FLAG beads, 
C=control beads. 
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pulled down the U17 and U64 snoRNAs (Figure 3.11C), indicating the absence of the 
catalytic activity of Dyskerin does not affect the formation of the H/ACA snoRNP. 
 
In conclusion, these data showed that the catalytic activity of Dyskerin is not required 
for the accumulation or snoRNP formation of either U17, U64, U19 or U70 H/ACA 
snoRNAs, indicating that the catalytic activity of Dyskerin is not likely to be required for 
H/ACA snoRNP accumulation. This is different from yeast data showing that 
inactivation of the catalytic activity of Cbf5 (yeast Dyskerin) resulted in a decreased 
accumulation of the H/ACA snoRNAs interacting with Cbf5, which are involved in either 
rRNA processing (snR10), LSU rRNA pseudouridylation (snR8, snR37) or SSU rRNA 
pseudouridylation (snR31) (Zebarjadian et al., 1999). Finally, inactivation of the 
catalytic activity of Dyskerin in mouse embryonic fibroblast cells also showed a similar 
phenotype to yeast, where several H/ACA snoRNAs, including U17 and U64, were 
significantly decreased in the cell (Gu et al., 2013), which differs from my data here. It 
will be interesting to investigate the interactions of the WT and the catalytic mutant 
Dyskerin with other H/ACA snoRNAs in human cells as well, in order to understand the 
function of Dyskerin in H/ACA snoRNP accumulation. It is worth noting that I have 
established here the first system in humans which allows us to investigate for rRNA 
processing defects affected by the absence of the catalytic activity of Dyskerin without 
affecting the levels of the snoRNAs in the cell.  
 
3.2.6 The catalytic activity of Dyskerin is essential for rRNA processing 
 
Inactivation of the catalytic activity of Dyskerin did not affect the accumulation of the 
tested H/ACA snoRNAs (Figure 3.11). This is different from yeast where the catalytic 
activity of Dyskerin is required for both H/ACA snoRNP accumulation and rRNA 
processing (Zebarjadian et al., 1999). This, therefore, provided us with the opportunity 
to investigate whether the catalytic activity of Dyskerin is important for human ribosome 
biogenesis. The endogenous protein was replaced by the WT or the D125A FLAG-
tagged Dyskerin in HEK293T cells as previously, and HEK293T cells containing the 
empty pcDNA5 vector were used as a control. RNA was extracted and loaded on a 
glyoxal-agarose gel and analysed by Northern Blotting using radiolabelled (32P) probes 
for 5’-ITS1, ITS1 or ITS2 regions (Figure 3.12A). 
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Figure legend on the next page. 
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 Knockdown of Dyskerin in HEK293T cells resulted in an accumulation of the 32S rRNA 
precursor, whereas the levels of 41S, 26S, 21S and 18SE rRNA precursors were 
significantly decreased (Figure 3.12, vector). The levels of the 41S, 21S and 18SE 
rRNA precursors were restored to normal in HEK293T expressing the RNAi resistant 
WT FLAG-tagged Dyskerin after Dyskerin knockdown (Figure 3.12B, C, WT). 
Furthermore, the levels of 30S rRNA remained unaffected after Dyskerin knockdown 
in these cells as compared to the control, whereas the levels of 26S rRNA precursor 
were slightly increased (Figure 3.12B, C, WT). Since no significant change was 
observed in the levels of 21S rRNA, it is unlikely that 26S rRNA accumulation is 
indicative of rRNA processing defects here. Expression of the RNAi resistant WT 
FLAG-tagged Dyskerin rescued the levels of the increased levels of 32S rRNA 
precursor after Dyskerin knockdown as compared to the control, whereas the levels of 
the 12S rRNA were not significantly altered (Figure 3.12 B, D, WT). These data 
indicated that expression of the RNAi resistant WT FLAG-tagged Dyskerin rescued the 
rRNA processing phenotype caused by Dyskerin knockdown in HEK293T cells. 
 
Expression of the RNAi resistant D125A FLAG-tagged Dyskerin resulted in a very 
slight increase in 41S rRNA precursor levels after Dyskerin knockdown as compared 
Figure 3.12. Inactivation of the catalytic activity of Dyskerin results in LSU late 
processing defects. (A) Schematic representation of the rRNA precursors in humans. 
The SSU precursors and mature rRNA are shown in green and the LSU precursors 
and mature rRNA are shown in blue. The cleavage sites are shown at the top and the 
5’ITS1, ITS1 and ITS2 sites recognized by the radiolabeled (32P) probed are shown in 
red (Adapted from (Sloan et al., 2013c)) (B) Knockdowns using Control or Dyskerin 
(DKC-2) siRNAs were performed for 48h in HEK293T cells containing the empty 
pcDNA5 vector or expressing the RNAi resistant FLAG-tagged WT or D125A mutant 
Dyskerin. 100ng/µl or 1000ng/µl tetracycline was used for 48h in WT-expressing cells 
or pcDNA5 and D125A-expressing cells respectively. RNA was extracted from the cells 
and separated on a 1.2% glyoxal-agarose gel. The RNA was transferred on a Hybond 
N membrane and incubated with radiolabeled-(32P)-oligo probes against ITS1, 5’ITS1 
(18SE) or ITS2, as indicated on the right of each membrane. A phosphorimager was 
used for visualization of the rRNAs, and ethidium bromide staining of 28S rRNA (UV) 
was used as a loading control. (C-D) ImageQuant software was used for quantitation 
of the northern blots. The graphs represent the relative levels of the rRNAs as averages 
of three independent experimental repeats, which were normalized to the loading 
control (28S UV) and the control knockdown in each case. Further normalization of the 
rRNA precursor levels to the 47/45S rRNA precursor was performed. The error bars 
represent the standard error (+/-SEM) and statistical analysis took place using an 
unpaired t-test. Lack of significance values indicates significant differences as 
compared to the control and the dotted line represents the rRNA precursor levels in 
control cells. The vector values are the same as the ones presented on Figure 3.6D. 
*p value < 0.05, **p value < 0.01, ***p value < 0.001. 
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to the control, but no change was observed in the levels of 30S or 26S rRNA precursors 
(Figure 3.12B, C, Mut). Importantly, the levels of 21S and 18SE rRNAs were 
significantly decreased by approximately 50% and 30% respectively after Dyskerin 
knockdown in HEK293T cells expressing the RNAi resistant D125A FLAG-tagged 
Dyskerin as compared to the control (Figure 3.12B, C, Mut), as well as the levels of 
the 12S rRNA precursors, which were approximately 40% lower (Figure 3.12B, D, Mut 
panel). No significant difference was observed in the levels of 32S rRNA precursor 
after Dyskerin knockdown as compared to the control in HEK293T cells expressing the 
RNAi resistant D125A FLAG-tagged Dyskerin (Figure 3.12B, D, Mut panel). Taken 
together, these data indicate that inactivation of the catalytic activity of Dyskerin 
rescues the early rRNA processing defects observed when Dyskerin is knocked-down, 
but results in late rRNA processing defects. 
 
I next used pulse-chase labelling to further characterize the effects of the catalytically 
inactive Dyskerin on rRNA production. HEK293T cells containing the empty pcDNA5 
vector were used as a control and the endogenous protein was replaced by the WT or 
D125A mutant FLAG-tagged Dyskerin as previously. The cells were then incubated 
with phosphate-free media for 1h, followed by the addition of radiolabelled phosphate 
(32P) for 1h. The cells were left to grow in normal media for 3h (chase) for detection of 
the newly-synthesized rRNAs. RNA was extracted, separated on an agarose gel and 
transferred on a Hybond N membrane. As seen previously (Figure 3.5), knockdown of 
Dyskerin in HEK293T cells containing the empty pcDNA5 vector resulted in a decrease 
in 47/45S and 32S rRNA precursors as well as a decrease in the newly-synthesized 
28S and 18S rRNA after 3h of chase (Figure 3.13A, B, vector). Expression of the RNAi 
resistant WT FLAG-tagged Dyskerin after Dyskerin knockdown rescued the levels of 
the 47/45S and 32S rRNA precursors and the levels of the newly-synthesized 28S and 
18S rRNAs as compared to the control knockdown in these cells after 3h (Figure 3.13A, 
B WT). A slight accumulation of the 47/45S rRNA precursor was observed after 
expression of the RNAi resistant WT FLAG-tagged Dyskerin (Figure 3.13A, B, WT), 
which might be due to experimental variation. Taken together, these data further 
support the previous data, showing that expression of the RNAi resistant WT FLAG-
tagged Dyskerin rescues the rRNA processing phenotype caused by Dyskerin 
knockdown. It is worth noting that this experiment was only performed twice due to 
time limitations. However, since the levels of the H/ACA snoRNAs (Figure 3.11) and 
rRNA precursors (Figure 3.12) were rescued after expression of the RNAi resistant WT 
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FLAG-tagged Dyskerin in cells where Dyskerin was knocked down, I am confident that 
the RNAi rescue system worked as expected. 
 
Knockdown of Dyskerin in HEK293T cells expressing the RNAi resistant D125A mutant 
FLAG-tagged Dyskerin resulted in approximately 35% and 40% decrease in the levels 
of the 47/45S and 32S rRNA precursors respectively, and approximately 40% and 45% 
Figure 3.13. Inactivation of the catalytic activity of Dyskerin is likely to result in 
slower accumulation of the newly-synthesized LSU and SSU rRNAs. (A) 
Knockdowns using Control and Dyskerin (DKC-2) siRNAs were performed for 48h in 
HEK293T cells containing the empty pcDNA5 vector or expressing the RNAi resistant 
FLAG-tagged WT or D125A mutant Dyskerin using 100ng/µl or 1000ng/µl tetracycline 
respectively for 48h. 1000ng/µl tetracycline was used in pcDNA5-containing cells for 
48h. During pulse chase labelling, phosphate depletion was performed followed by 
addition of radiolabelled phosphate (32P) for 1h. The cells were left to grow under 
normal conditions for 3h (chase), before RNA was extracted and separated on a 
glyoxal-agarose gel. The RNA was transferred on a Hybond N membrane and 
visualized using a Phosphorimager. The 28S rRNA levels after ethidium bromide 
staining (UV) were used as a loading control. (B) ImageQuant software was used for 
quantitation of the Northern blots. The graph represents the relative rRNA levels of 
one experimental repeat after Dyskerin knockdown and normalization against the 
loading control (28S UV) and the control knockdown for each cell line. The dotted line 
represents the rRNA precursor levels in control cells. (C) Schematic representation of 
the rRNA processing precursors and mature rRNAs in humans. The cleavage sites 
are indicated on the top (Adapted from (Sloan et al., 2013c)). 
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decrease in the levels of the newly-synthesized 28S and 18S rRNAs respectively, as 
compared to the control knockdown after 3h of chase (Figure 3.13A, B, Mut). These 
data indicate that inactivation of the catalytic activity of Dyskerin causes a slower 
accumulation of the newly-synthesized rRNAs, which further supports the theory that 
it is required for late rRNA processing in humans. 
 
3.2.7 Inactivation of the catalytic activity of Dyskerin does not activate p53 
 
Cells expressing the D125A mutated FLAG-tagged Dyskerin showed a reduction in the 
accumulation of the 28S and 18S rRNAs (Figures 3.12, 3.13). Since ribosome 
biogenesis defects are known to activate the p53 tumour suppressor, I investigated 
whether inactivation of the catalytic activity of Dyskerin resulted in p53 accumulation. 
U2OS cells containing the empty pcDNA5 vector were used as a control and the 
endogenous protein was replaced by the WT or D125A mutant FLAG-tagged Dyskerin 
as previously. Whole cell extracts were loaded on an SDS-PAGE gel and analysed by 
Western blotting, using α-p53 and α-p21 antibodies. The p21 gene is a target of p53, 
indicating p53 activity, even though the p21 mRNA levels were not assessed as p21 
can also be regulated post-translationally (Jung et al., 2010). Karyopherin was used 
as a loading control. 
 
Knockdown of Dyskerin in U2OS cells containing the pcDNA5 vector resulted in a 2-
fold increase in p53 levels as expected, due to defects in ribosome biogenesis. 
Furthermore, the levels of p21 were increased by approximately 3.5-fold, indicating an 
increase in p53 activity (Figure 3.14). Dyskerin knockdown in U2OS cells expressing 
the RNAi resistant WT FLAG-tagged Dyskerin did not result in a significant difference 
in p53 levels as compared to the control knockdown in these cells (Figure 3.14). 
However, there was an approximately 2-fold increase in p21 levels (Figure 3.14). This 
could be due to the fact that there is some over-expression of Dyskerin in U2OS cells, 
since the endogenous protein was still found at approximately 60%, as previously 
shown (Figure 3.10B). Dyskerin knockdown in cells expressing the RNAi resistant 
FLAG-tagged D125A mutant Dyskerin resulted in slightly lower p53 levels  as 
compared to the control, and an increase in p21 levels (Figure 3.14). This p21 increase 
was similar to the one observed in U2OS cells expressing the RNAi resistant WT 
FLAG-tagged Dyskerin. 
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 It is worth noting that the p53 levels were consistently higher in U2OS cells expressing 
the RNAi resistant FLAG tagged WT or D125A mutant Dyskerin. However, the p21 
levels were consistently low in control cells, resembling the levels of p21 in U2OS cells 
containing the pcDNA5 vector after control knockdowns. This indicated that there might 
be an induction in p53 levels in the cells expressing the RNAi resistant FLAG-tagged 
Dyskerin, but not p53 activity. Since p21 levels were not induced after control 
knockdowns, indicating that p53 activity was probably at normal levels, it is unlikely 
that p53 levels are saturated in these cells. Due to time constraints, it was not possible 
to explore this further (see Discussion). In conclusion, these results indicate that 
inactivation of the catalytic activity of Dyskerin does affect the levels of p53 in U2OS 
cells as compared to the WT Dyskerin.  
Figure 3.14. The catalytic activity of Dyskerin is not required for p53 
accumulation in U2OS cells. Knockdowns using control or Dyskerin siRNAs (DKC-
2) were performed in U2OS cells containing the pcDNA5 vector or expressing the 
RNAi resistant FLAG-tagged WT or the D125A mutant Dyskerin for 48h using 
1000ng/µl tetracycline. (A) Whole cell extracts were loaded on an SDS-PAGE and 
analysed by Western Blotting, using the antibodies indicated on the left of the panel. 
Results were viewed using the LICOR system. Karyopherin (Karyop.) was used as a 
loading control. The antibodies used are indicated on the left of the panel. (B) 
Quantitation of Western Blots was performed using the ImageQuant Software. The 
graphs represent the average p53 and p21 protein levels from three experimental 
repeats and the error bars show the standard error (SEM). Statistical analysis was 
performed using an unpaired t-test. Absence of significance values indicates no 
significant differences. *p value < 0.05, **p value < 0.01. 
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3.3 Discussion 
 
The H/ACA snoRNP, consisting of the pseudouridine synthase Dyskerin (Cbf5 in 
yeast), the core proteins NOP10, NHP2 and GAR1, and a snoRNA component, 
catalyses the pseudouridylation of the rRNA during ribosome biogenesis (Watkins and 
Bohnsack, 2011). Mutations in the gene encoding for Dyskerin have been found to 
cause X-linked Dyskeratosis Congenita (DC), a rare genetic disease characterized by 
bone marrow failure and tumour development (Mason and Bessler, 2011). The tumour 
suppressor p53 has been shown to be involved in the development of the majority of 
the clinical symptoms of DC in mouse (Ruggero et al., 2003, Ge et al., 2010b) and 
zebrafish (Ying Zhang et al., 2012) models. Ribosome biogenesis defects directly 
regulate the levels of p53 (Pelava et al., 2016) via inhibition of MDM2, the main 
suppressor of p53 through the 5S RNP. The 5S RNP is an LSU intermediate consisting 
of the ribosomal proteins RPL5, RPL11 and the 5S rRNA (Sloan et al., 2013a, Dai and 
Lu, 2004, Donati et al., 2013, Marechal et al., 1994, Nishimura et al., 2015). Despite 
the importance of Dyskerin in DC patients and, probably, in tumour development, not 
much is known about its function in humans. Therefore, the first part of this PhD aimed 
to investigate the roles of Dyskerin in human ribosome biogenesis and p53 regulation. 
I have shown that Dyskerin is required for rRNA processing for both large and small 
ribosomal subunit, and defects in ribosome biogenesis after Dyskerin knockdown 
caused p53 induction via the 5S RNP-MDM2 pathway. Interestingly, the catalytic 
activity of Dyskerin is not required for the accumulation of the H/ACA snoRNP in 
humans and it is likely to only be necessary for late stages of rRNA processing and 
potentially, rRNA stability. Finally, inactivation of the catalytic activity of Dyskerin 
indicated a slower accumulation of the newly-synthesized LSU and SSU rRNAs, but 
did not result in a change in p53 levels. 
 
Here, were have established an RNAi rescue system in HEK293T and U2OS human 
cells, where the RNAi resistant WT or D125A mutant FLAG-tagged Dyskerin replaced 
the endogenous protein, in order to study the effects of the inactivation of the catalytic 
activity of Dyskerin. This system was quite efficient in HEK293T, where the 
endogenous Dyskerin was decreased by more than 90% after siRNA transfections in 
cells expressing the RNAi resistant WT or D125A mutant FLAG-tagged Dyskerin 
(Figure 3.10A). Furthermore, expression of the RNAi resistant WT FLAG-tagged 
Dyskerin resulted in a rescue of the rRNA processing defects observed after Dyskerin 
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knockdown (Figure 3.12). However, the RNAi rescue system was not as efficient in 
U2OS cells, since the endogenous protein was only decreased by 30-40% in cells 
expressing the RNAi resistant WT or D125A mutant FLAG-tagged Dyskerin (Figure 
3.10B). This was only observed in some cases, since this decrease was often seen at 
50-60%. It is unclear why there were differences in the endogenous Dyskerin levels in 
HEK293T and U2OS cells as other knockdowns that have been performed in the lab 
were equally efficient in both cell lines. The RNAi rescue system established in 
HEK293T cells could be also used for studying the effects of other Dyskerin mutants 
found in DC patients. For example, S121G (Knight et al., 1999) and R158W (Knight et 
al., 2001) mutants, found in the catalytic domain of Dyskerin, have been shown to lead 
to the development of X-linked DC and Hoyeraal-Hreidarsson syndrome, which is a 
more severe form of the disease (Ohga et al., 1997). It would be interesting to identify 
whether these mutations affect the accumulation of the H/ACA snoRNP or rRNA 
processing in humans similarly to the catalytic mutant D125A studied here, possibly 
revealing molecular mechanisms on the way DC progresses, which could potentially 
lead to the development of future therapies. However, since the endogenous protein 
is only replaced by 40% in U2OS cells expressing the RNAi resistant FLAG-tagged 
proteins, the use of the RNAi rescue system in these cells for studying the effects of 
other mutants on p53 levels is probably not feasible. It would be beneficial to search 
for another cell line to be used instead of U2OS for studying p53 involvement after 
expression of DC mutations, which might present with a better knockdown efficiency 
and expression of the RNAi resistant FLAG-tagged Dyskerin. For example, HCT-116 
is a colorectal cancer cell line which expresses a wild-type p53, or A549 lung 
carcinoma cell line, which was used in previous studies for p53 function (Krzesniak et 
al., 2014, Fumagalli et al., 2012). 
 
I have shown here that Dyskerin knockdown in human HEK293T cells results in a 
decrease in the levels of the U17, U64, U19 and U70 H/ACA snoRNAs (Figure 3.4), 
which was expected, since Cbf5 depletion in yeast was shown to cause a decrease in 
the H/ACA snoRNAs levels (Zebarjadian et al., 1999). Furthermore, these data agree 
with recent micro-array data showing that depletion of Dyskerin in mouse livers 
resulted in a decrease in the H/ACA snoRNA levels (Ge et al., 2010a). In yeast, it was 
shown that expression of the Cbf5 catalytic mutant (D65A) resulted in a decreased 
interaction of Cbf5 with the tested H/ACA snoRNAs and a decrease in H/ACA snoRNA 
levels (Zebarjadian et al., 1999). The snoRNAs affected included the snR10, which is 
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involved in 18S rRNA processing (Tollervey, 1987), snR31, which is involved in 18S 
rRNA pseudouridylation (Balakin et al., 1993), and snR8 (Ni et al., 1997) and snR37 
(Ganot et al., 1997a), which are involved in 28S rRNA pseudouridylation. A similar 
pattern was observed in mouse embryonic fibroblast cells, where inactivation of the 
catalytic activity of Dyskerin resulted in a decrease in the levels of several H/ACA 
snoRNAs, including U17, U64 and U19 (Gu et al., 2013), which are involved in SSU 
rRNA processing (Enright et al., 1996), 28S rRNA pseudouridylation and processing 
(Ganot et al., 1997a) respectively. On the contrary, my data indicated that the catalytic 
activity of Dyskerin is not required for the accumulation of either U17, U64, U19 or U70 
H/ACA snoRNAs in human HEK293T cells and the interaction of Dyskerin with the 
H/ACA snoRNAs is not likely to be affected by inactivation of its catalytic activity (Figure 
3.11). These results indicate that Dyskerin, but not its catalytic activity, is likely to be 
required for the accumulation of the H/ACA snoRNP complex in humans, as opposed 
to previous yeast and mouse models. Furthermore, the establishment of the RNAi 
rescue system in HEK293T cells allowed us to analyse the role of pseudouridine 
formation on rRNA processing for the first time. 
 
There are two types of H/ACA snoRNAs involved in processing or modification of the 
rRNA (Watkins and Bohnsack, 2011). The majority of the H/ACA snoRNAs bind to the 
substrate RNA by base complementarity, which is essential for both the positioning 
and modification of the rRNA substrate, and for bringing the complex to the appropriate 
conformation for catalysis (Henras et al., 2008). Examples of snoRNAs involved in 
rRNA modifications include the U64 H/ACA snoRNA, which is important for 
pseudouridylation of U4975 of the 28S rRNA, and the U66 H/ACA snoRNA guides the 
pseudouridylation of U119 of the 18S rRNA (Ganot et al., 1997a). The U17/E1 (snR30 
in yeast) H/ACA snoRNA is required for the 18S rRNA processing in yeast (Morrissey 
and D.Tollervey, 1993) and in frog oocytes (Mishra and Eliceiri, 1997), and it is 
presumed that it has the same function in humans since it was found to directly interact 
with 18S rRNA precursors (Rimoldi et al., 1993). U17 is important for the early rRNA 
cleavage at A’ site (Enright et al., 1996) in mammals and contains a conserved 
pseudouridine loop, which is essential for its binding to the 18S rRNA on the 
eukaryotic-specific region ES6 (Atzorn et al., 2004, Fayet-Lebaron et al., 2009). This 
mechanism of action is unique to snR30 (Watkins and Bohnsack, 2011), as no other 
H/ACA snoRNAs have been found to function in the same mode yet. The snR10 
H/ACA snoRNA is also involved in SSU rRNA processing in yeast (Tollervey, 1987), 
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where the 5’ hairpin on the snR10 base pairs with the 5’ ETS region of the 18S rRNA 
precursor (Liang et al., 2010). To date, no H/ACA snoRNAs were found to be important 
for LSU rRNA processing in either yeast or higher eukaryotes that resemble the 
mechanism of action of U17/snR30 or snR10. However, TB11Cs2C2 snoRNA in 
Trypanosoma brucei, a protozoan parasite, was suggested to have specific roles in 
LSU rRNA processing (Gupta et al., 2010) and bioinformatics analysis of the 
Leishmania major snoRNAs, another protozoan parasite, suggested that some 
snoRNAs might be involved in both LSU and SSU rRNA processing (Eliaz et al., 2015). 
For example, LM35Cs3C5 is a snoRNA that is specific to Leishmania major and is 
likely to be involved in LSU rRNA processing and SSU rRNA modification (Eliaz et al., 
2015). My data suggest that there are H/ACA snoRNAs involved in LSU processing in 
humans, since absence of the catalytic activity of Dyskerin resulted in a significant 
decrease in 12S LSU rRNA precursor (Figure 3.12), while the H/ACA snoRNP still 
accumulated (Figure 3.11). However, the specific H/ACA snoRNAs involved in this are 
yet to be identified. 
 
In yeast, the H/ACA snoRNP is essential for the early steps of small ribosomal subunit 
biogenesis (Lafontaine et al., 1998), and for modifications on both the LSU and SSU 
rRNAs (Torchet et al., 2005). On the contrary, in human HEK293T cells, I have shown 
that knockdown of Dyskerin results in defects in early stages of LSU and SSU rRNA 
processing (Figures 3.5, 3.6). Interestingly, no A’ cleavage defects were observed after 
Dyskerin knockdown (Figure 3.6), even though the levels of the U17 H/ACA snoRNA 
were decreased (Figure 3.4). It was recently shown that A’ cleavage can be bypassed 
naturally in cells, as this is an extra step in pre-rRNA processing in eukaryotes (Sloan 
et al., 2014). It is, therefore, possible that Dyskerin depletion does not result in rRNA 
defects because of the lack of A’ cleavage because cleavage at A0 site occurs after 
the bypass of A’ cleavage. Inactivation of the catalytic activity of Dyskerin in human 
cells resulted in late rRNA processing defects (Figure 3.12) and a slower accumulation 
of the newly-synthesized LSU and SSU rRNAs (Figure 3.13). These data agree with 
previously published results where mouse embryonic fibroblast (MEF) cells expressing 
the D125A mutant Dyskerin appeared with a delayed accumulation of the newly-
synthesized 28S and 18S rRNA species and an accumulation of the precursor rRNAs 
(Gu et al., 2013). In this study, the authors have shown that the mature rRNAs 
produced were also very unstable, and the cell growth was significantly decreased in 
MEFs expressing the catalytically inactive Dyskerin (Gu et al., 2013). It is, therefore, 
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likely that the pseudouridines are required for rRNA stability rather than processing in 
humans. Furthermore, it is possible that the H/ACA snoRNP is involved in recruiting 
factors essential for ribosome biogenesis, since rRNA processing still occurs when the 
catalytic activity of Dyskerin is inactive. 
 
Mutations on the catalytic domain of Dyskerin (TruB) were shown to cause X-linked 
DC and, in some cases, the development of Hoyeraal-Hreidarsson syndrome 
(Podlevsky et al., 2008). Since the catalytic activity of Dyskerin is likely to be involved 
in the function, but not the accumulation, of the H/ACA snoRNP in humans, it is 
possible that the clinical symptoms of DC arise due to the production of unstable 
rRNAs. It was previously suggested that inactivation of the catalytic activity of Dyskerin 
results in a slow growth of mouse embryonic fibroblast (MEF) cells and the production 
of unstable rRNAs (Gu et al., 2013). It is possible that mutations in the catalytic site of 
Dyskerin found in DC patients, such as S121G (Knight et al., 1999) or R158W (Knight 
et al., 2001), or other domains of Dyskerin (Podlevsky et al., 2008), might affect the 
function of the H/ACA snoRNP. Since Dyskerin binds the snoRNA, NOP10 and GAR1 
(Watkins and Bohnsack, 2011), the mutations on Dyskerin could affect interactions 
with other processing factors, but it is more likely that the lack of pseudouridylation 
causes the observed defects. A high rate of ribosome biogenesis occurs during red 
blood cell development (Danilova and Gazda, 2015). Thus, a slower accumulation rate 
of mature rRNAs during embryogenesis could affect haematopoiesis, resulting in the 
anaemia seen in DC and other ribosomopathies, as well as the development of 
cancers, especially AML. It would be interesting to identify whether Dyskerin is involved 
in erythroid cell differentiation, causing the clinical symptoms of DC, perhaps by using 
an erythroid progenitor cell line, such as CD34+, which contains both hematopoietic 
and epithelial progenitor cell populations (Kuranda et al., 2011). 
 
Ribosome biogenesis defects result in p53 induction via the 5S RNP-MDM2 pathway 
(Sloan et al., 2013a, Nishimura et al., 2015). Here, I have shown that Dyskerin 
knockdown results in a p53 accumulation via the 5S RNP-MDM2 pathway (Figure 3.7), 
which agrees with previous studies showing that reduction of Dyskerin levels resulted 
in the activation of p53 in zebrafish (Ying Zhang et al., 2012) and mouse models (Ge 
et al., 2010b, Gu et al., 2008). It is possible that the LSU and SSU rRNA defects 
observed after Dyskerin knockdown, likely due to low levels of the H/ACA snoRNPs, 
lead to the accumulation of the free 5S RNP in the nucleoplasm. As a result, the free 
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5S RNP binds MDM2, leading to its inactivation, resulting in p53 stabilization. If this is 
the case in DC patients, the 5S RNP or MDM2 could be used as a target for future 
therapeutic treatments to reduce p53 tumour suppressor levels in patients. 
Furthermore, inactivation of the catalytic activity of Dyskerin did not result in an 
alteration on p53 levels in U2OS cells (Figure 3.14), even though a block in rRNA 
processing occurred. Presumably, the 5S RNP can still be integrated in the LSU so 
that MDM2 binds and inhibits p53. Interestingly, the levels of p53 were elevated when 
the RNAi resistant FLAG-tagged WT Dyskerin was expressed in U2OS cells, but the 
levels of its downstream target p21 were found to be normal. Since p21 levels were 
not induced after control knockdowns, it is unlikely that p53 levels are saturated in 
these cells. Due to time constraints, it was not possible to explore this further. However, 
treatment with Actinomycin D (ActD) in U2OS cells expressing the RNAi resistant 
FLAG-tagged WT Dyskerin would be an important control in order to test whether p53 
levels are induced as expected or whether p53 levels are saturated in these cells. ActD 
is an inhibitor of RNA polymerase I resulting in ribosome biogenesis block, and it is 
known to induce p53 levels and activity (Sloan et al., 2013a, Nishimura et al., 2015). It 
is also possible that Dyskerin over-expression might lead to p53 induction with a 
reduced activity. If this is the case, it would be important to identify whether this is due 
to other possible functions of Dyskerin in the cell, which are currently unknown, making 
Dyskerin a novel regulator of the p53 pathway in humans. It would be interesting to 
identify whether this is the case, probably by using other cell lines in order to identify 
whether this is a cell line-specific phenotype. 
 
The H/ACA RNP pseudouridylates the snRNAs, a modification needed for pre-mRNA 
splicing, and it is involved in telomere maintenance, by promoting telomere stability 
(Meier, 2005). However, not much is known about the functions of the complex in these 
processes. The H/ACA scaRNPs are required for the pseudouridylation of the small 
nuclear (sn)RNA during splicing, including U1, U2, U4, U5 and U6 snRNAs (Reichow 
et al., 2007). For example, the U85 H/ACA scaRNA is involved in the pseudouridylation 
of U46 residue of the U2 snRNA (Jady and Kiss, 2001). The H/ACA scaRNPs are 
mainly localized in Cajal bodies in the nucleus since they contain a Cajal body 
localization sequence, called the CAB box (Richard et al., 2003), and they are bound 
by TCAB1, a Cajal-body chaperone protein (Stern et al., 2012). It would be interesting 
to identify the levels of the H/ACA scaRNAs in the cell after knockdown of Dyskerin or 
inactivation of its catalytic activity. Given that the H/ACA snoRNAs accumulate in the 
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presence of the catalytically inactive Dyskerin, it is hypothesized that the H/ACA 
scaRNAs would be stable. It would be interesting to determine whether the activity of 
specific snRNAs are affected after Dyskerin knockdown or inactivation of its catalytic 
activity. In mouse embryonic fibroblast (MEF) cells, it was shown that the catalytic 
activity of Dyskerin was only required for the accumulation of the H/ACA snoRNAs in 
the cell, but not for H/ACA scaRNAs or snRNAs (Gu et al., 2013). Apart from its 
importance to pre-mRNA splicing, the H/ACA snoRNP was found to be important for 
maintenance of the telomerase complex. The human telomerase RNA (hTERC) 
contains an H/ACA box-like domain on its 3’ end (Mitchell et al., 1999), which is 
essential for its nuclear localization (Lukowiak et al., 2001). Furthermore, the H/ACA 
box-like domain of hTERC is important for interactions with the other H/ACA snoRNP 
components (Cohen et al., 2007) and for the recruitment of TCAB1 protein in the 
complex (Venteicher et al., 2009, Venteicher and Artandi, 2009). The presence of the 
H/ACA snoRNP complex was found to promote telomere maintenance and potentially 
assembly (Egan and Collins, 2012). Therefore, mutations in the gene encoding for 
Dyskerin found in DC patients, which presumably affect the accumulation and function 
of the H/ACA snoRNP in humans, might affect splicing and telomere maintenance as 
well as ribosome biogenesis. It is possible that these mutations may result in a slower 
accumulation of the H/ACA snoRNP complex in humans, leading to a decreased rate 
of snRNA pseudouridylation and, therefore, mRNA splicing, as well as telomere 
defects by affecting telomere stability. 
 
There is still some debate on whether DC is caused by ribosome biogenesis defects 
or telomere maintenance defects, since telomere shortening is observed in all forms 
(Podlevsky et al., 2008). Studies on induced pluripotent stem (iPS) cells from X-linked 
DC patients have shown that telomere maintenance was severely defective, whilst the 
ribosome biogenesis pathway was mostly unaffected (Gu et al., 2015). However, other 
studies showed that Dyskerin reduction did not correlate to telomere maintenance or 
length in mouse or zebrafish models (Ge et al., 2010b, Gu et al., 2008, Ying Zhang et 
al., 2012) and the disease phenotype occurred before any telomere defects were 
visible in mice (Gu et al., 2008). Furthermore, a recent study has showed that Dyskerin 
was over-expressed in cell lines from neuroblastoma patients, and Dyskerin depletion 
resulted in p53-dependent cell cycle arrest due to ribosome biogenesis defects, but 
not telomere maintenance defects (O'Brien et al., 2016b). These studies support the 
theory that defects in ribosome biogenesis, rather than telomere defects, are more 
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likely to be responsible for the accumulation of p53 in DC patients. In patients where 
mutations on TERT or TERC are found, it is possible that the H/ACA snoRNP has 
normal functions in ribosome biogenesis pathway, and therefore telomere 
maintenance defects could be the primary cause of DC. The possibility that the DC 
phenotype results from both ribosome biogenesis and telomere maintenance defects 
if both pathways are affected cannot be excluded. Whether Dyskerin depletion affects 
telomere maintenance in humans, due to low accumulation of the H/ACA snoRNPs, 
remains to be seen. One possibility is that inactivation of Dyskerin could cause p53-
dependent telomere maintenance defects after p53 induction due to ribosome 
biogenesis defects, leading to cell cycle arrest and apoptosis. Another possibility is that 
inactivation of Dyskerin would directly cause defects in telomere stability and 
maintenance, perhaps due to weaker interactions of the H/ACA snoRNP with the 
human telomerase complex, which would lead in a p53 induction via both ribosome 
biogenesis and telomere maintenance defects. Since U2OS cells do not express a wild 
type telomerase and use alternative lengthening of telomeres (ALT) to maintain 
telomere length, another human cell line has to be used for studying the involvement 
of Dyskerin in telomere maintenance and p53 induction, such as the human colorectal 
cancer cell line HCT-116. 
 
In conclusion, in the past few years, it was shown that Dyskerin plays a key role in the 
development of the clinical symptoms of DC and carcinogenesis. However, most 
studies have been done in yeast, where Dyskerin appears to have different functions 
in ribosome biogenesis pathway. Here, I have showed that Dyskerin is required for 
both LSU and SSU rRNA processing, and inactivation of its catalytic activity is likely to 
result in a slower production of, perhaps, unstable rRNAs. Furthermore, I have shown 
that Dyskerin depletion causes p53 accumulation via the 5S RNP-MDM2 pathway in 
humans, possibly due to ribosome biogenesis defects, which is in agreement with 
previous studies in mouse and zebrafish models. It is clear that further investigation of 
the functions of Dyskerin in both ribosome biogenesis and p53 accumulation in 
humans is necessary for the development of novel therapeutic treatments for DC 
patients. Finally, it would be interesting to explore the roles of the 5S RNP in tumour 
development in DC patients, which could be used as a target for future targeted 
treatments, not only for DC, but for other ribosomopathies as well. 
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4. Chapter Four. Defects in large or small ribosomal subunit 
production result in p53 accumulation 
 
4.1 Introduction 
 
Ribosomes consist of two subunits: the large (60S; LSU) and the small (40S; SSU). In 
humans, the LSU contains the 28S, 5.8S and 5S rRNAs and approximately 46 
ribosomal proteins, whereas the SSU contains the 18S rRNA and approximately 33 
ribosomal proteins (Freed et al., 2010b). The 28S, 5.8S and 18S rRNAs are transcribed 
in the nucleolus as a single transcript (47S) by RNA polymerase I, and the mature 
rRNAs are produced after a series of cleavage and modification steps (Figure 4.1) 
(Gamalinda and Woolford, 2015). In contrast, the 5S rRNA is transcribed in the 
nucleoplasm by RNA polymerase III, and is bound by the ribosomal proteins RPL5 and 
RPL11, resulting in the formation of the mature 5S RNP (Gamalinda and Woolford, 
2015), before being integrated in the LSU (Figure 4.1). Early steps of ribosome 
biogenesis take place in the nucleolus and the nucleoplasm, whereas subunit 
maturation is completed in the cytoplasm (Figure 4.1) (Gamalinda and Woolford, 
2015). 
 
The 47S rRNA precursor is cleaved at ITS1 for separation of the LSU and SSU rRNA 
precursors (Figure 4.1). A number of factors are involved in this cleavage step in 
humans, including the RNA-binding protein RRP5 and the ribosome biogenesis factors 
NOL12, BOP1 and RBM28 (Sloan et al., 2013c). Further processing of the 30S SSU 
rRNA precursor results in the formation of the 21S rRNA precursor, which is processed 
in the nucleoplasm, leading to the formation of the 18SE rRNA precursor (Figure 4.1). 
In turn, the 18SE rRNA precursor is exported to the cytoplasm (Henras et al., 2015) 
where it is further processed, by NOB1 endonuclease (Sloan et al., 2013c), producing 
the mature 18S rRNA (Figure 4.1). The 32S rRNA LSU rRNA precursor is processed 
in the nucleolus and nucleoplasm for the production of the mature 28S and 5.8S rRNAs 
(Figure 4.1) (Ansel et al., 2008). It is unclear whether the last stages of the pre-28S 
and pre-5.8S rRNA processing occur in the cytoplasm in humans, as it is in yeast 
(Thomson and Tollervey, 2010). It was originally thought that the biogenesis of LSU 
and SSU are two independent processes, but, in yeast, it was shown that the mature 
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LSU is required for the last stages of SSU rRNA precursor processing in the cytoplasm 
(Lebaron et al., 2012), suggesting that the two processes are likely to be linked. 
 
Ribosome biogenesis is directly linked with the levels of the tumour suppressor p53 in 
the cell (Figure 4.1) (Orsolic et al., 2015). p53 is a transcription factor, which, upon 
activation, causes the transcriptional activation of downstream targets involved in cell 
cycle arrest, metabolic changes, senescence and apoptosis (Brown et al., 2009). For 
example, p21 is a downstream target of p53 involved in cell cycle arrest (Karimian et 
al., 2016). The activation of p53 is controlled by various intracellular stimuli, such as 
DNA damage (Vogelstein et al., 2000), or extracellular stimuli, such as growth factors 
(Sherr and Weber, 2000). p53 is normally found in low levels in the cell, being targeted 
and inhibited for proteosomal degradation by the ubiquitin ligase MDM2, the main p53 
suppressor (Wade et al., 2013). Defects in ribosome biogenesis cause the 
accumulation of the free 5S RNP in the nucleoplasm, which binds MDM2, inhibiting its 
activity, leading to p53 stabilisation (Figure 4.1) (Pelava et al., 2016). It is clear that 
LSU production defects lead to p53 induction via the 5S RNP-MDM2 pathway (Sloan 
Figure 4.1. The ribosome biogenesis pathway and p53 induction via the 5S RNP-
MDM2 pathway. Schematic representation of the small (SSU) and large (LSU) 
ribosomal subunit biogenesis pathway in humans. p53 induction via the 5S RNP-
MDM2 pathway after ribosome biogenesis defects is shown. The stages where the 
ribosomal proteins (RSP19, RPL7, RPL18, RPL21) or ribosome biogenesis factors 
(PNO1, RIO2, PICT1), proteins focused on in this chapter, act are shown in red 
(Adapted from (Kressler et al., 2010)). 
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et al., 2013a, Donati et al., 2013, Nishimura et al., 2015), but there is minimal evidence 
of the mechanism by which SSU production defects lead to p53 induction. 
 
A number of rare genetic diseases, called ribosomopathies, arise due to defects in 
ribosome production (Narla and Ebert, 2010), from mutations in genes encoding for 
ribosome biogenesis factors or ribosomal proteins (Yelick and Trainor, 2015). Most of 
the genes mutated in ribosomopathies encode for SSU ribosomal proteins or ribosome 
biogenesis factors (Narla and Ebert, 2010). The most well-studied ribosomopathies 
include Diamond-Blackfan Anaemia (DBA), 5q syndrome and Treacher-Collins (TC) 
syndrome (Table 4.1). DBA arises due to mutations in genes encoding for SSU 
ribosomal proteins, such as RPS19 and RPS24, or LSU ribosomal proteins, such as 
RPL5 and RPL11 (Lipton and Ellis, 2010). 5q syndrome arises due to mutations in the 
gene encoding for the SSU ribosomal protein RPS14 (Ebert et al., 2008b), whereas 
TC syndrome arises mainly due to mutations in the gene encoding for a ribosome 
biogenesis factor, TCOF1 (Weiner et al., 2012) (Table 4.2). The majority of 
ribosomopathies appear with common phenotypes, such as the development of 
macrocytic anaemia, craniofacial defects and, in most cases, increased cancer risk, 
especially for acute myeloid leukaemia (AML) (Yelick and Trainor, 2015). Interestingly, 
in mouse models of DBA the development of anaemia was found to be dependent on 
the 5S RNP-MDM2 interaction (Jaako et al., 2015) and RPS19 depletion in a DBA 
zebrafish model resulted in p53-dependent defective erythropoiesis (Danilova et al., 
2008). In 5q syndrome mouse models, the development of anaemia due to 
haploinsufficiency of RPS14 was shown to be dependent on p53 (Table 4.2) 
(Schneider et al., 2016). Furthermore, depletion of either RPS14 or RPS19 in human 
erythroid progenitor cells resulted in p53 activation (Dutt et al., 2011). Moreover, the 
craniofacial defects observed in a mouse model where TCOF1 was mutated were also 
p53-dependent (Table 4.2) (Jones et al., 2008). 
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 The evidence from ribosomopathy animal models indicate that SSU production defects 
lead to p53 induction. Further confirming this, depletion of other SSU ribosomal 
proteins, apart from the ones involved in ribosomopathies, was also shown to cause 
p53 induction. For instance, RPS6 inactivation in mice resulted in the development of 
p53-dependent anaemia and other erythropoiesis defects (McGowan et al., 2011), and 
knockdowns of RPS6 or RPS7 in human cells resulted in p53 induction (Fumagalli et 
al., 2012). These studies raised the question on how defects on SSU production result 
in p53 induction. A few papers have reported that this is a result of binding of the 5S 
RNP on MDM2 (Fumagalli et al., 2009, Fumagalli et al., 2012, Golomb et al., 2014). If 
this is the case, it is unclear how defects on the SSU production feedback to the 
recruitment of the 5S RNP in the LSU, leading to p53 accumulation. 
 
It was proposed that there are two different pathways leading to p53 induction after 
either LSU or SSU defects (Figure 4.2) (Fumagalli et al., 2012). LSU defects directly 
lead to the accumulation of the free 5S RNP in in the nucleoplasm, resulting in its 
binding and inhibition of MDM2, and p53 induction (Figure 4.2) (Fumagalli et al., 2012), 
as previously suggested (Sloan et al., 2013a). The authors have proposed that defects 
in SSU biogenesis lead to low levels of the mature SSU, which results in changes in 
the translation dynamics in the cell. This leads to the up-regulation of the translation of 
ribosomal proteins, such as RPL11 (Figure 4.2) (Fumagalli et al., 2012). This is 
proposed to result in the production of more 5S RNP, which binds MDM2 and inhibits 
MDM2 (Figure 4.2). For either LSU- or SSU-mediated p53 accumulation, it has been 
proposed that p53 induction leads to G1 cell cycle arrest (Fumagalli et al., 2012). 
Ribosomopathy Gene defect Clinical 
manifestations 
Cancer risk p53 
involvement 
Diamond-Blackfan 
anaemia 
RPS19, RPS24, 
RPS17, RPS7, 
RPS15, RPS27A, 
RPL36, RPL35A, 
RPL5, RPL11 
Hypoplastic 
macrocytic 
anaemia 
Skeletal, 
urogenital and 
cardiac defects 
Short stature 
AML 
MDS 
osteosarcoma 
p53-
dependent 
anaemia 
5q syndrome RPS14 Macrocytic 
anaemia 
MDS 
AML 
p53-
dependent 
anaemia 
Treacher-Collins 
Syndrome 
TCOF1, POLR1C, 
POLR1D 
Craniofacial 
anomalies 
Hearing 
difficulties 
None reported p53-
dependent 
craniofacial 
defects 
Table 4.1. The most well-known ribosomopathies. The genes mutated in each 
ribosomopathy, the clinical symptoms, the cancer risk and the involvement of p53 are 
shown in each case (Adapted from (Narla and Ebert, 2010). 
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However, when both the LSU and the SSU biogenesis are co-impaired, it was 
predicted that there was both an up-regulation on 5S RNP production and a block in 
5S RNP integration into the LSU, leading to p53 supra-induction due to the two 
pathways being affected (Figure 4.2). This resulted in a stronger p53 response and 
both G1 and G2/M cell cycle arrest (Fumagalli et al., 2012). 
 
Even though a number of studies have investigated how defects in early, nucleolar 
stages of ribosome biogenesis, result in p53 induction, not much is known about how 
p53 levels are affected when later rRNA processing stages are affected. Furthermore, 
the pathway in which defects in SSU lead to p53 accumulation via the 5S RNP-MDM2 
is far from clear. Therefore, in this part of the PhD, I aimed to investigate: 
Figure 4.2. Schematic representation of the proposed model for the regulation 
of p53 after ribosome biogenesis defects. Large ribosomal subunit (LSU) defects 
lead to the accumulation of the free 5S RNP, which binds MDM2 resulting in p53 
induction. Small ribosomal subunit (SSU) defects lead to the upregulation of ribosomal 
protein production, resulting in the increased production of the 5S RNP, which binds 
both the LSU and MDM2, leading to p53 induction. Defects on both the LSU and SSU 
lead to the upregulation of ribosomal protein production and the accumulation of the 
increased 5S RNP produced, which only binds MDM2, resulting in p53 supra-induction  
(Adapted from: (Fumagalli et al., 2012)). 
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• Whether defects in early or late stages of the LSU or SSU biogenesis lead to 
p53 accumulation via the 5S RNP-MDM2 pathway 
• Whether p53 is induced because of ribosome production defects or a reduction 
in ribosomes 
• Whether SSU biogenesis defects lead to LSU production defects and activation 
of p53 through the 5S RNP-MDM2 pathway 
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4.2 Results 
 
4.2.1 Identification of targets to analyse ribosome biogenesis defects 
 
I firstly wanted to study whether defects in different stages of LSU or SSU production 
lead to p53 induction. For this, the ribosomal protein RPS19 and the ribosome 
biogenesis factors PNO1 and RIO2 proteins were studied for SSU rRNA processing, 
and the ribosomal proteins RPL7, RPL18, RPL21 and the ribosome biogenesis factor 
PICT1 were studied for LSU rRNA processing. siRNA-mediated knockdowns, targeting 
these proteins, were performed in human osteosarcoma U2OS cells for 48h. In order 
to establish knockdown efficiency, the whole cell extract was loaded on an SDS-PAGE 
gel and analysed by Western Blotting (Figure 4.3) using the corresponding antibodies. 
In the case of RPL21, where there was no available antibody in the lab, RT-PCR was 
performed after RNA was extracted from the cells (Figure 4.3). A reduction in protein 
levels was seen for all knockdowns, ranging from 60% (RPL5, Chapter 3) to 80% 
(RPS19, RIO2, PICT1) reduction (Figure 4.3A, B). Furthermore, the mRNA levels of 
RPL21 after knockdowns were approximately 95% decreased (Figure 4.3C), indicating 
that the protein levels were probably low after the knockdown. 
Figure 4.3. The chosen proteins were efficiently knocked down in U2OS cells. 
Knockdowns were performed in U2OS cells for 48h. (A-B) The whole cell extract was 
loaded on an SDS PAGE gel and analysed by Western Blotting using the 
corresponding antibodies (shown on the left). α-Tubulin (Tub.) and α-Karyopherin 
(Karyop.) were used as loading controls. Western Blots were visualized using ECL 
(A) or the LICOR system (B). (C) RNA was extracted from the cells and RT-PCR was 
performed. The samples were loaded on a 2% agarose/1X TBE gel and visualized 
using a Typhoon Phosphorimager. Primers specific for RPL21 or GAPDH (loading 
control) were used for detection of the mRNA (shown on the left). 
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I next addressed whether the knockdown of these proteins resulted in rRNA processing 
defects. As I was particularly interested in SSU defects, I wanted to identify the specific 
stages of SSU production that RPS19, PNO1 and RIO2 are involved in U2OS cells. 
RPL5, PICT1 (Sloan et al., 2013a), RPL7, RPL18 and RPL21 (Loren Gibson, Nick 
Watkins, personal communication) knockdowns all resulted in 28S rRNA processing 
defects. Knockdowns of RPS19, PNO1 or RIO2 were performed in U2OS cells for 48h, 
the RNA was extracted and loaded on a glyoxal-agarose gel before transferred to a 
Hybond N membrane. Incubation of the membrane with a radio-labelled (32P) probe 
specific for the 5’-ITS1 (Figure 4.4A) was performed, and the RNAs were visualized 
using a Typhoon Phosphorimager (Figure 4.4B). Knockdown of RPS19 resulted in a 
major accumulation of the 21S rRNA precursor and a decrease of the 18SE rRNA 
precursor levels as compared to the control (Figure 4.4B). Furthermore, an 
accumulation of the 21SC rRNA precursor was observed, no differences were 
observed in the levels of 47/45S or 41S precursors, and the levels of 30S and 26S 
rRNA precursors were slightly decreased (Figure 4.4B). Knockdown of RIO2 did not 
result in a significant change in the levels of the 47/41S, 41S, 30S or 26S rRNA 
precursors as compared to the control, but it caused a slight decrease in the levels of 
21S rRNA precursor and an accumulation of the 18SE rRNA precursor (Figure 4.4B). 
Finally, knockdown of PNO1 resulted in an accumulation of the 47/45S, 41S and 30S 
rRNA precursors, and to an ever greater accumulation of the 26S rRNA precursor as 
compared to the control. The levels of 21S and 18SE rRNA precursors were slightly 
decreased and there was an accumulation of the 21SC rRNA precursor (Figure 4.4B). 
Taken together, these data showed that RPS19, PNO1 and RIO2 knockdowns resulted 
in the expected rRNA processing phenotype in U2OS cells as previously shown in 
other cell lines (Choesmel et al., 2007, Vanrobays et al., 2004, Geerlings et al., 2003), 
further confirming the efficiency of the knockdowns. 
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 4.2.2 Defects in different stages of LSU or SSU production lead to p53 induction 
via the 5S RNP-MDM2 pathway 
 
Defects in either LSU (Sloan et al., 2013a, Donati et al., 2013) or SSU (Fumagalli et 
al., 2012) biogenesis were shown to cause p53 accumulation via the 5S RNP-MDM2 
pathway. I, therefore, wanted to investigate whether p53 was induced after inhibition 
of different stages of rRNA processing. Knockdowns were performed in U2OS cells for 
48h and the whole cell extract was loaded on an SDS-PAGE gel before analysed by 
Western Blotting using antibodies for p53 or its downstream target p21, indicating p53 
activity (Figure 4.5), even though other downstream targets of p53 were not examined. 
It is worth noting that p21 mRNA levels were not examined here due to time 
constraints, as p21 is regulated post-translationally as well (Jung et al., 2010). RPS19, 
RPL7, RPL18 and RPL21 are found in the nucleolus and the cytoplasm, PNO1 mainly 
Figure 4.4. RPS19, PNO1 and RIO2 knockdowns result in SSU rRNA processing 
defects. (A) Schematic representation of the human ribosome biogenesis pathway. 
The LSU precursor and mature rRNA are shown in blue, and the SSU precursor and 
mature rRNA are shown in green. The 5’-ITS1 site recognized by the radiolabelled 
(32P) probe is indicated in red (Adapted from (Sloan et al., 2013c)). (B) Knockdowns 
were performed for 48h in U2OS cells before the RNA was extracted and loaded on a 
1.2% agarose-glyoxal gel. The RNA was transferred on a Hybond N membrane, 
incubated with radiolabelled (32P) probe specific for the 5’-ITS1 site and visualized 
using a Typhoon Phosphorimager. The ethidium bromide staining (UV) of the 28S 
rRNA was used as a loading control. 
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functions in the nucleoplasm and RIO2 is found in both the nucleoplasm and 
cytoplasm. 
 
Either RPS19 or RIO2 knockdown resulted in a significant induction in p53 levels as 
compared to the control (Figure 4.5A, B). Furthermore, the levels of p21 also increased 
when RPS19 or RIO2 were knocked down (Figure 4.5A), indicating an increase in p53 
activity. Since all three components of the 5S RNP are required for its binding on 
MDM2 (Sloan et al., 2013a), RPL5 knockdown was performed in order to investigate 
whether this p53 accumulation was mediated by the 5S RNP-MDM2 pathway. RPL5 
knockdown alone did not result in a significant change in p53 or p21 levels as 
compared to the control (Figure 4.5A, B). Note that the efficiency of the double 
knockdowns on the target levels was not examined due to time constraints and, 
therefore, a slight variation in the knockdown efficiency might have occurred. Double 
knockdown of RPL5 and RPS19 resulted in a rescue of the p53 levels as compared to 
the RPS19 knockdown (Figure 4.5A, B). The same was observed when RIO2 and 
RPL5 were knocked down as compared to the RIO2 knockdown (Figure 4.5A, B). 
Finally, the levels of p21 were also decreased when double knockdowns of RPS19 or 
RIO2 with RPL5 were performed (Figure 4.5A), indicating a rescue in p53 activity. 
These results indicated that inhibition of SSU production in either early, nuclear steps, 
as seen by RPS19 knockdown, or late, cytoplasmic steps, as seen by RIO2 
knockdown, resulted in p53 induction via the 5S RNP-MDM2 pathway. 
 
Either RPL7, RPL18 or PICT1 knockdown resulted in a significant increase in p53 
levels (Figure 4.5A, B). Furthermore, knockdowns of RPL7, RPL18 or PICT1 resulted 
in a p21 increase, indicating an increase in p53 activity as well (Figure 4.5A). In order 
to investigate whether this increase in p53 levels and activity was due to the 5S RNP-
MDM2 pathway, double knockdowns of RPL7, RPL18 or PICT1 with RPL5 were 
performed (Figure 4.5). As previously, knockdown of RPL5 did not result in a significant 
change in p53 or p21 levels as compared to the control (Figure 4.5A, B). Double 
knockdown of RPL5 with RPL7, RPL18 or PICT1 resulted in a significant decrease on 
p53 levels as compared to the single knockdowns of these proteins (Figure 4.5A, B). 
Furthermore, the p21 levels were also decreased when double knockdowns with RPL5 
were performed, showing that both p53 levels and activity were rescued. These results 
indicated that defects in early or late stages of LSU biogenesis result in p53 induction 
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via the 5S RNP-MDM2 pathway, further confirming previous studies (Sloan et al., 
2013c, Golomb et al., 2014) 
 
Figure 4.5. Defects on different stages of SSU or LSU production lead to p53 
accumulation via the 5S RNP-MDM2 pathway. (A) Knockdowns were performed for 
48h in U2OS cells and the whole cell extract was loaded on an SDS-PAGE gel, 
followed by Western blot analysis using the LICOR system. The antibodies used are 
shown on the left and Karyopherin (Karyop.) was used as a loading control. (B) 
ImageQuant software was used for quantitation of the p53 levels of the Western Blot 
membranes, which were normalised against the loading control values (α-
Karyopherin). The graphs represent the average p53 protein levels of three 
experimental repeats and the error bars show the standard error (+/-SEM). Statistical 
analysis was performed using unpaired t-test. (C) Knockdowns were performed for 48h 
in U2OS cells expressing p53-driven luciferase. ActD treatment was performed for 18h 
and untreated cells are presented as “plain”. The p53-driven luciferase levels were 
analysed using a luminometer and cell numbers were measured using a Bradford 
assay. The luciferase values were normalized against the Bradford assay values. The 
graph shows the average luciferase intensity of three experimental repeats and the 
error bars represent the standard error (+/-SEM). Statistical analysis was performed 
using an unpaired t-test and absence of significance values indicates no significant 
differences as compared to the control. *p value<0.05, **p value<0.01, ***p 
value<0.0001. 
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In order to directly address the levels of p53 activity, knockdowns were also performed 
in U2OS cells expressing luciferase, regulated by a p53-promoter. The luciferase 
levels were analysed using a Luminometer (Figure 4.5C). Overnight treatment with 
Actinomycin D was used as a positive control, since it is a known ribosome biogenesis 
inhibitor that blocks RNA polymerase I, which leads to p53 induction via the 5S RNP-
MDM2 pathway (Sloan et al., 2013a). Indeed, the p53-driven luciferase levels were 
significantly induced after ActD treatment as compared to the plain, untreated cells 
(Figure 4.5C). RPS19 or RIO2 knockdowns resulted in a small, but significant increase 
in the p53-driven luciferase levels (Figure 4.5C) in comparison to the control 
knockdown. A significant increase in p53-driven luciferase levels was also observed 
after RPL7, RPL18 or PICT1 knockdowns (Figure 4.4D). These results indicated that 
defects in early or late stages of SSU or LSU production lead to an increase in both 
p53 levels and activity. In summary, these results showed that defects in early or late 
stages of either LSU or SSU production lead to p53 accumulation via the 5S RNP-
MDM2 pathway. 
 
4.2.3 Defects on different stages of LSU or SSU production have different 
effects on cell cycle 
 
It was recently reported that p53 activation after defects in either LSU or SSU 
production led to G1 cell cycle arrest (Fumagalli et al., 2012). Since p53 was induced 
after defects in different stages of human ribosome biogenesis, I wanted to investigate 
how the cell cycle might have been affected. Knockdowns were performed for 48h in 
U2OS cells or treated with ActD for 18h. ActD treatment was used as a positive control, 
since it was previously shown to result in G1 and G2/M cell cycle arrest (Fumagalli et 
al., 2012). The cells were fixed in 70% ethanol and the DNA was stained using 
propidium iodide. The cell cycle analysis was performed using the FACS Canto II flow-
cytometer and software. 
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 Figure 4.6. SSU or LSU defects result in G1 and a slight G2/M cell cycle arrest in 
U2OS cells. (A-F) ActD treatment was performed overnight, whereas knockdowns 
(control, RPS19, RPL7 and RPL18) were performed for 48h in U2OS cells. The cells 
were fixed using 70% ethanol and DNA was stained using propidium iodide. Cell cycle 
analysis was performed using the FACS Canto II flow cytometer and software. (G) The 
graph represents the average percentage levels of G1/G0 (dark grey), S (light grey) or 
G2/M (grey) phase of three experimental repeats. The error bars represent the 
standard error (+/-SEM) and statistical analysis was performed using an unpaired t-
test. Comparison of significance was performed against the plain U2OS cells for ActD 
or against the control knockdown for RPS19, RPL7, RPL18 knockdowns. Absence of 
significance values indicates no significant differences to the control. *p value<0.05, 
**p value<0.01, ***p value<0.0001. 
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Firstly, I investigated the effects of the ribosomal protein knockdowns on cell cycle. 
ActD treatment, as compared with the non-treated (plain) U2OS cells, resulted in a 
significant G1 cell cycle arrest and a significant reduction in S phase, showing a G2/M 
arrest, even though the levels of G2 phase were not significantly altered (Figure 4.6A, 
B, G). Knockdowns of either RPS19, RPL7 or RPL18 all resulted in a significant 
increase in G1 phase and a significant decrease in S phase (Figure 4.6). Even though 
the levels of G2/M phase were not significantly changed, these results indicate that 
p53 induction after RPS19, RPL7 or RPL18 knockdown results in a significant G1 and 
a mild G2/M cell cycle arrest, presumably due to p53 induction. This phenotype is 
similar to the one observed after ActD treatment, but the cell cycle arrest after 
ribosomal protein knockdowns RPS19 and RPL7 is not as strong as the cell cycle 
arrest observed after ActD treatment. This is consistent with the fact that ActD 
treatment resulted in a bigger increase in p53 activity than the ribosomal protein 
knockdowns. 
 
Additionally, I investigated the effects of knockdowns of the SSU and LSU ribosome 
biogenesis factors RIO2 and PICT1 on cell cycle regulation. As previously seen, ActD 
treatment resulted in a significant increase in G1 levels and a significant decrease in 
S phase levels, but not in a significant G2 phase levels change as compared with the 
non-treated (plain) U2OS cells (Figure 4.7A, B, F). Neither RIO2 nor PICT1 
knockdowns resulted in a significant change in either G1, S or G2/M phase in cell cycle 
(Figure 4.7). These results showed that knockdown of RIO2 or PICT1 ribosome 
biogenesis factors did not result in cell cycle arrest, even though p53 was significantly 
induced in both cases, although to a lesser extent than the p53 induction observed 
after ribosomal protein knockdowns (see discussion). 
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 Figure 4.7. Knockdowns of RIO2 or PICT1 do not affect the cell cycle in U2OS 
cells. (A-E) ActD treatment was performed overnight, whereas knockdowns using 
siRNAs against control, RIO2 or PICT1 were performed for 48h in U2OS, before being 
fixed using 70% ethanol. The DNA was stained using propidium iodide and the cell 
cycle was analysed using the FACS Canto II flow cytometer and software (F) The 
graph represents the average percentage levels of G1/G0 (dark grey), S (light grey) 
or G2/M (grey) phase of three experimental repeats. The error bars represent the 
standard error (+/-SEM) and statistical analysis was performed using an unpaired t-
test. Comparison of significance was performed against the plain U2OS cells for ActD 
or against the control knockdown for RIO2 and PICT1 knockdowns. Lack of 
significance values indicates no significant differences. *p value<0.05, **p value<0.01. 
 
              
                
             
              
           
            
119 
 
4.2.4 p53 levels increase as a result of ribosome production block 
 
It was previously suggested that changes in the steady-state levels of ribosomes, 
rather than defects in rRNA processing, result in p53 accumulation (Fumagalli et al., 
2012). In this paper, the authors suggest that defects in LSU result in the accumulation 
of the free 5S RNP in the nucleoplasm, whereas defects in SSU result in the up-
regulation of translation of the ribosomal proteins, which then results in high levels of 
the free 5S RNP in the nucleoplasm (Fumagalli et al., 2012). This would imply that the 
kinetics of LSU or SSU defects on p53 activation would be different, as the free 5S 
RNP accumulates by two different pathways. I, therefore, decided to test this by 
performing knockdowns of RPS19, RPL7, RPL18 or RPL21 in U2OS cells for 24h, 48h 
or 72h. Note that the RPL21 knockdown was previously shown in the lab to majorly 
decrease the 28S rRNA levels (Loren Gibson, Nick Watkins, personal communication). 
The whole cell extract was loaded on an SDS-PAGE gel, and analysed by Western 
blotting using p53 and p21 antibodies (Figure 4.8).  
 
RPS19 knockdown resulted in a significant 2-fold increase in p53 levels after 24h as 
compared to the control, which was sustained after 48h and 72h (Figure 4.8). 
Furthermore, the levels of p21 were also slightly increased after 24h, and further 
increased after 48h and 72h, suggesting an increase in p53 activity over time. 
Knockdown of either RPL7, RPL18 or RPL21 resulted in a significant, approximately 
5-fold p53 increase after 24h (Figure 4.8). The levels of p21 were also increased, 
indicating an increase in p53 activity after RPL7, RPL18 or RPL21 knockdowns (Figure 
4.8). p53 levels were still significantly increased after 48h or 72h as compared to the 
control after RPL7, RPL18 or RPL21 knockdowns, as were the p21 levels (Figure 4.8). 
However, the p53 levels decreased over time after knockdowns of the LSU ribosomal 
proteins (Figure 4.8). These results showed that p53 levels increased as early as 24h 
after a block in either LSU or SSU production. 
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 Next, I investigated whether the levels of the mature 28S or 18S rRNAs correlated with 
the levels of p53 induction in the cell. RNA was extracted after knockdown or ribosomal 
proteins, loaded on a glyoxal-agarose gel and then analysed with Northern Blotting. 
The membrane was incubated with radio-labelled (32P) probes that recognize the 
Figure 4.8. p53 induction after SSU or LSU defects occurs in less than 24h. (A) 
Knockdowns were performed for 24h, 48h or 72h in U2OS cells and the whole cell 
extract was loaded on an SDS-PAGE gel, followed by Western blot analysis. The 
antibodies used are shown on the left and Karyopherin (Karyop.) was used as a 
loading control. The membranes were visualised using the LICOR system. (B) 
ImageQuant software was used to quantitate the levels of p53, followed by 
normalization against the values of the loading control (α-Karyopherin). The graph 
represents the p53 protein level averages of three experimental repeats and the error 
bars show standard error (+/-SEM). Statistical analysis was performed using unpaired 
t-test. *p value<0.05, **p value<0.01, ***p value<0.001. 
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mature 28S or 18S rRNA (Figure 4.9). The levels of the mature 18S rRNA were 
compared to 28S rRNA for RPS19 knockdown, whereas the levels of the mature 28S 
rRNA were compared to the 18S rRNA for the RPL7, RPL81 and RPL21 knockdown 
 
RPS19 knockdown resulted in a significant 40% decrease in the levels of the mature 
18S rRNA after 24h of siRNA treatment, 60% decrease after 48h of siRNA treatment 
and a striking 75% decrease after 72h of siRNA treatment (Figure 4.9A, B). A similar 
pattern was observed after knockdowns of RPL7, RPL18 and RPL21 for 28S rRNA. 
An approximately 60-70% significant decrease on 28S rRNA levels was observed after 
RPL7, RPL18 or RPL21 knockdowns after 24h of treatment, 70% decrease after 48h 
and 85% after 72h (Figure 4.9A, C). These results showed that the mature 18S or 28S 
rRNA decrease in a linear manner after small or large ribosomal subunit defects 
respectively. 
 
Figure legend on the next page. 
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 4.2.5 p53 levels increase independently of the levels of 18S rRNA in the cell 
 
It was previously proposed that p53 induction after defects in SSU production is due 
to a decrease of the mature 18S rRNA levels in the cell (Fumagalli et al., 2012). Since 
p53 levels were induced after only 24h of either LSU or SSU block (Figure 4.8) when 
the 18S rRNA levels were already low (Figure 4.9), I decided to look at shorter time-
points after the knockdowns. Knockdowns of RPS19, RPL7, RPL18 or RPL21 were 
performed in U2OS for 12h or 24h. Cells were analysed by Western blotting using α-
p53 or α-p21 antibodies (Figure 4.10). 
 
RPS19 knockdown resulted in a significant p53 induction after 12h of siRNA treatment 
as compared to the control, as well as in a slight p21 increase (Figure 4.10). RPL7, 
RPL18 or RPL21 knockdown also resulted in a significant p53 induction as compared 
to the control, and a p21 increase as well (Figure 4.10). After 24h of siRNA treatment, 
RPS19 knockdown resulted in a significant p53 increase as compared to the control 
and an increase in p21 (Figure 4.10), as expected. Similarly, knockdowns of RPL7, 
RPL18 or RPL21 also resulted in a significant p53 increase and in an increase in p21 
levels, indicating an increase in p53 activity (Figure 4.10). These results showed that 
p53 levels were increased as early as 12h after block in either SSU or LSU production. 
Figure 4.9. The levels of the mature rRNAs decrease linearly over time after SSU 
or LSU defects. (A) Knockdowns were performed for 24h, 48h or 72h in U2OS cells 
and RNA was extracted and loaded on a 1.2% agarose/glyoxal gel. The membranes 
were incubated with radio-labelled (32P) probes that recognize the mature 18S or 28S 
rRNA, and visualized using the Typhoon Phosphorimager. (B-C) Quantitation of 
Northern Blots was performed using the ImageQuant software. The 18S rRNA was 
normalized to the 28S rRNA levels for RPS19 knockdown, whereas the 28S rRNA was 
normalized to the 18S rRNA levels after RPL7, RPL18 or RPL21 knockdowns. The 
graphs represent the average relative levels of 18S (B) or 28S (C) rRNA of three 
experimental repeats and the error bars show standard error (SEM). Statistical 
analysis was performed using unpaired t-test. **p value<0.01, ***p value<0.001. 
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 Next, I investigated whether the levels of the mature 18S or 28S rRNA has already 
changed after 12h of SSU or LSU production defects. RNA was extracted from cells 
after knockdowns, loaded on a glyoxal-agarose gel and analysed by Northern Blotting 
(Figure 4.11). 
 
Figure 4.10. p53 is induced as soon as 12h after SSU or LSU defects. (A) 
Knockdowns of control, RPS19, RPL7, RPL18 or RPL21 were performed in U2OS 
cells for 12h or 24h. The whole cell extract was loaded on an SDS-PAGE gel and 
analysed by Western Blotting. The antibodies used are shown on the left and 
Karyopherin (Karyop.) was used as a loading control. Visualization of the Western blot 
membrane was performed using the LICOR system. (B) The ImageQuant software 
was used for quantitation of Western Blots. The protein levels of p53 were normalized 
against the levels of the loading control (α-Karyopherin). The graph represents the 
averages of the relative p53 protein levels after each knockdown to the control of 12h 
or 24h respectively, of three experimental repeats. The standard error (+/-SEM) is 
shown by the error bars. Statistical analysis was performed using unpaired t-test. *p 
value<0.05, **p value<0.01. 
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RPS19 knockdown resulted in a slight, but not significant reduction of the levels of the 
mature 18S rRNA after 12h of siRNA treatment as compared to the control (Figure 
4.11A, B). However, RPS19 knockdown resulted in a significant 40% decrease in the 
levels of 18S rRNA after 24h of siRNA treatment (Figure 4.11A, B), as expected. In 
contrast, knockdowns of RPL7, RPL18 or RPL21 resulted in a significant decrease of 
the levels of the mature 28S rRNA after 12h of siRNA treatment as compared to the 
control, which was approximately 30-40% (Figure 4.11A, C). Similarly to the previous 
time-course (Figure 4.9), knockdowns of RPL7, RPL18 or RPL21 resulted in an 
approximately 60% significant decrease of the levels of the mature 28S rRNA after 24h 
of siRNA treatment as compared to the control (Figure 4.11A, C). 
 
In conclusion, these data indicated that p53 induction occurs very rapidly in the cell, in 
less than 12h, after block of either SSU or LSU. Furthermore, these results indicated 
that p53 induction, at least after RPS19 knockdown, does not correlate with the levels 
of the mature 18S rRNA in the cell after SSU block as previously suggested (Fumagalli 
et al., 2012), but rather, it is more likely to occur due to ribosome production defects. 
Finally, these data indicated that induction of p53 is more likely to occur due to 
ribosome biogenesis defects rather than the reduction of functional ribosomes as 
previously suggested, since it occurred before the newly-synthesized ribosomes were 
fully produced. 
 
Since RPS19 knockdown resulted in a p53 induction without a significant reduction in 
the mature 18S rRNA levels, I next investigated whether this was the case when the 
SSU biogenesis was blocked by ribosome biogenesis factor knockdowns. For this, 
RIO2 and PNO1 knockdowns were performed, for block of the late or middle SSU 
rRNA processing respectively, for 48h in U2OS cells (Figure 4.12). The proteins were 
analysed by Western Blotting, where the whole cell extract was loaded on an SDS-
PAGE gel, using p53 and p21 antibodies. The RNA was extracted from cells, loaded 
on a glyoxal-agarose gel, and analysed by Northern Blotting with radiolabelled (32P) 
probes targeting the mature 18S or 28S rRNA. 
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 The levels of the 18S rRNA were compared to the 28S rRNA (Figure 4.12). RIO2 or 
PNO1 knockdowns did not result in a change of the mature 18S rRNA levels as 
compared to the control (Figure 4.12). However, p53 was induced after knockdown of 
RIO2 or PNO1 (Figure 4.12). p21 was also increased after RIO2 or PNO1 knockdowns 
(Figure 4.12A), indicating an increase in p53 activity. These results indicated that 
defects in early or late stages of SSU rRNA processing result in p53 induction 
independently of the levels of the mature 18S rRNA. 
Figure 4.11. Defects in LSU or SSU rRNA processing occur over time. (A) 
Knockdowns of control, RPS19, RPL7, RPL18 and RPL21 were performed for 12h or 
24h in U2OS cells, before RNA was extracted and loaded on a 1.2% agarose-glyoxal 
gel, before being transferred on a Hybond N membrane. The membranes were 
incubated with radiolabelled (32P) probes against the mature 28S or 18S rRNA, and 
visualized using a Typhoon Phosphorimager. (B-C) ImageQuant software was used 
for quantitation of Northern Blots. The 18S rRNA after RPS19 knockdown was 
normalized to the levels of 28S rRNA (B), whereas the 28S rRNA after RPL7, RPL18 
or RPL21 knockdowns was normalized to the 18S rRNA (C). The graphs represent the 
average relative rRNA levels of three experimental repeats and the standard error is 
shown by the error bars (+/-SEM). Statistical analysis was performed using unpaired 
t-test and absence of significance values indicates no significant differences as 
compared to the control. *p value<0.05, **p value<0.01, ***p value<0.001. 
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 4.2.6 Combined defects on both the large and small ribosomal subunit result in 
p53 supra-induction in only a few cases 
 
It was previously proposed that combined defects in both the large and small ribosomal 
subunit result in p53 supra-induction, leading to a G1 and G2/M cell cycle arrest 
(Fumagalli et al., 2012). I investigated this further in U2OS cells using RPS19 
knockdown for a SSU production block and RPL7 or RPL18 knockdowns for an LSU 
production block. Even though the efficiency of the single knockdowns was tested 
previously (Figure 4.3), the expression levels of the targets were not tested after the 
double knockdowns; therefore a variation in the knockdown efficiency might have 
occurred. Knockdowns were performed for 48h and the whole cell extract was loaded 
Figure 4.12. Defects in early or late stages of SSU rRNA processing result in p53 
induction independently of the levels of the mature 18S rRNA. (A) Knockdowns 
were performed for 48h in U2OS cells. Half of the cells were analysed by Northern 
Blotting (indicated on the right) after RNA was extracted, loaded on a 1.2% glyoxal-
agarose gel, and transferred on a Hybond N membrane. Radiolabelled (32P) probes 
recognizing the mature 28S and 18S rRNA were used (shown on the left) and 
visualized using a Typhoon Phosphorimager. The remaining cells were analysed by 
Western Blotting (indicated on the right), where the whole cell extract was loaded on 
an SDS-PAGE gel. The antibodies used are shown on the left and Karyopherin 
(Karyop.) was used as a loading control. (B) ImageQuant software was used for 
quantitation of the northern or western blots. The 18S rRNA values were normalized to 
the 28S rRNA values and the p53 protein levels were normalized against the 
Karyopherin levels. The graph represents the relative 18S rRNA (dark grey) and p53 
protein (light grey) averages of four experimental repeats and the error bars show the 
standard error (+/-SEM). 
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on an SDS-PAGE gel. Western Blotting analysis was used, using the LICOR system, 
to monitor the levels of p53 and p21 (Figure 4.13). 
 
As expected, there was a significant p53 induction after RPS19, RPL7 or RPL18 
knockdown as compared to the control (Figure 4.13). Furthermore, there was an 
increase in the levels of p21 in all three cases, especially after RPL7 knockdown 
(Figure 4.13A), indicating an increase in p53 activity. Note that p21 can be regulated 
post-translationally, but p21 mRNA levels was not tested here and neither did other 
p53 downstream targets to measure p53 activity. After RPS19 and RPL7 double 
knockdowns, there was a significant p53 induction as compared to the control (Figure 
4.13). Comparing the levels of p53 of the double knockdown with either RPS19 or 
RPL7 single knockdowns, there was no significant difference between them (Figure 
4.13), indicating no supra-induction. Furthermore, the levels of p21 resembled those 
Figure 4.13. Combined LSU and SSU defects lead to p53 induction in U2OS cells, 
and supra-induction is only observed in one case. (A) Knockdowns of control, 
RPS19, RPL7 or RPL18 were performed in U2OS cells for 48h and the whole cell 
extract was loaded on an SDS PAGE gel, before being analysed by Western Blotting 
using the LICOR system. The antibodies used are shown on the left and. α-
Karyopherin (Karyop.) was used as a loading control. (B) The ImageQuant software 
was used for quantitation of the western blots and the levels of p53 were normalised 
against the loading control levels (α-Karyopherin). The graph represents the average 
p53 relative levels from three experimental repeats and the error bars show the 
standard error (+/-SEM). The p53 levels after RPS19, RPL7 or RPL18 knockdowns 
were compared to the control and p53 levels after the double RPS19 and RPL7 or 
RPL18 knockdowns were compared to the single knockdowns. Statistical analysis was 
performed using an unpaired t-test and absence of significance values on 
RPS19+RPL7 indicates no significant difference as compared to the single 
knockdowns. *p value<0.05. 
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seen with the single knockdowns, further supporting that there was no p53 supra-
induction. In contrast, knockdown of both RPS19 and RPL18 led to a significant p53 
induction as compared to the control (Figure 4.13), but comparing the double 
knockdown with either RPS19 or RPL18 single knockdowns, there was a significant 
increase in p53 levels (Figure 4.13), indicating a p53 supra-induction. However, the 
levels of p21 resembled the ones of the single knockdowns, especially the p21 levels 
observed after RPL18 knockdown (Figure 4.13). Taken together, these results showed 
that p53 supra-induction is not constantly seen after combined knockdowns of LSU or 
SSU ribosomal proteins, but might be seen with specific combinations of knockdowns. 
 
Next, I investigated whether p53 induction or supra-induction observed after the double 
RPS19 and RPL7 or RPL18 knockdowns resulted in a G1 and G2/M cell cycle arrest 
as previously suggested (Fumagalli et al., 2012). Knockdowns were performed for 48h 
in U2OS cells before the cells were fixed using 70% ethanol. The DNA was stained 
using propidium iodide and the cell cycle was analysed using the FACS Canto II flow-
cytometer and software. ActD overnight treatment was used as a positive control as 
previously (Figure 4.14). As shown earlier, treatment with Actinomycin D (ActD) 
resulted in a G1 and a G2/M cell cycle arrest (Figures 4.6, 4.7, 4.14). Furthermore, 
RPS19, RPL7 or RPL18 knockdowns resulted in an increase in cells in G1 and, to a 
lesser extent, G2/M stage, indicating arrest (Figures 4.6, 4.7, 4.14). After RPS19 and 
RPL7 or RPS19 and RPL18 double knockdowns, there was a significant G1 cell cycle 
arrest as compared with the control and a slight reduction in S phase, indicating a slight 
G2/M cell cycle arrest. No significant change was observed in the levels of G2 phase 
as compared to the control (Figure 4.14A, C). However, no major differences were 
observed between the single and double knockdowns in G1 or G2/M phase (Figure 
4.14). After RPS19 and RPL7 or RPS19 and RPL18 double knockdowns, the S phase 
levels were lower than the single RPS19 knockdown or RPL7 or RPL18 knockdowns 
respectively (Figure 4.14). Taken together, these data indicated that the p53 supra-
induction observed after RPS19 and RPL18 knockdown resulted in a G1 and a mild 
G2/M cell cycle arrest, similar to the one observed after RPS19 or RPL18 single 
knockdowns. 
 
 
 
129 
 
 Since my results were different from those published (Fumagalli et al., 2012), I next 
investigated whether this was specific to U2OS cells. For this, I have used the human 
breast cancer cell MCF7 and the human prostate cancer cell line LNCaP, which both 
confer a wild-type and active p53. Firstly, the knockdown efficiency in MCF7 cells was 
assessed by Western blotting after the knockdowns were performed for 48h. The 
protein levels of RPS19, RPL7 and RPL18 were decreased after knockdowns from 
60% (RPS19, RPL7) to 80% (RPL18) (Figure 4.15). Even though the knockdown 
Figure 4.14. Combined defects in LSU and SSU production lead to a G1 and a 
slight G2/M cell cycle arrest. (A-B) Knockdowns were performed for 48h in U2OS 
cells, which were then fixed using 70% ethanol. The DNA was stained with propidium 
iodide and cell cycle analysis was performed using the FACS Canto II flow cytometer 
and software. (C) The average percentage levels of G1 (dark grey), S (light grey) or 
G2/M (grey) phases of three experimental repeats are shown on the graph. The error 
bars represent the standard error (+/-SEM) and statistical analysis was performed 
using an unpaired t-test. The first six samples are the same as the ones used on Figure 
4.6. The RPS19 and RPL7 or RPL18 knockdowns were compared to the single RPS19 
knockdown and absence of significance values on indicates no significant differences. 
p value<0.05, **p value<0.01. 
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efficiency could not be analysed in LNCaP cells due to time limitations, taking in 
consideration that the knockdowns were efficient in both U2OS and MCF7, it was 
assumed that the siRNA treatment was efficient in LNCaP cells as well. 
 
I next investigated the levels of p53 after single or double knockdowns of RPS19, RPL7 
or RPL18 in MCF7 or LNCaP cells (Figure 4.16). Note that the knockdown efficiency 
of the double knockdowns on the expression levels of the targets was not assessed, 
which could have led to less efficient depletion of each target. Knockdowns were 
performed as usual for 48h and the whole cell extract was loaded on an SDS-PAGE 
gel, which was then analysed by Western Blotting using for p53 and p21 levels (Figure 
4.16). In both MCF7 and LNCaP cells, the levels of p53 were significantly increased 
after RPS19, RPL7 or RPL18 knockdowns as compared to the control (Figure 4.16). 
Furthermore, the p21 levels were also increased after the ribosomal protein 
knockdowns in both cell lines (Figure 4.16A, C). Double knockdowns of RPS19 and 
RPL7 or RPS19 and RPL18 resulted in a significant p53 induction as compared to the 
control. However, the p53 increase observed after the double knockdowns was not 
significant as compared to the single RPS19, RPL7 or RPL18 knockdowns in either 
MCF7 or LNCaP cell lines (Figure 4.16). Furthermore, the p21 levels after the double 
RPS19 and RPL7 or RPS19 and RPL18 knockdowns resembled those of the single 
knockdowns (Figure 4.16A, C). These results indicated that p53 is induced after either 
SSU or LSU block in MCF7 and LNCaP cells, as it was observed in U2OS cells (Figure 
4.5). However, defects in both SSU and LSU production resulted in p53 induction but 
not supra-induction in MCF7 or LNCaP cells, as opposed to previously published data 
(Fumagalli et al., 2012). Whether this induction was also seen on p53 activity cannot 
Figure 4.15. The knockdown efficiency of siRNAs in MCF7 cells. Knockdowns 
were performed for 48h in MCF7 cells and the whole cell extract was loaded on an 
SDS-PAGE gel before analysed with Western Blotting. Visualization with ECL (A-B) or 
the LICOR system (C) was performed. Antibodies for RPS19 (A), RPL7 (B) or RPL18 
(C) were used to detect the levels of the ribosomal proteins, whereas α-Karyopherin 
was used as a loading control in all cases (shown on the left of the panel). 
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be concluded, as p21 can be regulated post-translationally, but p21 mRNA levels or 
other p53 downstream targets were not assessed here. 
 
In the published paper, the authors have targeted different proteins using siRNAs 
against RPS6 or RPL7a ribosomal proteins for SSU or LSU block respectively. I, 
therefore, performed these knockdowns for 48h, using the siRNAs from the report 
(Fumagalli et al., 2012), for SSU or LSU block, in U2OS, MCF7 or LNCaP cells. The 
whole cell extract was loaded on an SDS-PAGE gel and analysed by Western Blotting 
for p53 and p21 levels (Figure 4.17). 
Figure 4.16. Combined defects in LSU and SSU result in p53 induction, but not 
supra-induction, in MCF7 or LNCaP cells. (A, C) Knockdowns were performed for 
48h in MCF7 (A) or LNCaP (C) cells and the whole cell extract was loaded on an SDS-
PAGE gel, before Western Blot analysis was performed using the LICOR system. The 
antibodies used are shown on the left and Karyopherin (Karyop.) was used as a 
loading control. (B, D) ImageQuant software was used for quantitation of the Western 
Blots and p53 levels were normalized to the levels of the loading control (α-
Karyopherin). The graph represents the average p53 relative levels from three different 
experimental repeats in MCF7 (B) or LNCaP (D) cells and the error bars represent the 
standard error (+/-SEM). The p53 levels after RPS19, RPL7 or RPL18 knockdowns 
were compared to the control and p53 levels after the double RPS19 and RPL7 or 
RPL18 knockdowns were compared to the single knockdowns. Statistical analysis was 
performed using an unpaired t-test and absence of significance values indicates no 
significant differences. *p value<0.05, **p value<0.01, ***p value<0.0001. 
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Knockdown of RPS6 resulted in a significant increase in p53 levels in U2OS, MCF7 
and LNCaP cells as compared to the control (Figure 4.17). Knockdown of RPL7a 
resulted in a significant increase in p53 levels in U2OS and MCF7 cells, and in an 
increase in p53 levels in LNCaP cells, which did not appear to be significant (Figure 
4.17). This might be due to differences in knockdown efficiencies between the cell 
lines. Furthermore, the p21 levels were also increased after RPS6 or RPL7a 
knockdowns (Figure 4.17A), indicating an increase in p53 activity. Double knockdowns 
of RPS6 and RPL7a resulted in an increase in p53 levels as compared to the control 
in all three cell lines. However, the p53 levels after the double RPS6 and RPL7a 
knockdowns were not significantly increased as compared to the single RPS6 or 
RPL7a knockdown in neither U2OS, MCF7 nor LNCaP (Figure 4.17). Moreover, p21 
levels after the double RPS6 and RPL7a knockdown resembled those after the single 
RPS6 or RPL7a knockdowns (Figure 4.17A). 
 
These data indicated that double RPS6 and RPL7a knockdowns do not result in p53 
supra-induction in U2OS, MCF7 or LNCaP cell lines. My data show little evidence of 
p53 supra-induction after combined defects in LSU and SSU, except one case and 
only in U2OS cells, as opposed to previously published data (Fumagalli et al., 2012).  
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 Figure 4.17. Combined defects in LSU and SSU after RPS6 and RPL7a 
knockdown result in p53 induction, but not supra-induction, in U2OS, MCF7 or 
LNCaP cells. (A) siRNA treatment was performed for 48h in U2OS, MCF7 or LNCaP 
cells and the whole cell extract was loaded on an SDS-PAGE gel, before being 
analysed with Western Blotting using the LICOR system. The antibodies used are 
shown on the left and Karyopherin (Karyop.) was used as a loading control. (B) 
ImageQuant software was used for quantitation of the western blots and p53 levels 
were normalized to the loading control (α-Karyopherin). The average relative p53 
protein levels of three experimental repeats are shown on the graph and the error bars 
show the standard error (+/-SEM). The p53 levels after RPS6 or RPL7a knockdowns 
were compared to the control and p53 levels after the double RPS6 and RPL7a 
knockdowns were compared to the single knockdowns. Statistical analysis was 
performed using an unpaired t-test and absence of significance values indicates no 
significant differences. *p value<0.05, **p value<0.01. 
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In the study by Fumagalli et al (2012) it was suggested that the combined LSU and 
SSU defects result in both G1 and G2/M cell cycle arrest after p53 supra-induction, 
using RPS6 and RPL7a siRNAs in A549 and U2OS cells. Since I did not observe any 
p53 supra-induction with these knockdowns, I investigated whether there was also no 
effect on cell cycle in U2OS cells. For this, knockdowns were performed for 48h in 
U2OS cells before being fixed using 70% ethanol. The DNA was then stained using 
propidium iodide and the cell cycle was analysed using the FACS Canto II flow 
cytometer and software (Figure 4.18). 
 
Single knockdown of either RPS6 or RPL7a resulted in a significant increase in G1 
phase as compared to the control (Figure 4.18), showing a G1 cell cycle arrest. The 
levels of the S phase were significantly decreased as compared to the control after 
knockdowns of RPS6 or RPL7a (Figure 4.18) and the levels of G2/M phase were 
significantly decreased (Figure 4.18). These results indicated a G1 and a slight G2/M 
cell cycle arrest after SSU or LSU block using RPS6 or RPL7a siRNAs in U2OS cells. 
After the double knockdown of RPS6 and RPL7a, there was a significant increase in 
G1 phase as compared to either RPS6 or RPL7a single knockdowns (Figure 4.18). 
Furthermore, there was a significant reduction in S phase after RPS6 and RPL7a 
double knockdowns in comparison to RPS6 or RPL7a single knockdowns (Figure 
4.18). The levels of G2 phase were not significantly changed after RPS6 and RPL7a 
double knockdown as compared to the single RPS6 knockdown, but they were 
significantly decreased as compared to the RPL7a single knockdown (Figure 4.18). 
 
These results show that RPS6 and RPL7a double knockdowns result in a bigger G1 
cell cycle arrest as compared to the single RPS6 or RPL7a, which is not seen with 
other combinations of siRNAs. 
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 4.2.7 Block in SSU production results in an accumulation of the free 5S RNP  
 
I have shown that defects in SSU biogenesis result in p53 accumulation via the 5S 
RNP-MDM2 pathway, independently of the levels of the 18S rRNA. However, no 
obvious defects on the LSU biogenesis were observed after knockdowns of the SSU 
factors RPS19, RIO2 or PNO1 in assays performed so far. Therefore, how defects in 
SSU production resulted in an accumulation of the free 5S RNP in the nucleoplasm 
Figure 4.18. SSU and LSU defects after RPS6 and RPL7a knockdowns result in 
G1 and a G2/M cell cycle arrest in U2OS cells. (A-D) Knockdowns of control, RPS6 
and RPL7a were performed in U2OS cells for 48h before the cells were fixed using 
70% ethanol. Propidium iodide was used for DNA staining and cell cycle analysis was 
performed using the FACS Canto II flow-cytometer and software. (E) The average 
values of the percentage levels of the G1 (dark grey), S (light grey) and G2/M (grey) 
phases of three experimental repeats are indicated on the graph. The error bars 
represent the standard error (+/-SEM) and the statistical analysis was performed 
using an unpaired t-test. The % levels of each phase after RPS6 or RPL7a 
knockdowns were compared to the control values, and the levels of each phase after 
the double RPS6 and RPL7a knockdown were compared to RPS6 single knockdown 
values. Lack of significance values indicates no significant differences. *p value<0.05, 
**p value<0.01, ***p value<0.001. 
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with no obvious LSU defects is unclear. It is possible that the LSU might still be 
produced, but there is an inhibition or retardation of its export from the nucleus to the 
cytoplasm if SSU production is blocked. This would result in a reduction in the 
integration of the 5S RNP into pre-LSU complex and would lead to its accumulation in 
the nucleoplasm and its binding on MDM2. To test this hypothesis, U2OS cell lines 
stably expressing tetracycline-inducible FLAG-tagged RPL11 were used (kindly 
provided by Dr Loren Gibson, Nick Watkins). Knockdowns of RPS19 and RPL7 were 
performed for 48h in these cells and tetracycline was also added for 48h. The whole 
cell extract was analysed by gradient analysis, using a 10%-40% glycerol gradient, to 
separate the small (free) and large (ribosomal) cellular complexes. The gradient was 
then fractionated and each of the fractions was loaded on an SDS-PAGE gel and 
analysed by Western Blotting using an α-FLAG antibody (Figure 4.19). 
 
In control cells, approximately 65% of the FLAG-tagged RPL11 was found in the 
ribosomal complexes and almost 35% in the free complexes (Figure 4.19). Knockdown 
of RPL7 resulted in a major accumulation of RPL11 in the free pool as compared to 
the control (almost 80%) (Figure 4.19) and a decrease of the FLAG-tagged RPL11 that 
was integrated in the ribosomal complexes (approximately 20%) (Figure 4.19). RPS19 
knockdown resulted in approximately 45% accumulation of the FLAG-tagged RPL11 
in the free pool, and a decrease of the FLAG-tagged RPL11 in the ribosomal 
complexes (55%) (Figure 4.19). This further supports the theory that SSU defects 
result in an accumulation of the 5S RNP in the nucleoplasm, resulting in its binding on 
MDM2 and, therefore, p53 activation. However, RPL11 still gets integrated in the 
ribosomal complexes after RPS19 knockdowns, probably as a part of the 5S RNP. It 
is worth noting that the gradient analysis was only performed twice and, therefore, 
another repeat is required to identify whether any differences observed in the 
localization of the FLAG-tagged RPL11 are significant. 
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 Figure 4.19. RPS19 knockdown results in a decreased integration of RPL11 in 
the ribosomal complexes. (A) siRNA treatment using Control, RPS19 or RPL7 
siRNAs was performed for 48h in U2OS cells expressing FLAG-tagged RPL11 for 48h 
using 1000ng/µl tetracycline. The whole cell extract was fractionated after 10-40% 
glycerol gradient analysis. Fractions were loaded on an SDS-PAGE gel, before being 
analysed by Western Blotting using an α-FLAG antibody. The image was generated 
using the LICOR system. “T” represents the 10% total sample before gradient analysis. 
The first experimental repeat is shown at the top (Rep.1) and the second at the bottom 
(Rep.2). (B) The ImageQuant software was used for quantitation of the Western Blots. 
The graph represents the average percentage of the two experimental repeats shown 
of the free complexes (dark grey), which is shown as the sum of fractions 1-6, and the 
ribosomal complexes (light grey), which is shown as the sum of fractions 9-16. 
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4.2.8 Defects in SSU production result in a decreased export of the LSU in the 
cytoplasm 
 
Since there was an accumulation of the free 5S RNP after a block in SSU production, 
I wanted to see whether this resulted in an accumulation of the free 5S RNP in the 
nucleoplasm or whether the 5S RNP was still integrated in the pre-LSU, but the export 
of the pre-LSU into the cytoplasm was retarded. For this, I have used 
immunofluorescence to identify the levels of the FLAG-tagged RPL11 in the 
nucleoplasm or cytoplasm. 
 
Firstly, the localization of RPL11 FLAG-tagged protein was assessed, to ensure that 
the FLAG-tagged protein were expressed and localized as expected. The U2OS cells 
expressing FLAG-tagged RPL11 were treated with Actinomycin D (ActD), which blocks 
ribosome biogenesis by inhibition of RNA polymerase I and it was previously shown to 
cause the nuclear accumulation of RPL11 in HEK293T cells (Sloan et al., 2013a). The 
cells were fixed using 4% paraformaldehyde and immunofluorescence was performed 
using α-FLAG antibody for the localization of the FLAG-tagged protein RPL11. 
Fibrillarin was used for nucleolar staining and DAPI was used for DNA staining. U2OS 
cells containing the empty pcDNA5 vector were used as a control (Figure 4.20). 
 
Figure 4.20. Defects in ribosome biogenesis result in nuclear accumulation of 
RPL5 and RPL11. U2OS cells stably expressing FLAG-tagged RPL11 were treated 
with 1000ng/µl tetracycline for 18h. ActD treatment was also performed for 18h and the 
U2OS cells containing the empty vector (pcDNA5) were used as a control. The cells 
were fixed using 4% paraformaldehyde and α-FLAG antibody was used to stain the 
FLAG-tagged RPL11 (red). α-Fibrillarin (Fib) was used to stain the nucleolus (green) 
and DAPI was used to stain DNA (blue). The merge image shows the three channels 
merged together. Visualization of the images was performed using the Zeiss  Axiovision 
inverted microscope and software. 
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Very little background signal was observed using the α-FLAG antibody in U2OS cells 
containing the empty pcDNA5 vector, and the nucleolar staining as seen by the α-
Fibrillarin antibody was as expected (Figure 4.20). The FLAG-tagged RPL11 localized 
mainly in the nucleolus and in the cytoplasm (Figure 4.20), whereas treatment with 
ActD caused its accumulation in the nucleoplasm (Figure 4.20). These results agreed 
with previously published results where the localization of the FLAG-tagged RPL11 
was investigated in HEK293T cell line (Sloan et al., 2013a). 
 
I next tested the localization of the FLAG-tagged RPL11 after a block in SSU 
production. For this, knockdowns using RPS19, RIO2 and RPS6 siRNAs in order to 
inhibit SSU biogenesis, and RPL7 siRNA for LSU biogenesis block as a positive control 
were performed for 48h in U2OS cells expressing the FLAG-tagged RPL11 for 48h. 
Therefore, the FLAG-tagged RPL11 was produced after the knockdowns. Knockdown 
of RPL7 was expected to show a nuclear accumulation of the FLAG-tagged RPL11, 
similarly to the ActD treatment. U2OS cells containing the empty pcDNA5 vector were 
used as a negative control to monitor background signal of the α-FLAG antibody during 
immunofluorescence. 
 
No background signal was observed in U2OS cells containing the empty pcDNA5 
vector when α-FLAG antibody was used, and staining with α-Fibrillarin and DAPI 
showed the expected nucleolar and DNA signal (Figure 4.21). The FLAG-tagged 
RPL11 localized to the nucleolus and cytoplasm in the control-treated cells, as 
expected (Figure 4.21). Knockdown of RPS6 or RPS19 resulted in the accumulation 
of the FLAG-tagged RPL11 in the nucleoplasm as compared to the control, with some 
also presented in the cytoplasm (Figure 4.21). RIO2 knockdown resulted in a slight 
accumulation of the FLAG-tagged RPL11 in the nucleoplasm as compared to the 
control but it was mainly found in the cytoplasm (Figure 4.21). Finally, RPL7 
knockdown resulted in a major accumulation of the FLAG-tagged RPL11 in the 
nucleoplasm (Figure 4.21), as expected. 
 
Taken together, these data suggested that the FLAG-tagged RPL11 accumulated in 
the nucleus after a block in SSU production, even though the 5S RNP was still 
integrated in the LSU (Figure 4.19), suggesting a retardation of export of the pre-LSU 
complexes in the cytoplasm. 
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 4.2.9 Inhibition of LSU export after SSU production defects lead to the 
accumulation of the pre-5.8S rRNA precursor 
 
In yeast, the last stages of 5.8S maturation take place in the cytoplasm (Thomson and 
Tollervey, 2010). Since I have shown that SSU production defects are likely to result 
in an accumulation of the LSU in the nucleus, I decided to investigate whether this 
causes defects in late stages of LSU rRNA processing. For this, knockdowns of RPS19 
or RPL7a were performed in U2OS cells for 48h, RNA was extracted and loaded on 
an 8% acrylamide/7M Urea gel. The RNA was transferred on a Hybond N membrane 
which was incubated with a radiolabelled (32P) probe recognizing the 5’ end of ITS2 
(Figure 4.22A) (Sloan et al., 2013c). The U1 snRNA was used as a loading control 
Figure 4.21. SSU defects result in an increased accumulation of RPL11 in the 
nucleoplasm. siRNA treatment using control, RPS6, RPS19, RIO2 or RPL7 siRNAs 
was performed for 48h in U2OS cells expressing RPL11 for 48h. The cells were treated 
with 1000ng/µl tetracycline for expression of the FLAG-tagged protein for 18h and 
U2OS cells containing the empty vector (pcDNA5) were used as a control. The cells 
were fixed using 4% paraformaldehyde and immunofluorescence followed. α-FLAG 
antibody was used for visualization of the FLAG-tagged RPL11 (red) and α-Fibrillarin 
(Fib) was used for nucleolar staining (green). DAPI was used for DNA staining (blue). 
The merge image shows the three channels merged together. Visualization of the 
images was performed using the Zeiss Axiovision inverted microscope and software. 
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(Figure 4.22B). RPL7a knockdown resulted in a decrease in both bands of the pre-
5.8S rRNA precursor as compared to the control (Figure 4.22 B, C), as expected, since 
it is involved in LSU production. RPS19 knockdown resulted in a decrease of the levels 
of the early pre-5.8S rRNA precursor (T), but an increase in the levels of the late pre-
5.8S rRNA precursor (B) as compared to the control (Figure 4.22B, C). This suggests 
that SSU production defects may result in a delay of the 5.8S rRNA maturation in the 
cytoplasm. This experiment was performed twice and the results were very similar and 
consistent both times. This is the first evidence that cytoplasmic export is required for 
the late stages of LSU rRNA processing in humans. Furthermore, this indicates that 
SSU production defects might cause defects in late stages of LSU production because 
of inhibition of export of the LSU in the cytoplasm.   
Figure 4.22. Defects in SSU production lead to the accumulation of the pre-5.8S 
rRNA precursor. (A) Schematic representation of the rRNA precursors of the small 
(SSU, green) and large (LSU, blue) ribosomal subunits. The site recognized by the 
radiolabelled (32P) pre-5.8S (5’-ITS2) probe is indicated in red (Adapted from: (Sloan 
et al., 2013c)).(B) Knockdowns using control, RPS19 or RPL7a were performed in 
U2OS cells for 48h. RNA was extracted and loaded on an 8% Acrylamide/7M Urea 
gel, and transferred on a Hybond N membrane. The membrane was incubated with a 
radiolabelled (32P) probe recognizing the pre-5.8S rRNA precursor and U1 snRNA was 
used as a loading control. Visualization of the RNAs was performed using a Typhoon 
Phosphorimager. The different bands seen with the pre-5.8S probe (T, B) are shown 
on the right. (C) ImageQuant software was used for quantitation of the RNAs. The 
levels of the pre-5.8S rRNA were normalized against the U1 RNA levels. The graph 
represents the average levels of the pre-5.8S T (dark grey) and B (light grey) of two 
experimental repeats. 
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4.3 Discussion 
 
Ribosome biogenesis is a complex and energy-consuming process, which is linked 
with the levels of the tumour suppressor p53 (Pelava et al., 2016). Mutations in genes 
encoding for ribosomal proteins or ribosome biogenesis factors lead to the 
development of ribosomopathies (Yelick and Trainor, 2015), a set of rare genetic 
diseases, such as Diamond-Blackfan Anaemia (DBA), characterized by craniofacial 
abnormalities, anaemia and increased cancer development, especially Acute Myeloid 
Leukaemia (AML) (Narla and Ebert, 2010). Even though it was originally thought that 
the LSU and SSU biogenesis were two independent processes, recent evidence 
suggests that this may not be the case (Lebaron et al., 2012, Lamanna and Karbstein, 
2011). Defects in SSU biogenesis were previously shown to cause p53 accumulation 
via the 5S RNP-MDM2 pathway MDM2 (Fumagalli et al., 2009, Fumagalli et al., 2012, 
Golomb et al., 2014), which was proposed to be due to the translation up-regulation of 
RPL5 and RPL11 (Fumagalli et al., 2012). Here, I have shown that defects in early or 
late stages of either SSU or LSU biogenesis result in p53 induction via the 5S RNP-
MDM2 pathway. The kinetics of p53 accumulation after defects in either LSU or SSU 
production are very similar, as p53 induction occurs very rapidly, in less than 12h, 
suggesting that there is only one pathway leading to the accumulation of the free 5S 
RNP in the nucleoplasm. Furthermore, p53 induction is independent of the levels of 
the mature 18S rRNA, indicating that it is more likely to be due to ribosome production 
defects rather than the lack of ribosomes. Finally, I have shown that defects in SSU 
result in a retardation of export of the LSU in the cytoplasm, which is likely to lead to 
defects in late stages of LSU production. 
 
Firstly, I have shown that defects in either early or late stage of LSU or SSU biogenesis 
lead to p53 induction via the 5S RNP-MDM2 pathway (Figure 4.5). A number of 
previously published studies have shown that defects in LSU rRNA processing result 
in a significant p53 accumulation via the 5S RNP-MDM2 pathway (Donati et al., 2013, 
Marechal et al., 1994, Sloan et al., 2013a, Dai and Lu, 2004, Horn and Vousden, 2008, 
Nishimura et al., 2015). Furthermore, knockdowns of several LSU ribosome biogenesis 
factors involved in the recruitment of the 5S RNP in the LSU, such as PICT1, have also 
resulted in p53 induction via the 5S RNP-MDM2 pathway (Donati et al., 2013). I further 
confirmed these results, by showing that knockdowns of the LSU ribosomal proteins 
RPL7 and RPL18, or the LSU ribosome biogenesis factor PICT1, resulted in a 5S RNP-
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dependent p53 induction. This was expected, since disruptions in the LSU rRNA 
processing would not affect the production of the 5S RNP, but would affect its 
integration in the mature LSU complex. Interestingly, I found that defects in either early 
or late stages of SSU rRNA processing also result in a 5S RNP-dependent p53 
induction. It was previously shown that RPS19 knockdown results in a 5S RNP-
dependent p53 induction in mouse (Jaako et al., 2015), zebrafish (Danilova et al., 
2008, Jia et al., 2013) or cell culture (Dutt et al., 2011) models. RPS6 knockdown was 
also shown to result in in p53 accumulation via the 5S RNP-MDM2 pathway in human 
cells (Fumagalli et al., 2009, Fumagalli et al., 2012). This was further confirmed here, 
where RPS19 knockdown indeed resulted in p53 induction via the 5S RNP-MDM2 
pathway and RPS6 knockdown resulted in a p53 induction, presumably also 
dependent on the 5S RNP. It was surprising to find that defects in late SSU rRNA 
processing defects, caused by RIO2 knockdown, also resulted in p53 induction via the 
5S RNP-MDM2 pathway. These results indicated that defects in SSU production 
feedback to the recruitment of the 5S RNP in the LSU. 
 
A recent publication has suggested that p53 is significantly induced only after depletion 
of ribosomal proteins that are involved in the late LSU assembly, and depletion of only 
one SSU ribosomal protein results in a significant p53 induction. All of these proteins 
appear to be structurally important around the active site of the ribosome (Nicolas et 
al., 2016). Knockdowns of some ribosomal proteins presented on this paper were 
previously shown to also result in a significant p53 induction, such as knockdown of 
RPL6 (Bai et al., 2014), knockdown of RPL7, which was shown here, or knockdown of 
RPS27a (Sun et al., 2011). In this study, the authors have used a 5-fold p53 induction 
as their significance threshold and a lot of the ribosomal proteins that did not appear 
to significantly induce p53 after depletion have been previously shown to be important 
for p53 accumulation. For example, knockdown of the ribosomal protein RPL23, which 
was suggested to not significantly induce p53 in this study (Nicolas et al., 2016), was 
previously found to be important for p53 stabilisation due to MDM2 inhibition after 
ribosome biogenesis defects (Dai et al., 2004, Jin et al., 2004). Furthermore, 
knockdown of the ribosomal protein RPL18 was also below the chosen significance 
threshold (Nicolas et al., 2016), whereas I have shown here that RPL18 knockdown 
results in a significant 5S RNP-dependent p53 induction. Moreover, they have 
suggested that knockdowns of the majority of SSU ribosomal proteins did not result in 
a significant p53 induction (Nicolas et al., 2016). However, I have shown here that 
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knockdowns of the SSU ribosomal protein RPS19 or the SSU ribosome biogenesis 
factor RIO2 resulted in a significant p53 induction, via the 5S RNP-MDM2 pathway. In 
addition, a number of previous studies have shown that knockdowns of SSU ribosomal 
proteins, such as RPS19 (Dutt et al., 2011), RPS6 (Fumagalli et al., 2009, Fumagalli 
et al., 2012) or RPS3 (Yadavilli et al., 2009), result in a significant p53 induction. 
 
I then investigated how defects in SSU lead to p53 accumulation via the 5S RNP-
MDM2 pathway. It was previously suggested that the induction of p53 after SSU 
defects is dependent on the levels of the mature 18S rRNA, since depletion of the SSU 
is necessary for the proposed mechanism of p53 accumulation (Fumagalli et al., 2012). 
However, I have shown here that defects in early or late stages of rRNA processing 
result in p53 accumulation independently of the steady state levels of 18S rRNA 
(Figures 4.10, 4.11, 4.12). Furthermore, I have shown that p53 was induced as early 
as 12h (Figures 4.10, 4.11), before the newly-synthesized ribosomes were produced, 
indicating that p53 accumulation occurs due to SSU rRNA processing defects. 
Moreover, it was suggested that defects in SSU production result in the translational 
up-regulation of ribosomal proteins, such as RPL11, so that the 5S RNP is produced 
in excess, in order to compete binding on both the LSU and MDM2 (Fumagalli et al., 
2012). This would suggest that there would be different kinetic rates for p53 induction 
after LSU or SSU defects. I have found no evidence of this, since p53 is significantly 
induced 12h after SSU or LSU production defects (Figure 4.10). Therefore, these 
evidence suggest that there is only one pathway that results in the accumulation of the 
free 5S RNP in the nucleoplasm leading to p53 induction after SSU or LSU defects, 
rather than two pathways as previously suggested (Fumagalli et al., 2012). 
 
Here, I have shown that RPS19 knockdown caused a small increase in the 
accumulation of the FLAG-tagged RPL11 in the free complexes, but most of it was 
integrated in the ribosomal complexes (Figure 4.19). Furthermore, I have shown that 
RPS19 knockdown resulted in a nuclear accumulation of the FLAG-tagged RPL11 
(Figure 4.21), which was much more than the accumulation of the free 5S RNP shown 
after gradient analysis. These results indicate that the 5S RNP gets integrated in the 
LSU, but there is an inhibition of export of the LSU in the cytoplasm. Furthermore, 
knockdown of RPS6 or RIO2 also resulted in a nuclear accumulation of the FLAG-
tagged RPL11 (Figure 4.21), indicating that defects in early or late stages of SSU 
production are likely to be causing a retardation of export of the LSU complexes in the 
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cytoplasm. Even though I cannot exclude the possibility of an increase in 5S RNP 
production, it is presumed that the 5S RNP is produced as normal or in slightly higher 
amounts, so that it still gets integrated in the ribosome, but there is some accumulation 
of the free 5S RNP complex in the nucleoplasm. This would result in its binding on 
MDM2, leading to p53 accumulation. Future work is required for identification of the 
rate of accumulation of the 5S RNP after LSU or SSU defects, perhaps by investigating 
the levels of the newly-synthesized 5S rRNA as part of the 5S RNP over time. 
Furthermore, it is necessary to investigate the localization of other LSU ribosomal 
proteins after SSU production defects, since RPL11 is a part of the 5S RNP. 
 
Combined defects in LSU and SSU were previously suggested to result in p53 supra-
induction because of two separate pathways (Fumagalli et al., 2012), for which, I have 
very little evidence. In the published paper, the SSU ribosomal protein RPS6 and the 
LSU ribosomal protein RPL7a were knocked down in lung cancer A549 cells. 
Furthermore, the authors have stated that the same result was observed in 
osteosarcoma U2OS cells, but no evidence was presented (Fumagalli et al., 2012). 
Here, I have shown that only co-depletion of the SSU ribosomal protein RPS19 and 
the LSU ribosomal protein RPL18 resulted in a p53 supra-induction in U2OS cells 
(Figure 4.13), but not the combined knockdowns of other SSU and LSU ribosomal 
proteins in U2OS, MCF7 or LNCaP cells (Figures 4.13, 4.16, 4.17), as previously 
suggested (Fumagalli et al., 2012). It is worth noting that the authors gave no evidence 
of statistical analysis, suggesting that the p53 supra-induction seen might have been 
a result of experimental variation. Interestingly, LNCaP cells were found to have 
mutations in a number of genes encoding for either ribosomal proteins, such as RPL22, 
or ribosome biogenesis factors, such as BMS1, whereas MCF7 have a mutation in only 
the gene encoding for RPL10L and no mutations in the genes encoding for known 
ribosome biogenesis factors (Iorio et al., 2016). In contrast, U2OS cells have no 
mutations in genes encoding for ribosomal proteins or known ribosome biogenesis 
factors (Iorio et al., 2016). These data suggest that LNCaP cells may behave differently 
when ribosome biogenesis is blocked, as they may be more prone to ribosome 
biogenesis defects. In the same study, it was suggested that defects on either LSU or 
SSU lead to a G1 cell cycle arrest, which is further supported by my data, but combined 
defects on both LSU and SSU result in G1 and G2/M cell cycle arrest (Fumagalli et al., 
2012). Here, I have found that RPS6, RPL7a (Figure 4.18) or RPL18 (Figure 4.6) single 
knockdowns resulted in both G1 and a G2/M cell cycle arrest, but knockdowns of 
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RPS19 or RPL7 results in a G1 and only a slight G2/M cell cycle arrest (Figure 4.6). 
Furthermore, the double RPS6 and RPL7a knockdown resulted in a higher G1 cell 
cycle arrest as compared to any of the single RPS6 or RPL7a knockdowns, but not to 
a G2/M cell cycle arrest in U2OS cells (Figure 4.18), as opposed to previously 
published data (Fumagalli et al., 2012). It is likely that ribosomal protein knockdowns 
result in a significant G1 cell cycle arrest, but the G2/M cell cycle arrest varies 
depending on the ribosomal protein that is knocked down. This could be because some 
ribosomal proteins might be more important for ribosome biogenesis and assembly 
than some others, resulting in a rapid increase in p53 levels and activity, which, in turn, 
results in more profound defects in the cell cycle (Thapa et al., 2013). It is also possible 
that some ribosomal proteins have other functions in the cell apart from ribosome 
biogenesis, such as RPS6 (Magnuson et al., 2012) and RPL7a (Ziemiecki et al., 1990, 
Kozma et al., 1988), which might contribute for the increased G1 and G2/M cell cycle 
arrest after their knockdowns due to combined defects of ribosome biogenesis and 
other cellular processes. 
 
In addition, knockdown of PICT1 or RIO2 did not result in any change in the cell cycle, 
even though p53 levels were significantly induced (Figure 4.7). This could indicate that 
p53 might be induced slower after defects in late stages of ribosome biogenesis, so 
that its effects on cell cycle are not visible after 48h. Indeed, p53 levels after PICT1 or 
RIO2 knockdowns were not as high as after the ribosomal protein knockdowns (Figure 
4.5). Another possibility would be that defects in late stages of ribosome biogenesis 
activate p53, which is involved in other downstream processes, such as metabolic 
changes. If this is the case, future work is needed, identifying whether p53 regulates 
downstream targets involved in glycolysis, such as the glucose transporters GLUT1 
and GLUT4 (Schwartzenberg-Bar-Yoseph et al., 2004), or oxidative phosphorylation, 
such as TIGAR and reactive oxygen species (ROS) (Bensaad et al., 2006). 
 
It was previously shown in yeast that processing of the late stages of LSU biogenesis 
take place in the cytoplasm (Thomson and Tollervey, 2010). However, not much is 
known about the late processing stages of LSU production in humans. My data here 
suggest that SSU production defects lead to the accumulation of the pre-5.8S rRNA 
precursor (Figure 4.22), which is indicative of the lack of export of the LSU in the 
cytoplasm (Figure 4.21). This suggests that the last steps of LSU rRNA precursor 
processing in humans take place in the cytoplasm, as in yeast. These data, and 
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previous studies (Lebaron et al., 2012, Lamanna and Karbstein, 2011), suggest that a 
cross-talk between the LSU and SSU rRNA biogenesis is highly likely, possibly by the 
involvement of a single ribosome biogenesis factor, or even a group of proteins, 
required for both LSU and SSU rRNA production (Figure 4.23). 
 
It is proposed here that under normal conditions, the 5S RNP gets integrated in the 
LSU and both SSU and LSU are exported to the cytoplasm. My data suggest that a 
factor or a group of proteins, which is still uncharacterized, link the SSU production 
with the LSU export and late LSU rRNA maturation stages (Figure 4.23). Defects in 
LSU production result in the accumulation of the free 5S RNP in the nucleoplasm, 
which binds and inhibits MDM2, leading to p53 induction (Figure 4.23), as previously 
shown (Donati et al., 2013, Sloan et al., 2013a). Defects in SSU production lead to the 
integration of the 5S RNP in the LSU but the pre-LSU is not exported to the cytoplasm, 
resulting in the accumulation of the 5S RNP in the nucleoplasm. Thus, the free 5S RNP 
binds and inhibits MDM2, resulting in p53 induction (Figure 4.23). Furthermore, SSU 
biogenesis defects may lead to defects in the late stages of LSU rRNA processing. 
Figure 4.23. The proposed model for p53 induction via the 5S RNP-MDM2 
pathway after defects in LSU or SSU production. 
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Finally, defects in both LSU and SSU production lead to the accumulation of the free 
5S RNP, resulting in p53 induction but not supra-induction (Figure 4.23).  
 
In conclusion, my data support the fact that the processes of LSU and SSU production 
during ribosome biogenesis are highly likely to be linked, and that the interaction of the 
5S RNP with MDM2 is important for p53 induction after defects in either LSU or SSU 
production. I have further shown that SSU rRNA processing defects, but not lack of 
ribosomes, are more likely to cause p53 accumulation, independently of the levels of 
the mature rRNAs. Given the high importance of ribosome biogenesis in 
ribosomopathy patients and in cancer development in general, it is essential to further 
investigate and understand how the biogenesis of LSU and SSU are linked. In addition, 
the interaction of the 5S RNP with MDM2 is a promising target for the development of 
future targeted therapeutic treatments for ribosomopathy patients. Finally, the 
nucleolus is increasingly targeted for anti-cancer therapies and it is becoming clear 
that it is, indeed, an important player in tumour development. 
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5. Chapter Five. The role of RPS27a- and RPL40-Ubiquitin 
proteins in human ribosome biogenesis and p53 induction 
 
5.1 Introduction 
 
Ubiquitin is a small, highly conserved protein which is highly abundant in the cell, that 
constitutes approximately 0.5-1% of the total cellular protein in the cell (Ryu et al., 
2007). Ubiquitination is a post-translational modification important for multiple cell 
functions. Mono-ubiquitination, which involves the addition of a single ubiquitin 
molecule on the substrates, is important for several cellular processes such as 
endocytosis and membrane trafficking (Ikeda and Dikic, 2008), DNA damage repair 
pathways (Ikura et al., 2007), gene regulation (Hammond-Martel et al., 2012) and cell-
cycle regulation (Mukhopadhyay and Riezman, 2007). In contrast, poly-ubiquitination, 
which involves the addition of several ubiquitin molecules on the substrates, targets 
the protein substrate for proteosomal degradation (Lecker et al., 2006) and is also 
involved in cellular processes, such as inflammation (Nathan et al., 2013). 
 
The ubiquitination process involves ATP hydrolysis and three different enzymes 
(Figure 5.1) (Kimura and Tanaka, 2010). Firstly, the E1 ubiquitin-activating enzyme 
forms a bond with the ubiquitin molecule (Figure 5.1) (Pickart and Eddins, 2004). The 
ubiquitin is then transferred to the E2 ubiquitin-conjugating enzyme and, finally, to the 
E3 ubiquitin ligase, which is responsible for its attachment on the protein substrate 
(Figure 5.1) (Pickart and Eddins, 2004). Ubiquitination is a reversible modification, 
where de-ubiquitinases, a group of proteases, cleave the ubiquitin bond between the 
ubiquitin and the substrate (Reyes-Turcu et al., 2009). Ubiquitin homeostasis is a 
tightly regulated process, involving more than 600 E3 ubiquitin ligases and 
approximately 100 de-ubiquitinases in mammals (Li et al., 2008). 
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 In yeast, ubiquitin is encoded by four genes: UBI1 and UBI2, which encode for RPL40-
ubiquitin protein, UBI3, which encodes for RPS27a-ubiquitin protein, and UBI4, which 
encodes for a five-ubiquitin chain (Figure 5.2). In mammals, Ubb and Ubc encode for 
a four- or nine-ubiquitin chain, RPS27a (Uba80 in mouse) encodes for the RPS27a-
ubiquitin protein and RPL40 (Uba52 in mouse) encodes for the RPL40-ubiquitin protein 
(Figure 5.2) (Kimura and Tanaka, 2010). RPS27a and RPL40 are highly conserved 
amongst species, especially amongst eukaryotes (Kimura and Tanaka, 2010). 
RPS27a was identified as a part of the small ribosomal subunit (40S; SSU) in yeast 
(Finley et al., 1989) and rat (Redman and Rechsteiner, 1989), whereas RPL40 was 
identified as a part of the large ribosomal subunit (60S; LSU) in yeast (Finley et al., 
1989). RPS27a and RPL40 are the only ribosomal proteins that are expressed as 
ubiquitin-fusion proteins and their transcriptional regulation is highly controlled, since 
both ribosome production and ubiquitin homeostasis are tightly regulated processes 
(Kimura and Tanaka, 2010). 
Figure 5.1. Schematic representation of the ubiquitin transfer process. Ubiquitin 
is bound on E1 ubiquitin-activating enzyme (dark grey) by ATP hydrolysis. The 
ubiquitin is then transferred on E2 ubiquitin-conjugating enzyme (grey) and, 
subsequently, on E3 ubiquitin-ligase (light grey). Poly-ubiquitination of the protein 
substrate (green) leads to proteosomal degradation and mono-ubiquitination is 
important for other cellular processes (Adapted from (Ardley and Robinson, 2005)). 
 
          
          
         
            
           
          
         
           
 
          
          
 
 
            
                
               
          
          
          
          
            
          
           
          
   
 
          
          
         
            
           
          
         
           
 
          
          
Figure 5.2. Graphical representation of the ubiquitin-encoding genes in yeast
Saccharomyces cerevisiae, humans and mice (Adapted from: (Kimura and Tanaka,
2010). 
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The ribosome is a ribonucleoprotein particle essential for protein synthesis in the cell. 
Ribosomes consist of two subunits: the small ribosomal subunit (40S; SSU), containing 
the 18S rRNA and approximately 30 ribosomal proteins, and the large ribosomal 
subunit (60S; LSU), containing the 28S, 5.8S and 5S rRNAs and approximately 46 
ribosomal proteins (Granneman and Baserga, 2004). The 28S, 18S and 5.8S rRNAs 
are transcribed in the nucleolus by RNA polymerase I as a single transcript (47S), 
whereas the 5S rRNA is transcribed in the nucleolus by RNA polymerase III 
(Gamalinda and Woolford, 2015). The 5S rRNA is bound by the ribosomal proteins 
RPL5 and RPL11, forming the 5S RNP, which is integrated in the large ribosomal 
subunit in the nucleolus (Gamalinda and Woolford, 2015). Ribosome biogenesis, a 
high energy-consuming process and tightly regulated in the cell, is linked with the levels 
of the tumour suppressor p53 in humans (Figure 5.3). Under normal conditions, the 5S 
RNP gets integrated in the LSU. At the same time, the E3 ubiquitin ligase MDM2 
targets p53 for proteosomal degradation. Upon stress, defects in ribosome biogenesis 
lead to the accumulation of the free 5S RNP in the nucleoplasm which binds and 
inhibits MDM2, resulting in p53 stabilisation (Figure 5.3) (Pelava et al., 2016). 
Interestingly, all three components of the 5S RNP are essential for p53 activation after 
ribosome biogenesis defects (Sloan et al., 2013a, Donati et al., 2013, Nishimura et al., 
2015). The importance of ribosome biogenesis is highlighted in ribosomopathies, a set 
of genetic diseases that arise due to mutations in genes encoding for ribosomal 
proteins or ribosome biogenesis factors (Narla and Ebert, 2010). Ribosomopathy 
patients appear with anaemia and increased cancer risk, especially for acute myeloid 
leukaemia (AML), and the levels of p53 have been found to be de-regulated in animal 
and cell culture models (Pelava et al., 2016). 
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 Despite the high conservation and importance of the ubiquitin-ribosomal proteins 
RPS27a and RPL40, not much is known about their processing or cellular functions in 
humans. It was recently found that RPS27a is highly expressed in solid tumours and 
up-regulated in chronic myeloid leukaemia (CML) and acute myeloid leukaemia (AML) 
patients (Wang et al., 2014). Furthermore, it was found that expression of RPS27a was 
also elevated in K562 CML cell line, promoting proliferation and inhibiting apoptosis 
(Wang et al., 2014). This is of particular importance knowing that ribosomopathy 
patients are highly susceptible in developing leukaemia, especially AML. In addition, 
RPS27a was shown to be another potential regulator of the p53 inhibition by MDM2. It 
was found that knockdown of RPS27a reduced the induction of p53 levels after 
ribosome biogenesis defects and over-expression of RPS27a resulted in p53 activation 
by inhibition of p53 ubiquitination by MDM2. Finally, RPS27a was shown to bind and 
inhibit MDM2 when over-expressed, thus resulting in p53 activation (Sun et al., 2011). 
Yet, it is not clear whether RPS27a interacts with MDM2 as the ubiquitin-ribosomal 
protein precursor or as the cleaved ribosomal protein. 
 
These studies indicate that the two ubiquitin fusion ribosomal proteins, especially 
RPS27a, might be key players in the regulation of the p53-MDM2 pathway. However, 
not much is known about the processing of the ubiquitin-ribosomal protein precursors 
Figure 5.3. Schematic representation of the stabilization of p53 after 5S RNP 
binding on MDM2. MDM2 is shown in orange, p53 is shown in green and the ubiquitin 
molecules are shown in yellow. The 5S RNP consists of the 5S rRNA (red), RPL5 
(blue) and RPL11 (light blue). 
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or their functions in ribosome biogenesis and cellular signalling. Therefore, the third 
part of this PhD project aimed to investigate: 
• When the ubiquitin-RPS27a or RPL40 precursors are processed for the release 
of the ubiquitin molecule and ribosomal proteins from the precursor 
• The functions of RPS27a and RPL40 in human ribosome biogenesis 
• The roles of RPS27a and RPL40 in p53 regulation 
154 
 
5.2 Results 
 
5.2.1 RPS27a- and RPL40-ubiquitin precursors are likely to be processed at 
very early stages 
 
RPS27a and RPL40 are expressed as ubiquitin-fusion ribosomal proteins (Kimura and 
Tanaka, 2010), but not much is known about how the precursor is processed to release 
the ubiquitin molecule and ribosomal proteins. Therefore, I firstly investigated the 
processing of RPS27a- and RPL40-ubiquitin precursors in human cells. For this, stable 
U2OS cells lines were created, where the tagged RPS27- or RPL40-ubiquitin proteins 
were found under a tetracycline promoter to control their expression. A FLAG tag was 
found at the C-terminus of the protein and an HA tag was added to the N-terminus of 
the expressed protein, so that the FLAG tag was bound on the ubiquitin and the HA 
tag was bound on the ribosomal protein (Figure 5.4A). 
 
U2OS cells were treated with different concentrations of tetracycline (0-1000 ng/µl) 
overnight for expression of the tagged ubiquitin-ribosomal protein RPS27a or RPL40. 
The whole cell extract was loaded on an SDS-PAGE gel and analysed by Western 
Blotting. α-HA antibody was used to detect the expressed ribosomal protein and α-
FLAG antibody was used to detect the expressed ubiquitin (Figure 5.4B, C). Due to 
the unavailability of commercial antibodies, the endogenous ribosomal proteins could 
not be detected. 
 
The RPS27a- or RPL40-ubiquitin proteins were optimally expressed in U2OS cells 
using 1000ng/µl tetracycline, since both the ribosomal protein and ubiquitin component 
was expressed in higher levels at this concentration (Figure 5.4B, C). Interestingly, the 
α-HA antibody revealed the expected cleaved HA-tagged RPS27a (Figure 5.4B) and 
RPL40 (Figure 5.4C), but there was no indication of the ubiquitin-ribosomal protein 
precursor. Furthermore, the α-FLAG antibody showed the expected ubiquitin-like 
phenotype, revealing the conjugated-ubiquitin and histone-ubiquitin (Figure 5.4B, C). 
However, there was no indication of the ubiquitin-ribosomal protein precursor using the 
α-FLAG antibody either (Figure 5.4B, C). 
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Figure 5.4. The expression of RPS27a and RPL40 in U2OS stable cell lines after 
tetracycline treatment. (A) Schematic representation of the open reading frame of 
the ubiquitin-ribosomal proteins as expressed in U2OS cell lines. The FLAG tag (blue) 
is found at the C-terminus bound on the ubiquitin (red) and the HA tag (green) is found 
at the N-terminus bound by the ribosomal protein RPS27a or RPL40. (B-C) U2OS cells 
were treated with different concentrations of tetracycline (0-1000ng/µl) (shown on top) 
overnight (18h) for expression of the ubiquitin fusion RPS27a (B) or RPL40 (C) 
proteins (shown at the bottom). The whole cell extract was loaded on an SDS-PAGE 
gel and analysed by Western blotting using the antibodies shown on the left. The 
membranes were visualised using the LICOR system (top) or ECL (bottom). 
Karyopherin (Karyop.) was used as a loading control. The molecular weight (kDa) is 
shown on the left and the expected precursor, the cleaved RP, the conjugated ubiquitin 
(Ub) and histone-ubiquitin are shown on the right. 
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Since the ubiquitin-ribosomal protein precursor could not be seen after tetracycline-
inducible expression of the tagged proteins, it was speculated that the precursor is 
likely to be processed efficiently and, therefore, found in low levels in the cell. I 
hypothesized that the ubiquitin component might be cleaved when the two ribosomal 
proteins are integrated in the ribosomal complexes. To test this hypothesis, 
Actinomycin D (ActD) was used, which blocks RNA polymerase I, inhibiting ribosome 
biogenesis (Andersen et al., 2005). The tagged proteins were expressed overnight and 
treatment with ActD was also performed overnight, so that the tagged proteins were 
expressed after ribosome biogenesis block. The whole cell extract was loaded on an 
SDS-PAGE gel and analysed by Western Blotting (Figure 5.5). 
 
ActD treatment resulted in a significant decrease of the HA-tagged RPS27a or RPL40 
levels (Figure 5.5). This was somewhat expected, since ActD treatment blocks 
ribosome biogenesis and ribosomal proteins that are not integrated into the ribosome 
and are known to be unstable (Lam et al., 2007). The levels of ubiquitin did not 
significantly change after ActD treatment in either case (Figure 5.5), indicating that the 
production of ubiquitin was as normal and only the ribosomal protein production was 
affected. Surprisingly, the ubiquitin-fusion RPS27a or RPL40 precursor could not be 
detected after ActD treatment (Figure 5.5), indicating that the ubiquitin is more likely to 
be cleaved at very early stages after or during translation. 
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 Figure 5.5. Inhibition of ribosome biogenesis resulted in a decrease of the 
expressed RPS27a and RPL40. (A-B) ActD treatment was performed overnight in 
U2OS cells expressing the RPS27a (A) or RPL40 (B) ubiquitin fusion proteins using 
1000ng/µl tetracycline. U2OS cells containing the empty pcDNA5 vector, treated with 
1000ng/µl tetracycline, were used as a control. In both cases, the whole cell extract 
was loaded on an SDS-PAGE gel and analysed by Western Blotting using the LICOR 
system. The antibodies used are shown on the left and Karyopherin (Karyop.) was 
used as a loading control (shown on the left). The molecular weight (kDa) is shown on 
the left, and the conjugated ubiquitin and the histone ubiquitin are shown on the right. 
(C) Quantitation of three independent experimental repeats was performed using 
ImageQuant and the averages of the relative levels of the HA-tagged ribosomal 
proteins (dark grey) and conjugated ubiquitin (light grey) are represented on the graph. 
Normalization to the levels of the loading control (α-Karyopherin) was performed for 
each experiment. The standard error (+/-SEM) is shown by the error bars. Statistical 
analysis was performed using unpaired t-test and lack of significance values indicates 
no significant differences as compared to the control. ***p value<0.001. 
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I then investigated whether specific inhibition of either the small or large ribosomal 
subunits resulted in a decrease in the levels of the HA-tagged RPS27a or RPL40, but 
not a change in the ubiquitin levels, as seen by ActD treatment. In order to test this, 
siRNAs against RPS19 (SSU block) and RPL7 (LSU block) were used, as they are 
known to affect the SSU and LSU biogenesis respectively (see Chapter 4). 
Knockdowns of RPS19 or RPL7 were performed for 48h in U2OS cells expressing the 
tagged ubiquitin-RPS27a or RPL40, where tetracycline was added for 48h as well. 
Simultaneous treatment of tetracycline and knockdowns allowed for the knockdown to 
affect the expressed protein as well and not only the endogenous one. The whole cell 
extract was loaded on an SDS-PAGE gel and analysed by Western blotting, using α-
HA antibody to detect the levels of the expressed ribosomal proteins and α-FLAG 
antibody to detect the levels of the expressed ubiquitin (Figure 5.6). 
 
No signal was detected using the α-HA antibody in U2OS cells containing the empty 
pcDNA5 vector (Figure 5.6A, B). Knockdown of RPS19 resulted in the significant 
decrease of the HA-tagged RPS27a as compared to the control (Figure 5.6A, C). 
However, knockdown of RPL7 did not result in a significant change in the levels of the 
HA-tagged RPS27a (Figure 5.6A, C). In contrast, knockdown of RPS19 did not result 
in a significant change on the levels of the HA-tagged RPL40 (Figure 5.6B, C). 
However, RPL7 knockdown resulted in a significant decrease in the levels of the HA-
tagged RPL40 (Figure 5.6B, C). The levels of ubiquitin did not significantly change by 
knockdown of RPS19 or RPL7 in either case (Figure 5.6), further confirming that the 
ubiquitin is produced as normal after specific block in either SSU or LSU production. 
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 Figure 5.6. SSU and LSU defects affect the levels of RPS27a and RPL40 
respectively. (A-B) Knockdowns of RPS19 and RPL7 were performed for 48h in 
U2OS cells expressing the HA-tagged RPS27a or RPL40, which were treated with 
1000ng/µl tetracycline for 48h. U2OS cells containing the empty pcDNA5 vector, 
treated with 1000ng/µl tetracycline for 48h, were used as a negative control. The whole 
cell extract was loaded on an SDS-PAGE gel and analysed by Western Blotting using 
the LICOR system. The antibodies used are shown on the left and Karyopherin 
(Karyop.) was used as a loading control. The molecular weight (kDa) is shown on the 
left, the conjugated ubiquitin, histone-ubiquitin and the expected precursor are 
indicated on the right. (C) ImageQuant software was used for quantitation of Western 
blots. Normalization to the levels of the loading control (α-Karyopherin) was performed 
for each sample. The graph represents the averages of the relative HA-tagged 
ribosomal protein levels of three experimental repeats and the error bars show the 
standard error (+/-SEM). Statistical analysis was performed using an unpaired t-test 
and absence of significance values indicates no significant differences as compared to 
the control. ***p value<0.0001. 
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It is known that ribosomal proteins are produced in excess and the free proteins are 
quickly degraded by the proteasome (Lam et al., 2007). Since there was no evidence 
of the ubiquitin-ribosomal protein precursor when ribosome biogenesis was blocked 
and the ubiquitin was produced as normal (Figures 5.5, 5.6), it was hypothesized that 
the ubiquitin component might be cleaved before the possible proteosomal 
degradation of any excess ribosomal proteins, so that the ubiquitin can still be 
integrated in the ubiquitin pool. In order to test this, U2OS cells expressing the tagged 
ubiquitin-RPS27a or RPL40 were treated overnight with MG132, a proteosomal 
inhibitor (Oh et al., 2013). Tetracycline was added to the cells overnight, so that MG132 
affected the expressed proteins. The whole cell extract was loaded on an SDS-PAGE 
gel and analysed by Western Blotting (Figure 5.7). 
 
The levels of the expressed HA-tagged RPS27a did not significantly change when the 
proteasome was blocked by treatment with MG132 (Figure 5.7A, C). In contrast, the 
levels of the expressed HA-tagged RPL40 were significantly increased after inhibition 
of the proteasome by MG132 (Figure 5.7B, C). These results indicate that RPL40 is 
probably produced in excess and rapidly turned-over by the proteasome. The levels of 
ubiquitin were not significantly affected by treatment with MG132 in either case, 
indicating that the ubiquitin is produced as normal. No accumulation of the expected 
ubiquitin-fusion ribosomal protein precursor was detected after inhibition of the 
proteasome by MG132 (Figure 5.7). 
 
Taken together, these data indicated that the processing of the ubiquitin-fusion 
RPS27a and RPL40 is more likely to occur at very early stages after translation, before 
their integration in the ribosome or the proteosomal degradation of RPL40. 
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Figure 5.7. Inhibition of the proteasome resulted in stabilization of RPL40 but not 
RPS27a. (A-B) MG132 treatment was performed overnight in U2OS cells expressing 
the ubiquitin fusion RPS27a (A) or RPL40 (B). 1000ng/µl tetracycline was added to 
the cells overnight. U2OS cells containing the pcDNA5 empty vector, treated with 
1000ng/µl tetracycline overnight, were used as a control. The whole cell extract was 
loaded on an SDS-PAGE gel and analysed by Western Blotting using the LICOR 
system. The antibodies used are shown on the left and Karyopherin (Karyop.) was 
used as a loading control (shown on the left). The molecular weight (kDa) is shown on 
the left, the expected precursor, conjugated ubiquitin and histone-ubiquitin are shown 
on the right of each panel. (C) ImageQuant software was used for quantitation of the 
Western Blots. The average relative levels of the expressed RPS27a or RPL40 of three 
independent experimental repeats is represented on the graph, and the error bars 
show the standard error (+/-SEM). The values of each sample were normalized to the 
loading control values (α-Karyopherin). Statistical analysis was performed using 
unpaired t-test and absence of significance values indicates no significant differences 
as compared to the untreated cells. *p value<0.05. 
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5.2.2 RPS27a and RPL40 are found in the small and large ribosomal subunit 
complexes respectively 
 
I next investigated where the HA-tagged RPS27a and RPL40 localize in the cell. In 
order to do this, immunofluorescence was performed using U2OS cells containing the 
pcDNA5 empty vector or U2OS cells expressing the HA-tagged RPS27a or RPL40 
proteins. An α-FLAG antibody was used to stain the cleaved FLAG-tagged ubiquitin 
and an α-HA antibody was used to detect the cleaved HA-tagged ribosomal protein. 
DAPI was used for DNA staining (Figure 5.8). 
 
U2OS cells containing the pcDNA5 empty vector showed a clear DAPI staining but 
only background signal was seen when either the α-HA or the α-FLAG antibodies were 
used (Figure 5.8). HA-tagged RPS27a was localized in both the nucleolus and the 
cytoplasm (Figure 5.8), which resembled the localization pattern of other ribosomal 
proteins, such as RPL11 (Chapter 4). In contrast, HA-tagged RPL40 was found mainly 
in the cytoplasm and almost not at all in the nucleus (Figure 5.8). The FLAG-tagged 
Figure 5.8. The HA-tagged RPS27a or RPL40 show different localization patterns 
in U2OS cells. U2OS cells containing the empty pcDNA5 vector were used as a 
control. 1000ng/µl tetracycline was added overnight to U2OS cells expressing the 
tagged ubiquitin-RPS27a or RPL40, or containing the pcDNA5 vector. 
Immunofluorescence followed, using an α-FLAG antibody to detect the levels of the 
FLAG-tagged ubiquitin (red), whereas an α-HA antibody was used to detect the levels 
of the HA-tagged ribosomal protein (green). DAPI was used for DNA staining (blue). 
The cells were visualized using the Zeiss Axiovision inverted microscope and software. 
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ubiquitin was found mainly in the cytoplasm, with some traces in the nucleus but not in 
the nucleolus (Figure 5.8). This agrees with previous data showing that the FLAG-
tagged ubiquitin was found in higher levels as conjugated ubiquitin (Figure 5.4), which 
is found in the cytoplasm, and histone ubiquitin (Figure 5.4), which is found in the 
nucleus. 
 
I next wanted to identify which complexes these proteins are found in. To do this, I 
used glycerol gradient analysis to separate the free and the ribosomal complexes. 
U2OS cells were expressing the HA-tagged RPS27a or RPL40 after addition of 
tetracycline overnight. The whole cell extract was fractionated using a 10-40% glycerol 
gradient. Each fraction was loaded on an SDS-PAGE gel and analysed by Western 
blotting (Figure 5.9). An α-HA antibody was used to identify the HA-tagged ribosomal 
proteins expressed, and an α-RPL7 antibody was used as a control to identify the 
endogenous ribosomal protein RPL7 (Figure 5.9). 
 
The HA-tagged RPS27a was found in the small ribosomal subunit complexes (Figure 
5.9, fractions 6-9) and no HA-tagged RPS27a was found in the non-ribosomal 
complexes (Figure 5.9, fractions 1-5). The HA-tagged RPL40 was also found in the 
large ribosomal subunit complexes (Figure 5.9, fractions 10-15) and at the same place 
where the SSU complexes accumulate (Figure 5.9, fractions 6-9). In contrast with 
RPS27a, the HA-tagged RPL40 was also found in the non-ribosomal complexes 
(Figure 5.9, fractions 1-5). 
 
The accumulation of the HA-tagged RPS27a in the SSU complexes was expected, as 
it is a part of the SSU, as was the accumulation of the HA-tagged RPL40 in the LSU 
complexes, as it is a part of the LSU. Interestingly, the HA-tagged RPL40 accumulated 
in the non-ribosomal complexes, but no nuclear accumulation was seen during 
immunofluorescence (Figure 5.8). It is possible that RPL40 is more unstable because 
it is found as a free ribosomal protein and gets degraded quickly by the proteasome. 
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 5.2.3 RPS27a and RPL40 are required for SSU and LSU production respectively 
 
It is known that RPS27a and RPL40 are ribosomal proteins (Kimura and Tanaka, 
2010). I, therefore, investigated their role in the accumulation of the small or large 
ribosomal subunits. Knockdown efficiency was tested by RT-PCR due to the lack of 
commercially available antibodies. Knockdowns were performed for 48h in U2OS cells 
and RNA was extracted, followed by reverse transcription and PCR using primers 
specific for the human RPS27a or RPL40 open reading frame (ORF). Primers specific 
the levels of the house-keeping mRNA GAPDH were used as a loading control (Figure 
5.10). As compared to the control, knockdown of either RPS27a or RPL40 resulted in 
a major decrease in the mRNA levels of the ribosomal proteins (Figure 5.10), showing 
that the knockdowns were efficient. 
Figure 5.9. Gradient analysis of RPS27a and RPL40 expressing U2OS cells. 
U2OS expressing the HA-tagged RPS27a or RPL40 (shown on the right) were 
targeted for glycerol gradient analysis. The whole cell extract (approximately 8x106 
cells) was loaded on a 10-40% glycerol gradient and fractionated by centrifugation. 
The fractions were loaded on an SDS-PAGE gel and analysed by Western Blotting 
using the LICOR system. The antibodies used are shown on the left. “T” represents 
10% of the total sample before fractionation. Fractions 1-5 represent the free 
complexes, fractions 6-9 represent the small ribosomal subunit complexes (SSU) and 
fractions 10-15 represent the large ribosomal subunit complexes (LSU) (shown at the 
top). 
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 Next, I investigated the importance of these proteins to human ribosome biogenesis. 
Knockdowns were performed in U2OS cells for 48h and pulse-chase labelling followed, 
where the phosphate was depleted for 1h using phosphate-free media. Next, 
radiolabelled (32P) phosphate was added to the cells for 1h and the cells were then left 
to grow in normal media for 3h (chase). RNA was extracted from the cells, loaded on 
a glyoxal-agarose gel, and transferred on a Hybond N membrane, which was 
visualized by the Typhoon Phosphorimager (Figure 5.11A). 
 
Pulse-chase labelling revealed that the levels of the newly-synthesized 18S rRNA after 
RPS27a knockdown were barely visible as compared to the control (Figure 5.11A). 
Furthermore, the levels of the mature 18S rRNA were also reduced, as seen by the 
ethidium bromide staining (UV) (Figure 5.11A). The levels of the other newly-
synthesized rRNAs (47/45S, 32S and 28S) were also lower after RPS27a knockdown 
as compared to the control, whereas the loading was approximately the same as seen 
by the 28S UV levels (Figure 5.11A). After RPL40 knockdown the levels of the newly 
synthesized 28S rRNA were lower by approximately 30% as compared to the control 
(Figure 5.11A). The ratio of the mature 28S to 18S rRNA, as seen by the ethidium 
bromide staining (UV) was decreased by approximately 30% after knockdown of 
RPL40 as compared to the control (Figure 5.11A), showing a reduction in the levels of 
the mature 28S rRNA as well. Furthermore, no major change was observed in the 
levels of the newly-synthesized 47/45S, 32S or 18S rRNAs after RPL40 as compared 
to the control (Figure 5.11A). These data indicated that RPS27a is required for SSU 
biogenesis, whereas RPL40 is required for LSU biogenesis, as expected. Furthermore, 
Figure 5.10. The efficiency of RPS27a and RPL40 knockdowns in U2OS cells. 
Knockdowns of RPS27a (A) or RPL40 (B) were performed for 48h in U2OS cells. RNA 
was extracted and RT-PCR was performed using primers specific for RPS27a (A) or 
RPL40 (B). Primers recognizing GAPDH were used as a loading control. The samples 
were loaded on a 2% agarose/1x TBE DNA gel and visualized using the Typhoon 
Phosphorimager. 
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since knockdown of RPS27a affected the levels of the newly-synthesized 47/45S, 32S 
and 28S rRNAs as well (Figure 5.11A), it is possible that it is an important protein for 
transcription. 
 
 
 
 
 
 
Figure legend on the next page. 
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 In order to identify when these proteins act during ribosome biogenesis in humans, 
knockdowns were performed for 48h in U2OS cells and RNA was extracted and loaded 
on a glyoxal-agarose gel, which was analysed by Northern blotting using radiolabelled 
(32P) probes recognizing ITS1 and ITS2 (Figure 5.11B) (Sloan et al., 2013c). The levels 
of the 28S or 18S rRNA visualized by ethidium bromide staining (UV) were used as a 
loading control for RPS27a or RPL40 knockdowns respectively (Figure 5.11C). 
 
RPS27a knockdown resulted in an accumulation of the 30S SSU rRNA precursor as 
compared to the control (Figure 5.11C) and a slight decrease in 21S rRNA levels was 
observed, demonstrating that RPS27a is needed for the processing of the 30S SSU 
rRNA precursor. No major change in the levels of the 47/45S, 41S, 32S, or 12S rRNA 
precursors after RPS27a knockdown (Figure 5.11C). In contrast, RPL40 knockdown 
resulted in the accumulation of the 36S and 32S LSU rRNA precursors as compared 
to the control (Figure 5.11C). Furthermore, a slight accumulation of the 41S rRNA 
precursor was observed (Figure 5.11C) but no other major change was observed in 
the levels of the 47/45S, 30S, 26S, 21S or 12S rRNA precursors after RPL40 was 
knocked down (Figure 5.11C). These data showed that RPS27a is required for the 
SSU biogenesis for cleavage of the 5’ ETS, whereas RPL40 is required for the LSU 
biogenesis for cleavage at site 2 of ITS1. 
 
 
Figure 5.11. RPS27a and RPL40 knockdowns affect the SSU and LSU biogenesis 
respectively. (A) Knockdowns of RPS27a or RPL40 were performed for 48h in U2OS 
cells, followed by pulse-chase labelling, where the phosphate was depleted for 1h. 
Radiolabelled (32P) phosphate was added for 1h and the cells were left to grow in 
normal media for 3h (chase). The RNA was extracted, loaded on a 1.2% 
agarose/glyoxal gel and transferred on a Hybond N membrane. The RNA was 
visualized using a Typhoon Phosphorimager. The 28S and 18S rRNA ethidium 
bromide staining (UV) was used as a loading control. (B) Schematic representation of 
the human LSU (blue) and SSU (green) precursor and mature rRNAs. ITS1 and ITS2, 
recognized by the radiolabelled (32P) probes, are marked in red (Adapted from (Sloan 
et al., 2013c)). (C) RNA was extracted after knockdowns of RPS27a or RPL40 in U2OS 
cells for 48h, and loaded on a 1.2% agarose/glyoxal gel. The RNA was transferred on 
a Hybond N membrane, which was incubated with radiolabelled (32P) probes 
recognizing ITS1 or ITS2 (indicated on the left) for identification of the precursor rRNAs 
(shown on the right) whereas 28S and 18S rRNA ethidium bromide staining (UV) was 
used as a loading control. 
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5.2.4 Knockdowns of RPS27a and RPL40 in U2OS cells do not affect the levels 
or activity of p53  
 
Defects in ribosome biogenesis cause p53 accumulation via the 5S RNP-MDM2 
pathway (Chapter 4,(Sloan et al., 2013a). Since RPS27a and RPL40 knockdowns 
resulted in SSU and LSU biogenesis defects respectively, I wanted to investigate 
whether they also affected p53 levels. For this, siRNA-mediated knockdowns of 
RPS27a or RPL40 were performed in U2OS cells for 48h, and the whole cell extract 
was loaded on an SDS-PAGE gel and analysed by Western Blotting to detect p53 and 
p21 levels. Furthermore, in order to investigate the activity of p53, knockdowns were 
performed for 48h in U2OS cells expressing p53-driven luciferase. However, there was 
no investigation of p21 mRNA levels or other p53 downstream targets for measuring 
p53 activity. The whole cell extract was treated according to the manufacturer’s 
instructions (Promega Luciferase Kit) and the luciferase levels were analysed using a 
Luminometer (Figure 5.12). 
 
ActD treatment was used as a positive control, and resulted in a 6-fold significant 
increase in p53-driven luciferase levels as compared to the plain, untreated cells 
(Figure 5.12C). The knockdown of RPS27a or RPL40 did not result in a significant 
change in p53 protein levels (Figure 5.12A, B). Furthermore, neither knockdown 
resulted in a change of p21 levels, and the slight decrease seen here was due to 
experimental variation (Figure 5.12A). In order to confirm that p53 activity was not 
induced, the levels of p53-driven luciferase were measured (Figure 5.12C), since p53 
can be induced in these cells without changing p53 levels. Knockdowns of RPS19, 
which affects SSU production (Chapter 4), or RPL7 or RPL18, which affect LSU 
production (Chapter 4), resulted in a significant increase in p53-driven luciferase levels 
(Figure 5.12C). In contrast, knockdowns of RPS27a or RPL40 did not result in a 
significant change in the p53-driven luciferase levels (Figure 5.12C). These data 
indicated that RPS27a or RPL40 do not affect p53 levels or activity in U2OS cells, 
despite the fact that they result in ribosome biogenesis defects. 
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Figure 5.12. RPS27a or RPL40 knockdowns do not affect the levels or activity of 
p53 in U2OS cells. (A) siRNA treatment of U2OS cells was performed for 48h. Whole 
cell extract for knockdown cells was loaded on an SDS-PAGE gel and analysed by 
Western Blotting using the LICOR system. The antibodies used are shown on the left 
and Karyopherin (Karyop.) was used as a loading control. (B) ImageQuant software 
was used for quantitation of the western blots. The graph represents the averages of 
p53 protein relative levels of three experimental repeats and the error bars show 
standard error (+/-SEM). Normalization of the value of each sample to the loading 
control values (α-Karyopherin) was performed. Statistical analysis was performed 
using an unpaired t-test and absence of significance values indicates no significant 
differences compared to the control. (C) U2OS cells expressing p53-driven luciferase 
were treated with ActD overnight or the respective siRNAs for 48h. Non-treated U2OS 
cells are shown as “plain” (see Chapter 4). The graph represents the average p53-
driven luciferase levels of three experimental repeats and the error bars represent the 
standard error (+/-SEM). Normalization to the cell numbers measured by Bradford 
assay in each sample was performed. Statistical analysis was performed using an 
unpaired t-test and absence of significance values indicates no significant differences 
compared to the control. *p value<0.05, **p value<0.01, ***p value<0.0001. 
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Since p53 levels or activity were not changed after RPS27a or RPL40 knockdowns, I 
hypothesized that the knockdowns would have no change in the cell cycle. To confirm 
this, knockdowns of RPS27a or RPL40 were performed in U2OS cells for 48h, and 
overnight treatment with ActD was used as a positive control. The cells were then fixed 
in 70% ethanol and the DNA was stained with propidium iodide, before analysed using 
the FACS Canto II flow cytometer and software for cell cycle analysis. 
 
As previously (Chapter 4), there was a G1 and G2/M cell cycle arrest after ActD 
treatment as expected as compared with the non-treated cells (Figure 5.13A, B, F). 
After knockdown of RPS27a or RPL40, there was no significant difference between 
G1, S or G2/M phase as compared to the control (Figure 5.13C-F). These results 
showed that RPS27a or RPL40 knockdowns did not affect the regulation of the cell 
cycle in U2OS cells, consistent with the lack of p53 induction. These results indicated 
that, while RPS27a and RPL40 knockdowns induced ribosome biogenesis defects, 
they did not induce p53, which is consistent with previous data showing that RPS27a 
knockdown did not result in p53 activation in U2OS cells (Sun et al., 2011). 
 
So far I have shown that knockdowns of the ribosomal proteins RPS27a or RPL40 do 
not change the levels or activity of p53. The only other two ribosomal proteins showing 
this phenotype is RPL5 and RPL11, which are components of the signalling pathway 
connecting ribosome biogenesis and p53 signalling (Pelava et al., 2016). Therefore, I 
wanted to investigate whether knockdowns of RPS27a or RPL40 prevent the activation 
of p53 after ribosome biogenesis defects, similarly to RPL5 and RPL11. Knockdowns 
of RPS27a or RPL40 were performed in U2OS cells for 48h and ActD was added to 
the cells overnight, for inhibition of ribosome production. The whole cell extract was 
loaded on an SDS-PAGE gel and analysed by Western blotting for detection of p53 
and p21 (Figure 5.14). 
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 Figure 5.13. RPS27a or RPL40 knockdowns have no effect on cell cycle in U2OS 
cells. (A-E) ActD treatment was performed overnight, siRNA treatment was performed 
for 48h in U2OS cells and non-treated U2OS cells are shown as “plain U2OS”. The 
cells were fixed in 70% ethanol and the DNA was stained with propidium iodide. Cell 
cycle analysis was performed using the FACS Canto II flow cytometer. The first two 
samples are the same as the ones presented in Chapter 4. (F) The graph represents 
the averages of three independent experimental repeats of the percentage levels of 
G0/G1 (dark grey), S (light grey) or G2/M (grey) phases. The error bars show the 
standard error (+/-SEM). Statistical analysis was performed using an unpaired t-test 
and absence of significance values indicates no significant difference as compared to 
the control. *p value<0.05, ***p value<0.001. 
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 Treatment with ActD in control cells resulted in a 4-fold increase in p53 levels (Figure 
5.14A, B) and in an increase in p21 levels (Figure 5.12A), indicating an increase in p53 
activity, even though p21 mRNA levels or other p53 downstream targets were not 
assessed. Knockdowns of either RPS27a or RPL40 in U2OS cells treated with ActD 
did not significantly change the levels of p53 as compared to the ActD-treated control 
cells (Figure 5.14A, B). Furthermore, the levels of p21 after knockdowns of RPS27a or 
RPL40 in ActD-treated cells remained mostly unaffected as compared to the ActD-
treated control cells, and the slight decrease seen here is due to experimental variation 
(Figure 5.14A). These results indicate that RPS27a or RPL40 do not induce p53, but 
they also do not prevent its activation after ribosome production defects. This is not the 
case with knockdown of RPL5 and RPL11. This is different from previously published 
data showing that RPS27a knockdown diminished the induction of p53 after ribosome 
biogenesis defects with ActD in U2OS cells (Sun et al., 2011). 
 
 
Figure 5.14. Knockdown of RPS27a or RPL40 does not diminish the p53 
induction caused by ribosome biogenesis defects. (A) Knockdowns of RPS27a or 
RPL40 were performed in U2OS cells for 48h, which were treated with ActD overnight 
(18h). The whole cell extract was loaded on an SDS-PAGE gel and analysed by 
Western blotting using the antibodies shown on the left. The membranes were 
visualised using the LICOR system and Karyopherin (Karyop.) was used as a loading 
control. (B) ImageQuant software was used for quantitation of the western blots. The 
graph represents the relative p53 levels of three experimental repeats after 
normalisation to the loading control (Karyop.) and the control. The error bars indicate 
standard error (+/-SEM) and statistical analysis was performed using an unpaired t-
test. Absence of significance values indicates no significant differences as compared 
to the ActD-treated control. *p value<0.05. 
 
            
           
            
             
              
             
             
           
             
              
             
            
          
          
          
              
              
              
           
              
            
             
            
           
       
 
            
           
173 
 
5.2.5 Over-expression of RPS27a or RPL40 results in an increase in p53 levels 
with reduced activity 
 
Surprisingly, I have shown that knockdown of either RPS27a or RPL40 did not result 
in a change in p53 levels or activity in U2OS cells. A recent study has shown that 
RPS27a overexpression resulted in a p53 increase due to inhibition of MDM2 in U2OS 
cells (Sun et al., 2011). I, therefore, wanted to investigate whether overexpression of 
RPS27a or RPL40 affected p53 levels or activity. For this, tetracycline was added to 
U2OS cells expressing the tagged RPS27a or RPL40 proteins overnight. The whole 
cell extract was loaded on an SDS-PAGE gel and analysed by Western Blotting to 
monitor p53 and p21 levels (Figure 5.15). Over-expression of RPS27a or RPL40 
resulted in a significant 5-fold p53 increase as compared to the U2OS cells containing 
the empty pcDNA5 vector (Figure 5.15). Surprisingly, even though the p53 levels were 
elevated, no significant difference was observed in the levels of p21 after expression 
of the HA-tagged RPS27a or RPL40 (Figure 5.15). These results indicate that 
overexpression of the HA-tagged RPS27a or RPL40 results in an increase in p53 levels 
with reduced activity, even though p21 mRNA levels or other p53 downstream targets 
were not assessed for p53 activity. 
 
I next wanted to see whether over-expression of RPS27a or RPL40 can affect p53 
levels when ribosome biogenesis is blocked. To test this, I used overnight treatment 
with ActD to block rRNA transcription. Tetracycline was added to the cells overnight, 
as previously. Treatment with ActD in U2OS containing the empty pcDNA5 vector 
resulted in a significant 2-fold p53 increase and a significant 5-fold increase in p21 
levels as compared to the non-treated cells, indicating an increase in p53 levels and 
activity as expected (Figure 5.15). ActD treatment in U2OS cells expressing the HA-
tagged RPS27a or RPL40 did not result in a significant change in p53 levels as 
compared to the non-ActD treated U2OS cells expressing the HA-tagged ribosomal 
proteins (Figure 5.15). However, ActD treatment resulted in a significant p21 increase 
in U2OS cells expressing either HA-tagged RPS27a or RPL40 as compared to the 
non-treated U2OS cells expressing the HA-tagged ribosomal proteins (Figure 5.15). 
Interestingly, the levels of p21 after ActD treatment in U2OS cells expressing the HA-
tagged RPS27a or RPL40 were significantly lower than the levels of p21 in the ActD-
treated U2OS cells containing the empty pcDNA5 vector (Figure 5.15). 
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These results indicated that expression of the HA-tagged RPS27a and RPL40 resulted 
in a stabilisation of p53 levels but not activity, which is different from previously 
published data showing that over-expression of RPS27a leads to an increase in both 
p53 levels and activity (Sun et al., 2011). Furthermore, these results show that over-
expression of RPS27a or RPL40 results in a decreased p53 activity after ribosome 
biogenesis defects. 
 
5.2.6 RPS27a and RPL40 knockdowns result in an increase of p53 levels in both 
MCF7 and LNCaP cells 
 
Since RPS27a and RPL40 knockdowns resulted in no change in p53 levels in U2OS 
cells, I wanted to investigate whether these effects were cell-type specific. I, therefore, 
repeated the knockdowns in breast cancer MCF7 cells and prostate cancer LNCaP 
cells. The knockdown efficiency was investigated with RT-PCR using primers specific 
for RPS27a or RPL40. Primers targeting the house-keeping GAPDH mRNA were used 
Figure 5.15. RPS27a and RPL40 over-expression results in a stabilisation in p53 
levels, but not activity, even after ribosome biogenesis defects. (A) ActD 
treatment was performed overnight in U2OS cells containing the empty pcDNA5 
vector or expressing the HA-tagged RPS27a or RPL40. Tetracycline was added to the 
cells overnight and the whole cell extract was loaded on an SDS-PAGE gel. Western 
blotting analysis was performed using the antibodies shown on the left and the 
membranes were visualized using the LICOR system. Karyopherin (Karyop.) was 
used as a loading control. (B) ImageQuant software was used for quantitation of 
western blots. Normalization of each sample to the levels of the loading control (α-
Karyopherin) was performed and the averages of the relative p53 and p21 levels of 
three independent experimental repeats are represented on the graph. The error bars 
show standard error (+/-SEM) and statistical analysis was performed using an 
unpaired t-test. Absence of significance values indicates no significant difference. *p 
value<0.05, **p value<0.01, ***p value<0.001. 
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as a loading control (Figure 5.16). Knockdown of either RPS27a or RPL40 in MCF7 or 
LNCaP cells resulted in a major decrease in the mRNA levels of the ribosomal proteins 
(Figure 5.16), indicating that the knockdowns were efficient in both cell lines. 
 
Next, I investigated the effects of RPS27a and RPL40 knockdowns on p53 levels in 
MCF7 and LNCaP cells. The whole cell extract produced from knockdown cells was 
loaded on an SDS-PAGE gel followed by Western Blotting analysis for detection of p53 
or p21 (Figure 5.17). Knockdown of RPS27a resulted in an approximately 3.5-fold and 
5-fold increase in p53 levels in MCF7 and LNCaP cells respectively, as compared to 
the control (Figure 5.17). Furthermore, p21 levels were also increased after knockdown 
of RPS27a in both MCF7 and LNCaP cells (Figure 5.17A), indicating that p53 activity 
was also induced. Knockdown of RPL40 resulted in a 2.5-fold and 4-fold increase in 
p53 levels in MCF7 and LNCaP cells respectively, as compared to the control (Figure 
5.17), and in an increase in the levels of p21 (Figure 5.17A), indicating an increase in 
p53 activity. These results show that RPS27a or RPL40 knockdowns in MCF7 or 
LNCaP cells result in an increase in p53 levels and activity, as opposed to U2OS cells. 
Note that p21 can be regulated post-translationally (Jung et al., 2010), but there was 
Figure 5.16. Knockdown efficiency of siRNA treatment in MCF7 and LNCaP cells 
tested by RT-PCR. siRNA-mediated knockdowns of control, RPS27a (top) or RPL40 
(bottom) was performed in MCF7 (A) or LNCaP (B) cells. RNA was extracted from the 
cells and reverse transcription was performed. PCR followed using primers targeting 
RPS27a or RPL40 were used, whereas primers recognizing GAPDH were used as a 
loading control. The samples were loaded on a 2% agarose/1x TBE DNA gel and 
visualized using the Typhoon Phosphorimager. 
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no assessment of p21 mRNA levels or other p53 downstream targets for p53 activity 
measure. 
  
Figure 5.17. RPS27a or RPL40 knockdowns result in p53 induction in MCF7 and 
LNCaP cells. (A-B) siRNA-mediated knockdowns for control, RPS27a or RPL40 were 
performed for 48h in MCF7 (A) or LNCaP (B) cells and the whole cell extract was 
loaded on an SDS-PAGE gel. Western blot analysis was performed using the LICOR 
system. The antibodies used are shown on the left and Karyopherin (Karyop.) was 
used as a loading control. (C) ImageQuant software was used for quantitation of the 
western blots and normalization of the p53 values was performed against the loading 
control values (Karyopherin). The graph represents the average relative p53 levels of 
three independent experimental repeats and the error bars represent the standard error 
(+/-SEM). Statistical analysis was performed using an unpaired t-test. **p value<0.01, 
***p value<0.0001. 
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5.3 Discussion 
 
The RPS27a and RPL40 genes encode for the ubiquitin-ribosomal protein precursors 
RPS27a and RPL40 in humans, (Redman and Rechsteiner, 1989) and are highly 
conserved amongst eukaryotes (Kimura and Tanaka, 2010). Ubiquitin is an important 
and highly conserved molecule, involved in protein degradation and signal transduction 
pathways (Pickart and Eddins, 2004). Despite the high conservation of these proteins 
and the importance of both ubiquitination and ribosome biogenesis to the cell, not much 
is known about their production or function in humans. In this chapter, I have shown 
that the ubiquitin-ribosomal protein precursor is likely to be processed at very early 
stages after or during translation. Furthermore, I have shown that RPS27a is important 
for SSU production and RPL40 is important for LSU production. Since ribosome 
biogenesis defects result in the stabilisation of p53 via the 5S RNP-MDM2 pathway 
(Sloan et al., 2013a, Donati et al., 2013, Nishimura et al., 2015), it was of a surprise to 
find that p53 was not induced after depletion of either RPS27a or RPL40 in U2OS cells. 
 
I firstly investigated when the ubiquitin-ribosomal protein precursor is processed in the 
cell using U2OS stable cell lines expressing tagged RPS27a or RPL40, under the 
control of a tetracycline promoter. I found that no precursor was detected when the 
HA-tagged ubiquitin-fusion RPS27a or RPL40 were expressed in U2OS cells (Figure 
5.4), indicating that the de-ubiquitination of these proteins occurs early or the precursor 
is not stable in the cell. The ubiquitin-fusion precursor was also not visible after block 
of ribosome biogenesis by ActD (Figure 5.5). These results agree with previously 
published data where they showed that cleavage of the ubiquitin monomer occurs very 
rapidly in the cell from the Ubiquitin-RPS27a precursor (Sun et al., 2011). It is, 
therefore, likely that the ubiquitin molecule is cleaved extremely quickly after or during 
translation of these proteins, which agrees with a recent study showing that the 
processing of the ubiquitin-ribosomal protein precursors is most likely to occur post-
translationally in mice and human cells (Grou et al., 2015). In future studies, it would 
be interesting to identify possible de-ubiquitinases that are important for the processing 
of these proteins. Two likely candidates are the ubiquitin C-terminal hydrolase (UCH) 
L3 and the ubiquitin-specific protease (USP) 7, which were shown to be involved in the 
maturation of the ubiquitin-ribosomal protein precursors in mice and human cells (Grou 
et al., 2015). Furthermore, UCHL3 is mainly found in the cytosol and USP7 is found in 
both the nucleus and the cytosol (Grou et al., 2015), further supporting the theory that 
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the processing of the ubiquitin-ribosomal protein precursors takes place during or 
immediately after translation. 
 
It is known that some ribosomal proteins are produced in excess and rapidly degraded 
by the proteasome (Lam et al., 2007). Indeed, I showed that the HA-tagged RPL40, 
but not RPS27a, was stabilised when the proteasome was inhibited using MG132 
(Figure 5.7), indicating that RPL40 is likely to be very unstable when it is found free 
and quickly degraded by the proteasome, whereas RPS27a is probably produced in 
normal levels. Furthermore, the levels of the FLAG-tagged ubiquitin did not change by 
treatment with MG132, showing that inhibition of the proteasome only affects the free 
RPL40 but not the ubiquitin-ribosomal protein precursor. Further supporting these 
data, I showed that the HA-tagged RPL40, but not RPS27a, is found in the non-
ribosomal complexes (Figure 5.9) and that the HA-tagged RPS27a is found in both the 
nucleolus and the cytoplasm, whereas the HA-tagged RPL40 is mainly found in the 
cytoplasm (Figure 5.8). It is likely that the RPL40 detected in the free complexes is 
unstable and it is quickly integrated in the ribosome or degraded by the proteasome if 
produced in excess. Since I am inclined to assume that the ubiquitin-ribosomal protein 
precursor is cleaved in the cytoplasm, the mature RPS27a and RPL40 are probably 
then transported to the nucleus where ribosome biogenesis takes place. In addition, I 
showed that the HA-tagged RPS27a accumulated in the SSU complexes and the HA-
tagged RPL40 accumulated in the LSU complexes, as expected (Figure 5.9). 
Surprisingly, the HA-tagged RPL40 accumulated in the same place as the SSU 
complexes, but I have no evidence that it accumulates in the SSU. It is still unclear 
why this was observed. 
 
Inhibition of rRNA transcription after ActD treatment (Figure 5.5) or specific block of 
SSU or LSU production (Figure 5.6) resulted in a significant decrease in the levels of 
the HA-tagged RPS27a or RPL40, but no change was observed in the levels of the 
FLAG-tagged ubiquitin. These results indicate that ribosome biogenesis defects result 
in a decrease in the ribosomal protein production but not in a decrease in the ubiquitin-
ribosomal protein precursor. Interestingly, depletion of RPS27a and RPL40 affected 
the small and large ribosomal subunit biogenesis respectively (Figure 5.11). My data 
indicated that RPS27a is likely to be involved in 30S SSU rRNA precursor processing 
in humans (Figure 5.11), by cleavage at 5’ ETS and ITS1, for the production of the 
mature 18S rRNA (Sloan et al., 2014). RPL40 is likely to be important for site 2 
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endonucleolytic cleavage of ITS1 (Figure 5.11), which separates the SSU and LSU 
rRNA precursors in humans. A cleavage block at this site results in cleavage of site 
2a, leading to the accumulation of the 36S LSU rRNA precursor (Sloan et al., 2013c). 
It is possible that RPS27a and RPL40 interact with ribosome biogenesis factors 
important for these cleavage steps. For example, RPL40 could interact or be involved 
with RRP5 and NOL12 ribosome biogenesis factors, which were found to play an 
important role in ITS1 site 2 cleavage in humans (Sloan et al., 2013c). This is the first 
evidence for the direct involvement of both RPS27a and RPL40 in human ribosome 
biogenesis, and future work is necessary to identify how these proteins may function. 
 
Defects in ribosome biogenesis are directly linked with the levels of the tumour 
suppressor p53 via the 5S RNP-MDM2 pathway (Pelava et al., 2016). Surprisingly, 
p53 levels or activity were not significantly changed after RPS27a or RPL40 
knockdowns in U2OS cells (Figure 5.12), even though they resulted in ribosome 
biogenesis defects. My data agree with previously published data where RPS27a 
knockdown had no major effect on p53 levels in U2OS cells (Sun et al., 2011). 
Furthermore, I showed that the induction of p53 levels and activity after ribosome 
biogenesis defects by ActD treatment were not changed after knockdown of RPS27a 
or RPL40 (Figure 5.14), as opposed to knockdowns of RPL5 or RPL11, which prevent 
the activation of p53 after ribosome biogenesis defects (Dai and Lu, 2004, Lohrum et 
al., 2003, Sun et al., 2010, Zhang et al., 2003). In a previous study, it was shown that 
knockdown of RPS27a resulted in the significant decrease of p53 levels caused by 
inhibition of rRNA transcription after treatment with ActD in U2OS cells (Sun et al., 
2011), as opposed to my data. Why this difference is observed is not clear. 
 
In addition, I show here that the lack of p53 induction seems to be cell-type specific 
since p53 levels and activity were induced by knockdowns of RPS27a and RPL40 in 
breast cancer MCF7 cells and prostate cancer LNCaP cells (Figure 5.17). A recent 
publication has shown that knockdown of RPS27a resulted in a significant increase in 
p53 levels in HCT116 colorectal carcinoma cells (Nicolas et al., 2016), further 
confirming that the p53 response is cell-type specific. Interestingly, LNCaP cells have 
been shown to have mutations in a number of genes encoding for ribosomal proteins, 
such as RPL22, or ribosome biogenesis factors, such as NOB1. In addition, a mutation 
in the gene encoding for RPL10L was found in MCF7 and a mutation in RPL22 gene 
in HCT-116 cells, but no ribosomal protein genes are mutated in U2OS cells (Iorio et 
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al., 2016). Furthermore, LNCaP cells have a variety of mutations in six genes encoding 
for ubiquitin-like modifiers, such as UBE3A, but only a few genes were found mutated 
in MCF7 and HCT-116 cells, and only one in U2OS cells.(Iorio et al., 2016). Moreover, 
LNCaP cells have mutations in more than 10 genes encoding for USP de-ubiquitinases 
and HCT-116 have mutations in 9 USP genes, but only one or two USP de-
ubiquitinases are mutated in U2OS or MCF7 cells respectively (Iorio et al., 2016). 
These data suggest that LNCaP, HCT-116 and, probably, MCF7 cells may be more 
prone in p53 activation after ribosome biogenesis defects by RPS27a or RPL40 
depletion than U2OS cells, since a number of genes involved in the ubiquitin 
homeostasis are mutated in these cells. Another explanation for the cell-line specific 
phenotype might be that the protein levels of RPS27a vary in different cell lines, since 
MCF7 cells express RPS27a in medium levels, whereas U2OS cells contain high levels 
of RPS27a protein. Even though there is no information for LNCaP cells, RPS27a 
protein is found in medium levels in another prostate cancer cell line, PC-3, similarly to 
MCF7 cells (Ponten et al., 2008). It was previously suggested that RPS27a binds 
MDM2, leading to p53 activation when over-expressed, providing a novel regulation of 
p53 levels (Sun et al., 2011). It may be that, in U2OS, RPS27a or RPL40 are needed 
for the binding of the 5S RNP to MDM2, but not in MCF7 or LNCaP cells. Why this is 
the case is unclear and future work is needed to determine this. 
 
I have shown here that over-expression of either RPS27a or RPL40 in U2OS cells 
resulted in an increase in p53 levels, but not activity (Figure 5.15). Since knockdown 
of RPS27a or RPL40 had contrasting effects on p53 levels in different cell lines, it 
would be interesting to see whether over-expression of these proteins in other cell lines 
affect p53 levels and activity differently. My results are somewhat different from a 
previous publication where over-expression of RPS27a in U2OS cells resulted in an 
induction in both p53 levels and activity (Sun et al., 2011), but it is not clear why this is 
the case. Even though the authors have also used U2OS cells, there are still variations 
between cells, which might be the main cause of this difference. Furthermore, in the 
published study, the authors have used transient DNA transfections for over-
expression of RPS27a, whereas I have created a U2OS cell line which stably 
expressed the tetracycline-inducible tagged protein. It is unlikely that this would cause 
such a difference, but I cannot exclude this possibility. Another explanation would be 
the use of different tags on the ubiquitin-RPS27a open reading frame, since they have 
used V5 and FLAG tags (Sun et al., 2011), whereas I have used FLAG and HA tags. 
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Again, it is not clear whether the different tags would interfere with the function of the 
expressed protein, but it is a possibility we cannot exclude. Furthermore, I have shown 
that p53 activity in U2OS cells expressing the HA-tagged RPS27a or RPL40 is 
reduced, even after ribosome biogenesis defects by ActD treatment (Figure 5.15). 
These data indicate that RPS27a and RPL40 regulate p53 levels and activity differently 
than other ribosomal proteins and future work is needed to identify their exact functions 
in p53 homeostasis. 
 
Inhibition of p53 by MDM2 is achieved by binding of the p53-binding domain of MDM2 
on the transactivation (TAD) domain of p53 (Poyurovsky et al., 2010) and of the central 
domain of MDM2, including the acidic domain and zinc finger domain, on the 
transactivation domain of p53 (Cross et al., 2011, Ma et al., 2006) (Figure 5.18). 
Ribosome biogenesis defects lead to the binding of the 5S RNP on MDM2, resulting 
in a conformational change on MDM2-p53 complex. RPL5 binds the acidic and ring 
domain of MDM2 whereas RPL11 was shown to only bind the zinc finger domain 
(Figure 5.18) (Lindstrom et al., 2007, Zheng et al., 2015). This leads to changes in 
MDM2 arrangement, resulting in an active conformation of the DNA binding domain of 
p53, which leads to p53 stabilisation and transcriptional activation of downstream 
targets (Figure 5.18) (Zheng et al., 2015). Sun et al. (2011) have shown that both the 
expressed and the endogenous RPS27a bind to the acidic domain of MDM2 (Sun et 
al., 2011). It is possible that RPL40, as RPS27a, can also bind MDM2 when over-
expressed, leading to an induction of the p53 levels, by preventing its ubiquitination by 
MDM2. However, this binding might not be sufficient to activate p53, as it may not be 
able to bind DNA for transcriptional activation of downstream targets. Furthermore, 
binding of the 5S RNP on MDM2 after ribosome biogenesis defects might still occur 
when RPS27a or RPL40 are over-expressed, leading to a collaborative inhibition of 
MDM2. It is proposed here that binding of either RPS27a or RPL40 and the 5S RNP 
to MDM2 may result in differential conformational changes of the MDM2-p53 complex, 
leading to the stabilisation of p53 levels, but not activity, as the DNA-binding domain 
may remain in the inactive conformation (Figure 5.18). This is only one possibility of 
how RPS27a and RPL40 may be involved in p53 homeostasis in the cell, but there 
might be other reasons for this, which are currently unknown. Future research is 
required to identify whether this is indeed the case or whether other mechanisms exist 
for p53 regulation by the 5S RNP and RPS27a or RPL40. 
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 However, one problem with this theory is that it does not explain the fact that p53 levels 
were not changed after RPS27a or RPL40 depletion in U2OS cells, even though 
ribosome biogenesis was defective, which would result in an accumulation of the 5S 
RNP. One possibility would be that the binding of the 5S RNP to MDM2 is dependent 
on the presence of RPS27a and RPL40 in U2OS cells but not in MCF7 or LNCaP cells, 
potentially through interactions on MDM2. Further work is needed to identify whether 
RPS27a and RPL40 are bound on MDM2 at the same time with the 5S RNP or if they 
interact directly with either RPL5, RPL11 or the 5S rRNA using crosslinking and 
immunoprecipitation techniques. If this is indeed the case, it would be essential to 
identify whether this mechanism is different in a number of cell types, since 
knockdowns of RPS27a or RPL40 resulted in a differential response in p53 levels or 
activity in the cell lines tested here. 
 
In conclusion, I have shown that the ubiquitin-RPS27a and RPL40 proteins are likely 
to be processed very rapidly after translation in humans. Furthermore, they play an 
important role in ribosome biogenesis in humans, since RPS27a is required for the 
SSU rRNA processing and RPL40 is required for the LSU rRNA processing. RPS27a 
Figure 5.18. Schematic representation of the proposed model of p53 regulation 
by the 5S RNP and RPS27a or RPL40. The p53-binding domain (p53 BD), acidic 
domain (AD), zinc finger domain (Zn) and ring domain of MDM2 are shown in orange, 
and the domain and domain of p53 are shown in green. The 5S RNP is shown by 
RPL5, RPL11 and the 5S rRNA. RPS27a may also be replaced by RPL40 in this 
model. The conformational changes on DNA-binding domain of p53 are indicated. 
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and RPL40 might be novel regulators of p53 induction via the 5S RNP-MDM2 pathway. 
This seems to be cell-type specific, which still remains a mystery. Future work is 
necessary to identify the functions of RPS27a and RPL40 in p53 homeostasis. 
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6. Chapter Six. Discussion 
 
6.1 Overview 
 
Ribosome biogenesis is a complex and energy-consuming process, which is directly 
linked with the regulation of the tumour suppressor p53 (Pelava et al., 2016). Defects 
in ribosome biogenesis result in the accumulation of the free 5S RNP in the 
nucleoplasm, which binds and inhibits MDM2, the main p53 inhibitor (Donati et al., 
2013, Sloan et al., 2013a). This results in p53 stabilisation and activation, leading to 
activation of downstream pathways involved in cell cycle arrest and apoptosis. 
Ribosome biogenesis is an important process that has been linked to a variety of 
diseases, including neurodegenerative disorders (Lee et al., 2014, Parlato and Liss, 
2014), skeletal diseases (Trainor and Merrill, 2014) and cancer (Gentilella et al., 2015). 
Furthermore, defects in ribosome biogenesis result in the development of 
ribosomopathies, a number of genetic diseases that arise due to mutations in 
ribosomal proteins or ribosome biogenesis factors, such as X-linked Dyskeratosis 
Congenita (DC) and Diamond-Blackfan Anaemia (DBA) (Narla and Ebert, 2010). 
These diseases present with anaemia and increased cancer risk, especially for AML 
(Yelick and Trainor, 2015), and the levels of p53 have been found to be de-regulated 
in cell culture and animal models of ribosomopathies (Pelava et al., 2016). 
 
Despite the high significance of ribosome biogenesis in health and disease, not much 
is known about the large (LSU) and small (SSU) ribosomal subunit biogenesis in 
humans. Furthermore, even though the mechanism by which LSU production defects 
lead to p53 induction via the 5S RNP-MDM2 pathway has been identified, there is 
minimal and conflicting evidence on how SSU production defects lead to p53 up-
regulation. Therefore, this PhD aimed to further explore the processes of LSU and SSU 
production in humans, and to investigate in more detail how defects in different stages 
of the human ribosome biogenesis pathway affect p53 regulation. Table 6.1 
summarizes the main findings of this project. 
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Treatment Cell line Effects on rRNA 
processing 
Effects on p53 levels 
ΔDyskerin HEK293T Early SSU and LSU 
production defects 
N/A 
Dyskerin D125A HEK293T Late SSU and LSU 
production defects 
N/A 
ΔDyskerin U2OS N/A p53 induction via 5S RNP 
ΔRPS19 
 
U2OS 21S rRNA 
accumulation 
p53 induction via 5S RNP 
MCF7 
LNCaP 
N/A p53 induction 
ΔRPS6 U2OS 
MCF7 
LNCaP 
N/A p53 induction 
ΔRIO2 U2OS 
 
18SE rRNA 
accumulation 
p53 induction via 5S RNP 
ΔPNO1 U2OS 
 
26S rRNA 
accumulation 
p53 induction 
ΔRPL7 
 
U2OS 
 
N/A p53 induction via 5S RNP 
MCF7 
LNCaP 
N/A p53 induction 
ΔRPL18 
 
U2OS 
 
N/A p53 induction via 5S RNP 
MCF7 
LNCaP 
N/A p53 induction 
ΔRPL7a U2OS 
MCF7 
N/A p53 induction 
ΔPICT1 U2OS N/A p53 induction via 5S RNP 
ΔRPS19+ΔRPL7 U2OS 
MCF7 
LNCaP 
N/A p53 induction 
ΔRPS19+ΔRPL18 
 
U2OS N/A p53 supra-induction 
MCF7 
LNCaP 
N/A p53 induction 
ΔRPS6+ΔRPL7a U2OS 
MCF7 
LNCaP 
N/A p53 induction 
ΔRPS27a U2OS 30S rRNA 
accumulation 
No difference 
MCF7 
LNCaP 
N/A p53 induction 
ΔRPL40 U2OS 32S, 36S rRNA 
accumulation 
No difference 
MCF7 
LNCaP 
N/A p53 induction 
Table 6.1. Summary of the main findings of this PhD project. 
 
Firstly, my data indicate that the SSU production is linked to LSU maturation in 
humans, similarly to yeast, where it was shown that the LSU is needed for the last 
stages of SSU maturation (Lebaron et al., 2012). I provide evidence that defects in 
SSU production in humans lead to inhibition of export of the pre-LSU complexes in the 
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cytoplasm, resulting in defects in the last stages of LSU rRNA processing. This is the 
first data indicating that the last stages of LSU maturation in humans are likely to take 
place in the cytoplasm, which agrees with previous yeast data showing that the last 
maturation steps of LSU production occur in the cytoplasm (Thomson and Tollervey, 
2010). Therefore, it is likely that a, yet uncharacterized, factor or group of proteins is 
involved in the cross-talk between LSU and SSU production. Moreover, my data 
support previous studies showing that defects in LSU production after ribosomal 
protein depletion result in a 5S RNP-dependent p53 accumulation (Donati et al., 2013, 
Sloan et al., 2013a, Golomb et al., 2014, Fumagalli et al., 2009, Fumagalli et al., 2012). 
In addition, I have shown that p53 is induced via the 5S RNP-MDM2 pathway after 
depletion of, not only LSU ribosomal proteins, but also of SSU ribosomal proteins or 
ribosome biogenesis factors, probably by leading to LSU defects, resulting in the 
accumulation of the free 5S RNP in the cytoplasm. Surprisingly, knockdowns of 
RPS27a or RPL40, which are transcribed as ubiquitin-ribosomal protein precursors, 
only induced p53 in specific cell lines, even though they resulted in ribosome 
biogenesis defects. These data suggest that RPS27a and RPL40 might be novel 
regulators of the 5S RNP-MDM2 loop. 
 
In this study, I have shown that the H/ACA snoRNP, which is involved in the 
pseudouridylation of the rRNA, is important for both LSU and SSU production in 
humans, in contrast with yeast, where it is required for SSU biogenesis (Atzorn et al., 
2004, Henras et al., 2004, Lafontaine et al., 1998). This suggests that there are some, 
yet uncharacterized, H/ACA snoRNAs in humans involved in LSU rRNA processing, 
similarly to the box C/D U8 snoRNA, which was previously shown to be involved in this 
pathway (Sloan et al., 2014, Srivastava et al., 2010). Furthermore, depletion of 
Dyskerin, the pseudouridine synthase of the H/ACA snoRNP which is mutated in X-
linked DC, resulted in a 5S RNP-dependent p53 stabilisation. My data suggest that the 
X-linked DC symptoms might be due to the 5S RNP-MDM2 interaction (Jaako et al., 
2015) or due to desensitization of p53-dependent downstream pathways (Pelava et 
al., 2016), as previously shown in other ribosomopathy models. 
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Taken together, my data indicate that defects in any stage of ribosome biogenesis, 
nuclear or cytoplasmic, result in p53 induction via the 5S RNP-MDM2 pathway. I 
propose that defects in SSU production feedback to LSU production by inhibition of 
export of the pre-LSU in the cytoplasm, leading to an accumulation of the free 5S RNP 
in the nucleoplasm, which binds MDM2, resulting in p53 stabilisation (Figure 6.1). 
 
6.2 Human ribosome biogenesis and disease 
 
6.2.1 Human ribosome biogenesis 
 
The 18S, 28S and 5.8S rRNAs are transcribed as a single 47S rRNA precursor, which 
is further cleaved and modified for the production of the mature rRNAs (Gamalinda and 
Woolford, 2015). The rRNA processing pathway in humans is highly conserved from 
yeast and involves more than 200 proteins, most of which remain unknown (Henras et 
al., 2008). In this study, I have shown that RPS27a is involved in SSU production, as 
it is important for the processing of 30S SSU rRNA precursor, and RPL40 is required 
for LSU production for cleavage at ITS1. Furthermore, I have identified that PNO1 
ribosome biogenesis factor is important for cleavage at site 3 of the 26S SSU rRNA 
precursor in humans, as previously shown in yeast (Vanrobays et al., 2004). 
Figure 6.1. Defects on SSU lead to inhibition of export of the pre-LSU in the 
cytoplasm, resulting in p53 activation via the 5S RNP-MDM2 pathway. The p53 
homeostasis under normal conditions (A) or after SSU production defects (B). The 
small ribosomal subunit (SSU) is shown in light green and the large ribosomal subunit 
(LSU) is shown in blue. The 5S RNP consists of RPL5 (blue), RPL11 (light blue) and 
the 5S rRNA (red). The MDM2 ubiquitin ligase is shown in orange and p53 is shown in 
green. The nucleus and the cytoplasm are separated by a light grey dotted line. 
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In addition, I have shown that Dyskerin, the pseudouridine synthase of the H/ACA 
snoRNP, is required for the production of both LSU and SSU in humans, as opposed 
to yeast, where Cbf5 (yeast Dyskerin) was shown to be important for SSU biogenesis 
(Atzorn et al., 2004, Henras et al., 2004, Lafontaine et al., 1998). This further supports 
the theory that the processes of LSU and SSU biogenesis are linked. Furthermore, I 
have shown that inactivation of the catalytic activity of Dyskerin resulted in defects in 
late stages of rRNA maturation, whilst the H/ACA snoRNP still accumulated. During 
rRNA processing, a number of snoRNAs were shown to be essential for processing 
rather than modification. The most well-known H/ACA snoRNAs are U17 (snR30 in 
yeast) (Atzorn et al., 2004, Fayet-Lebaron et al., 2009, Enright et al., 1996) and snR10 
(Tollervey, 1987), which are both involved in 18S rRNA processing. To date, no H/ACA 
snoRNAs were found in eukaryotes to be involved in LSU processing, that resemble 
the mode of action of either U17/snR30 or snR10. It was previously shown that the box 
C/D components Fibrillarin, NOP56 and NOP58 are important for the production of 
both LSU and SSU in humans (Sloan et al., 2014), similarly to Dyskerin, and the U8 
box C/D snoRNA was found to be involved in LSU rRNA processing (Sloan et al., 2014, 
Srivastava et al., 2010). My data indicate that there are some H/ACA snoRNAs in 
humans that are involved in LSU rRNA processing. 
 
In humans, it is not clear where and how the last stages of LSU rRNA processing occur. 
In yeast, it was shown that the mature LSU is required for the final processing steps of 
the SSU rRNAs in the cytoplasm (Lebaron et al., 2012). I show here that the mature 
SSU is required for the export of the pre-LSU in the cytoplasm in humans, since defects 
in either early or late stages of SSU production resulted in an accumulation of the pre-
LSU complexes in the nucleus. This is similar to the previous data from yeast (Lebaron 
et al., 2012, Lamanna and Karbstein, 2011), showing that the LSU and SSU production 
are linked. In addition, it was shown in yeast that the last stages of LSU rRNA 
processing occur in the cytoplasm (Thomson and Tollervey, 2010). My data indicate 
that this is likely to be the case in humans as well, since defects in SSU production 
were shown to cause the accumulation of the pre-5.8S rRNA precursor, presumably 
due to inhibition of export of the pre-LSU complexes in the cytoplasm. 
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6.2.2 The importance of human ribosome biogenesis in ribosomopathies 
 
Ribosomopathies are a set of rare genetic diseases caused by mutations in genes 
encoding ribosomal proteins or ribosome biogenesis factors (Narla and Ebert, 2010). 
Examples include Diamond-Blackfan Anaemia (DBA), 5q syndrome, Treacher-Collins 
(TC) syndrome and Dyskeratosis Congenita (DC). Mutations in genes encoding for 
SSU ribosomal proteins are found in DBA (Lipton and Ellis, 2010) or 5q syndrome 
patients (Ebert et al., 2008b), mutations in genes encoding for LSU ribosomal proteins 
are found in DBA patients (Cmejla et al., 2009) and mutations in genes encoding for 
ribosome biogenesis factors, such as TCOF1 (Gonzales et al., 2005, Weiner et al., 
2012) and DKC1 (Heiss et al., 1998, Knight et al., 2001, Angrisani et al., 2014), are 
found in TC and X-linked DC patients respectively. Interestingly, only a few LSU 
ribosomal proteins have been found to be mutated in ribosomopathies, since most 
diseases arise due to mutations in SSU ribosomal proteins or ribosome biogenesis 
factors (Narla and Ebert, 2010). I have shown that block in LSU production results in a 
rapid and strong p53 activation and that SSU defects result in p53 activation via the 
5S RNP-MDM2 after blocking LSU export in the cytoplasm (Figure 6.1). It is likely that 
most mutations in genes encoding for LSU ribosomal proteins are lethal, as they may 
not be tolerated for embryonic development. Therefore, haploinsuffiency of some or 
most LSU ribosomal proteins may result in p53 activation, leading to apoptosis in utero, 
so that the embryos are not viable. It is worth noting that, to date, there is no evidence 
of inactivation of both alleles encoding for a ribosomal protein in humans (Narla and 
Ebert, 2010), as it is most likely lethal, resulting in embryonic death. 
 
Ribosomopathy patients present with developmental and erythropoeitic defects, such 
as craniofacial abnormalities and anaemia (Nakhoul et al., 2014, Narla and Ebert, 
2010). It is still unclear, however, how defects in ribosome biogenesis affect the 
development and maturation of blood cells but no other tissues, even though 
ribosomes are important in all cells. It is possible that ribosome biogenesis is increased 
during erythropoiesis, since blood cells require more ribosomes than normal cells 
(Shenoy et al., 2012). Therefore, defects in ribosome production in normal cells would 
result in the slower accumulation of ribosomes, but defects in ribosome production in 
erythroid cells would result in the possible production of dysfunctional ribosomes 
(Yelick and Trainor, 2015). Alternatively, normal cells might be able to cope with 
defects in ribosome biogenesis, but the need of a high production of ribosomal proteins 
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in erythroid cells could result in a major imbalance. It would be interesting to identify 
whether LSU or SSU ribosome biogenesis defects result in an unusual erythropoiesis, 
using erythroid precursor cells, such as CD34+, or, perhaps, stem cells, where 
knockdowns or expression of mutant genes involved in ribosomopathies are used, 
such as RPS19. Another remaining question is how ribosome dysfunction leads to a 
variety of clinical manifestations in ribosomopathy patients, even though they are all 
blood disorders. For example, DBA patients present with erythropoiesis defects, 
whereas SDS patients present with neutropenia, where neutrophils, a type of white 
blood cell, are found in low numbers (Khanna-Gupta, 2013). It is therefore clear that 
identifying the molecular mechanisms underlying ribosomopathies might be a 
complicated, but essential task, in order to further understand the development of 
these diseases for the development of future treatments. 
 
A number of studies have shown that p53 and the 5S RNP interaction with MDM2 are 
important for the clinical symptoms observed in ribosomopathy patients, and my data 
indicates that SSU defects result in p53 activation via the 5S RNP-MDM2 pathway 
after defects in LSU export (Figure 6.1). Some of the Diamond-Blackfan Anaemia 
(DBA) symptoms are dependent on p53 in mouse models, whereas the development 
of anaemia is dependent on the 5S RNP binding on MDM2 (Jaako et al., 2015). 
Furthermore, haploinsufficiency of RPS14 in a mouse model of 5q syndrome resulted 
in a p53-dependent anaemia (Schneider et al., 2016), and mice harbouring a mutation 
in TCOF1, the gene mutated in Treacher-Collins (TC) syndrome, developed p53-
dependent craniofacial defects (Jones et al., 2008). I have shown here that p53 
induction after RPS19 depletion, which is mutated in DBA, is dependent on the 5S 
RNP-MDM2 pathway, due to ribosome biogenesis defects, which further supports 
previous studies. In addition, I have shown that knockdown of Dyskerin, which is 
mutated in X-linked DC, also leads to p53 induction via the 5S RNP-MDM2 pathway. 
It is, therefore, surprising and counter-intuitive that ribosomopathy patients have an 
increased risk in developing cancers (Narla and Ebert, 2010), since p53 levels are 
increased. It is hypothesized that ribosomopathy patients become desensitized to p53-
dependent tumour suppressor pathways in the cells, leading to an increased 
oncogenic susceptibility (Pelava et al., 2016). Future research is required to identify 
whether this is indeed the case. 
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6.2.3 The importance of human ribosome biogenesis in cancer 
 
The nucleolus and ribosome biogenesis play a key role during cancer development. 
First, the nucleolar structure is altered in cancer cells (Nicolas et al., 2016), since the 
size and the shape of the nucleolus are increased (Derenzini et al., 2009, Orsolic et 
al., 2015). Furthermore, ribosome biogenesis is up-regulated during cancer 
development, since tumour cells require a larger number of ribosomes (Orsolic et al., 
2015). A number of ribosomal proteins are mutated in cancers, especially leukaemia, 
including RPL5 (Iorio et al., 2016), RPL10 (De Keersmaecker et al., 2013), RPL22 
(Rao et al., 2012, Iorio et al., 2016), RPS15 (Ljungstrom et al., 2016) and RPS20 
(Nieminen et al., 2014). For example, mutations in RPS15 are mostly found in 
association with mutations in p53 and they result in an aggressive form of chronic 
lymphocytic leukaemia (CLL) (Ljungstrom et al., 2016). Furthermore, RPL5 was found 
to be commonly mutated in acute lymphocytic leukaemia (ALL), but also in a variety of 
solid tumours, such as invasive breast cancer, lung squamous cell carcinoma (LUSC), 
cutaneous melanoma (SKCM) and uterine corpus endometrial carcinoma (UCEC) 
(Iorio et al., 2016). In addition, the nucleolar protein nucleophosmin (NPM1) is mutated 
in a number of cancers and especially leukaemia. Up to 60% of AML cases present 
with a mutant NPM1 gene (Grummitt et al., 2008) and it is mutated in almost 30% of 
all leukaemia and myelodysplastic syndromes (MDS) (Naoe et al., 2006). 
 
Consequently, a number of anti-cancer drugs have been developed, targeting the 
nucleolus. For example 5-Fluouracil (5-FU) blocks rRNA processing (Burger et al., 
2010, Ghoshal and Jacob, 1994, Longley et al., 2003) and data from my lab show that 
treatment with 5-FU induces p53 in a 5S RNP-dependent manner (Loren Gibson, Nick 
Watkins, personal communication). Several anti-cancer drugs inhibit ribosome 
biogenesis by inhibition of RNA polymerase I. Actinomycin D (ActD) intercalates with 
rDNA in low doses and prevents RNA polymerase I elongation (Ginell et al., 1988), as 
does the small molecule BMH-21 (Peltonen et al., 2014). CX-3543 also prevents the 
RNA polymerase I elongation by inhibition of the stabilization between the complexes 
on the rDNA gene (Drygin et al., 2009). Cisplatin cross-links with the rDNA and 
prevents the association of the transcription factor UBF at the promoter region, thus 
preventing the elongation of RNA polymerase I (Jordan and Carmo-Fonseca, 1998). 
CX-5461 targets the association of SL1 complex with RNA polymerase I, preventing 
initiation of rDNA transcription (Bywater et al., 2012). 
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Other drugs are also used for chemotherapeutic treatments of cancer, which target a 
number of ribosome biogenesis stages. Firstly, the mTOR pathway is targeted by a 
variety of drugs, leading to a decreased rDNA transcription. MK-2206 inhibits the 
activation of the mTORC1 complex by Akt pathway (Chan et al., 2011), whereas 
Rapamycin inhibits the mTORC1 complex directly (Mahajan, 1994). A few drugs target 
the cyclin-dependent kinase CDK2, including roscovitine, olomoucine (David-Pfeuty et 
al., 2001) and DRB (CK2 inhibitor 5,6-dichloro-1-beta-ribofuranosylbenzimidazole) (te 
Poele et al., 1999), or CDK9, such as Flavopiridol (Sedlacek, 2001), leading to cell 
cycle arrest and inhibition of rDNA transcription initiation. 
 
Apart from targeting ribosome biogenesis pathway, a number of drugs targeting the 
interaction between MDM2 and p53 are at the stage of pre-clinical development or 
clinical trials. These drugs are commonly used in cancers expressing a wild-type p53 
and they block the binding of MDM2 to p53 by competing for MDM2 binding (Shangary 
and Wang, 2008), leading to apoptosis of the cancer cells. Nutlin 3a is one example of 
a drug that inhibits the interaction between MDM2 and p53, leading to cell cycle arrest 
and senescence of the cancer cells (Shangary and Wang, 2008). Cancer cells that do 
not harbour a functional p53 were shown to be resistant to treatment with nutlin 3a 
(Manfe et al., 2012). Nevertheless, combined treatment with nutlin 3a and other 
chemotherapeutic drugs, such as doxorubicin or cisplatin, was more effective in 
inducing cytotoxicity as compared to treatment with single chemotherapeutic agents 
(Ohnstad et al., 2011). Other drugs that bind and inhibit MDM2 are MI-219 (Zheng et 
al., 2010) and MI-63 (Ding et al., 2006), leading to p53 activation. 
 
The high number of ribosomal proteins or ribosome biogenesis factors that are mutated 
in cancers and the existing chemotherapeutic drugs highlight the importance of 
ribosome biogenesis in cancer development. It is, therefore, essential to further explore 
the mechanisms by which ribosome production occurs in humans, in order to develop 
more targeted and efficient treatments for cancer. 
 
6.3 Future Directions 
 
In this project, I provide new and exciting information on ribosome biogenesis in 
humans. Firstly, my data suggest that there are some H/ACA snoRNAs that are 
involved in LSU rRNA processing in humans, as U17/snR30 and snR10 are involved 
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in SSU rRNA processing (Fayet-Lebaron et al., 2009, Atzorn et al., 2004, Tollervey, 
1987). My data show that there are H/ACA snoRNAs involved in LSU processing in 
higher eukaryotes. It was previously shown that the U8 box C/D snoRNA is involved in 
LSU rRNA processing in humans (Sloan et al., 2014, Srivastava et al., 2010) and some 
H/ACA snoRNAs were identified in protozoan parasites T. brucei (Gupta et al., 2010) 
and L. major (Eliaz et al., 2015) that might be involved in LSU rRNA processing. It is 
not clear which H/ACA snoRNAs might be involved in this pathway in humans and, 
therefore, future research is required. It is possible that these H/ACA snoRNAs present 
with base complementarity to the 28S rRNA, similarly to the mechanism of U17/snR30 
(Atzorn et al., 2004, Fayet-Lebaron et al., 2009) and snR10 (Tollervey, 1987). There is 
a number of snoRNAs with unknown functions, called orphan snoRNAs (Bachellerie et 
al., 2002). It might be that some of these orphan snoRNAs are required for LSU rRNA 
processing in higher eukaryotes and further research is required to identify which ones 
are involved in this and their exact mechanism of action. 
 
Secondly, my results, in addition to previous yeast data (Lebaron et al., 2012, Lamanna 
and Karbstein, 2011), indicate that the SSU and LSU processing pathways are linked 
by a single factor or a group of proteins, in contrast to previous theories suggesting 
that the two processes are separate. One likely candidate linking the two processes is 
the ribosome biogenesis factor ATP-binding-cassette F2 (ABCF2), a member of the 
ABC protein family of transporters which shuttle between the nucleus and the 
cytoplasm (Jones and George, 2004). The yeast homologue of ABCF2, ARB1, was 
shown to be important for both LSU and SSU ribosome biogenesis in yeast (Dong et 
al., 2005). Depletion of ARB1 in S. cerevisiae resulted in the accumulation of the 20S 
SSU rRNA precursor and a defect in the export of the pre-SSU complex in the 
cytoplasm, as well as a delayed LSU rRNA processing (Dong et al., 2005). 
Furthermore, ARB1 was found to be associated with pre-40S, pre-60S and 80S 
ribosomal complexes, and with proteins involved in either 60S maturation, such as 
LSG1, 40S maturation, such as SCP160, or both 60S and 40S maturation, such as 
DED1 (Dong et al., 2005). It was also demonstrated by various publications that 
ABCF2 is highly associated with different types of cancer (Nishimura et al., 2007, 
Ogawa et al., 2006, Hlavata et al., 2012, Nishimura et al., 2008). These studies indicate 
that ABCF2 might be an important ribosome biogenesis factor which links the LSU and 
SSU production, and it is possible that it is involved in tumour development due to 
ribosome biogenesis defects. It would, therefore, be interesting to identify whether the 
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biogenesis of LSU or SSU is affected after ABCF2 knockdown in human cells, and 
whether this effect is global or specific to certain stages of ribosome biogenesis. If so, 
it would be important to identify whether ABCF2 depletion affects p53 levels via the 5S 
RNP-MDM2 pathway, which would explain how SSU processing defects feedback to 
the 5S RNP integration in the ribosome. 
 
In this study, I have shown that depletion of either ribosomal proteins or ribosome 
biogenesis factors acting in different stages of ribosome biogenesis lead to p53 
activation via the 5S RNP-MDM2 pathway, and not just depletion of LSU ribosomal 
proteins. This is of particular importance for ribosomopathies, which arise due to 
mutations in genes encoding for either ribosomal proteins or ribosome biogenesis 
factors (Narla and Ebert, 2010). Since ribosomopathy patients present with an 
increased cancer risk and de-regulated p53 levels in cell culture and animal models 
(Pelava et al., 2016), the interaction between the 5S RNP and MDM2 is an important 
target for the development of future therapies for ribosomopathy patients. The existing 
treatments for ribosomopathy patients result in the relief of the symptoms and include 
steroids for the anaemia or surgery for the craniofacial defects (Narla and Ebert, 2010). 
Since it was shown that the anaemia phenotype, at least for DBA, is dependent on the 
interaction between the 5S RNP-MDM2 in mouse models (Jaako et al., 2015), 
targeting this interaction would potentially replace the need for blood transfusions in 
ribosomopathy patients. Furthermore, the de-regulation of p53 in ribosomopathy 
models in vivo and the increased cancer incidence in these patients suggest that the 
interaction between the 5S RNP and MDM2 could result in a reduction of 
tumourigenesis in ribosomopathy patients. 
 
In addition, the 5S RNP-MDM2 interaction can be targeted for future cancer 
treatments. Most of the existing chemotherapeutic treatments for cancer target the 
nucleolus, by inhibition of rDNA transcription by blocking RNA polymerase I (Quin et 
al., 2014), and are genotoxic. Some of the drugs also target the mTORC1 activation, 
which controls the protein production by activation downstream pathways for ribosome 
biogenesis and mRNA translation (Laplante and Sabatini, 2009a). Inhibiting the 
interaction between the 5S RNP and MDM2 could provide a more targeted approach 
in cancer therapeutics, since it would mainly be active in cancer cells with an increased 
or defective ribosome production, leading to less side effects with no genotoxic stress. 
In addition, I have shown here that block in LSU production leads to a very quick and 
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high p53 induction. Therefore, blocking the biogenesis of LSU in cancer cells, where 
the ribosome production is increased, would be an interesting target, since it would 
lead to a quick p53 activation, leading to cell cycle arrest and apoptosis. This could 
also be a more targeted approach in developing drugs that would only target an up-
regulated LSU production, excluding somatic cells, where ribosome biogenesis takes 
place as normal. 
 
6.4 Conclusions 
 
In summary, this PhD project has shown that ribosome biogenesis in humans is a more 
complex process than originally thought, highlighting the importance of Dyskerin in the 
production of both LSU and SSU, and providing evidence of a link between the LSU 
and SSU biogenesis. Furthermore, it was shown here that defects in ribosome 
biogenesis lead to p53 activation, not only due to depletion of ribosomal proteins, but 
also because of depletion of ribosome biogenesis factors involved rRNA modification 
or early or late stages of rRNA processing, which is of particular importance in 
ribosomopathy patients. This information, in addition to ongoing research on the 5S 
RNP-MDM2 interaction, is important for the development of more targeted and efficient 
therapies for both ribosomopathy patients and cancer in general, especially for 
leukaemia. To conclude, ribosome biogenesis is an important process in human health 
and disease, and an important regulator of p53 homeostasis via the 5S RNP-MDM2 
interaction, which is an emerging target for future cancer treatments. 
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